

CURRICULUM VITAE

ANIL KUMAR SOOD, M.D., FACOG, FACS

October 1, 2023

DATE OF BIRTH: [REDACTED]

CITIZENSHIP: [REDACTED]

CURRENT POSITION: Professor

WORK ADDRESS: M. D. Anderson Cancer Center
Department of Gynecologic Oncology and Reproductive Medicine
Unit 1362, P. O. Box 301439
1155 Herman Pressler, CPB 6.3275
Houston, TX 77230-1439

OFFICE PHONE: (713) 745-5266

OFFICE FAX: (713) 792-7586

E-Mail: asood@mdanderson.org

HOME ADDRESS: [REDACTED]

HOME PHONE: [REDACTED]

E-Mail: [REDACTED]

ACADEMIC APPOINTMENTS:

University of Iowa

1998 – 2002 Assistant Professor, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 4630 JCP, University of Iowa Hospitals and Clinics, Iowa City, IA 52242

1999 – 2002 Member, Holden Comprehensive Cancer Center at the University of Iowa

University of Texas M. D. Anderson Cancer Center

2002 – 2006 Associate Professor, Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 440, Houston, TX 77030 (*Tenure approved March, 2005)

2002 – 2006 Associate Professor, Department of Cancer Biology, M. D. Anderson Cancer Center

2003 – Present Graduate Faculty, Regular Member, Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston

2006 – Present Professor, Department of Gynecologic Oncology, M. D. Anderson Cancer Center

2006 – Present Professor, Department of Cancer Biology, M. D. Anderson Cancer Center

2005 – 2009 Director, Ovarian Cancer Research, Department of Gynecologic Oncology, M. D. Anderson Cancer Center

2007 – 2011 Co-Director, Blanton-Davis Ovarian Cancer Research Program, M. D. Anderson Cancer Center, Houston, TX

2007 – 2016 Bettyann Asche Murray Distinguished Professorship in Ovarian Cancer Research, M. D. Anderson Cancer Center

2009 – Present Co-Director, Center for RNA Interference and Non-Coding RNA (Red and Charline

	McCombs Institute for the Early Detection and Treatment of Cancer), M. D. Anderson Cancer Center
2010 – Present	Vice Chairman, Translational Research, Department of Gynecologic Oncology, M. D. Anderson Cancer Center
2011 – Present	Director, Blanton-Davis Ovarian Cancer Research Program, M. D. Anderson Cancer Center
2012 – Present	Co-Director, Women's Cancer Moonshot Program, M.D. Anderson Cancer Center
2016 – Present	Frank McGraw Memorial Chair in Cancer Research, M.D. Anderson Cancer Center
2017	American Cancer Society Professor

EDUCATION:

1991	M.D., University of North Carolina Chapel Hill, North Carolina
1986	B.S., Davidson College Davidson, North Carolina
1982 - 84	University of Arkansas Fayetteville, Arkansas

POSTGRADUATE:

July 1, 1991 – June 30, 1995	Resident in Obstetrics and Gynecology University of Florida, Shands Teaching Hospital Gainesville, Florida 32610 Patrick Duff, M.D., Residency Director
July 1, 1995 – June 30, 1998	Fellow in Gynecologic Oncology University of Iowa Hospitals and Clinics Iowa City, Iowa 52242 Barrie Anderson, M.D., Fellowship Director

HONORS AND AWARDS:

1992 - 1995	Outstanding Student Teaching Award, University of Florida
1994, 1995	Outstanding performance on CREOG exam award
1995	Outstanding Laparoendoscopic Resident Surgeon, University of Florida
1996	J. G. Moore Award for the best research presentation by a fellow, The Annual Meeting of the Western Association of Gynecologic Oncologists, San Diego, CA.
1997	Best all-around clinical poster. The 28 th annual meeting of the Society of Gynecologic Oncologists (SGO).
1998	Young investigator award--Fourth Joint Conference of the American Association for Cancer Research (AACR) and the Japanese Cancer Association meeting.
2002	Invited expert for the <i>Biological Mechanisms of Psychosocial Effects on Disease</i> (BiMPED) conference sponsored by the Basic Biobehavioral Research Branch (BBRB) of the National Cancer Institute, Bethesda, Maryland.
2002	James F. Nolan Award for the best overall research presentation, The Annual Meeting of the Western Association of Gynecologic Oncologists, Newport Beach, CA.
2003	Outstanding educator, The University of Texas M. D. Anderson Cancer Center.
2003	Charles A. Hunter, Jr. Prize Thesis Award, The American Gynecological and Obstetrical Society, Napa, CA.
2004	Invited speaker for the "Exploring the Integration of Psychoneuroimmunology and Tumor

- Immunology in Cancer Control Research*" conference sponsored by the Basic Biobehavioral Research Branch (BBRB) of the National Cancer Institute, Bethesda, Maryland.
- 2004 James F. Nolan Award for the best overall research presentation, Western Association of Gynecologic Oncologists and the Felix Rutledge Society, Monterey, CA.
- 2005, 2007 Educator of the month, M. D. Anderson Cancer Center, September, 2005; and July, 2007
- 2006 - 2009 Faculty Scholar Award, M. D. Anderson Cancer Center.
- 2008 Elected to Alpha Omega Alpha Honor Medical Society
- 2007 The Gynecologic Cancer Foundation/Margaret Greenfield/Carmel Cohen, MD "Excellence in Ovarian Cancer Research Award"
- 2008 Elected Fellow, the American Gynecological and Obstetrical Society
- 2009 Excellence in Teaching Award, Association of Professors of Gynecology and Obstetrics, M. D. Anderson Cancer Center
- 2009 Elected Member, the American Society for Clinical Investigation (ASCI)
- 2010 Elected, Fellow of the Academy of Behavioral Medicine
- 2011, 2012 America's Top Doctors for Cancer, Castle Connolly Medical Ltd. (U.S. News & World Report rankings)
- 2011 GCF/Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher
- 2011 Dallas/Fort Worth Living Legend Faculty Achievement Award in Basic Research, M.D. Anderson Cancer Center
- 2012 Elected Fellow, the American Association for the Advancement of Science (AAAS)
- 2014 Society for Gynecologic Investigation President's Achievement Award
- 2014 Rosalind Franklin Ovarian Cancer Research award (Ovarian Cancer National Alliance)
- 2015 Making a Difference Award, The Belinda Sue Fund
- 2015 Outstanding Achievement Award, Society of American Asian Scientists in Cancer Research (SAASCR)
- 2017 American Cancer Society Research Professor Award
- 2017 Elected, Association of American Physicians (AAP)
- 2021 Elected, National Academy of Medicine (NAM)
- 2023 Distinguished Alumnus Award, University of Iowa

MEDICAL CERTIFICATION:

Federation Licensing Examination, 1991

American Board of Obstetrics and Gynecology, Diplomat, November 12, 1999

American Board of Obstetrics and Gynecology, Certification of Special Qualification in Gynecologic Oncology, April 2001

LICENSURE:

Florida – 1993, ME# 0064641
DEA# BS3729045

Iowa – 1995, License No. 30511, Inactive status

Texas – 2002, License No. L5570

NCI Investigator Number: 39152

PROFESSIONAL ASSOCIATION:

American Association for the Advancement of Science
American Association for Cancer Research
American College of Obstetricians and Gynecologists, Fellow
American College of Surgeons, Fellow
American Gynecological and Obstetrical Society
American Psychosomatic Society
American Society for Biochemistry and Molecular Biology (ASBMB)
American Society of Clinical Oncology
Felix Rutledge Society, Member
International Gynecologic Cancer Society
Psycho-Neuro-Immunology Research Society, Member
Society of Gynecologic Oncologists, Full Member
Western Association of Gynecologic Oncologists, Full Member

INVITED REVIEWER (Intermittent):

Acta Biochimica et Biophysica Sinica
American Journal of Obstetrics and Gynecology
American Journal of Pathology
American Society of Health-System Pharmacists
Apoptosis
BioMed Central
Brain, Behavior & Immunity
British Journal of Cancer
Cancer
Cancer Cell
Cancer Chemotherapy and Pharmacology
Cancer Discovery
Cancer Research
Cell Metabolism
Cell Reports
Clinical Cancer Research
Clinical and Experimental Metastasis
Current Women's Health Reviews
European Journal of Oral Sciences
Expert Review of Anticancer Therapy
Gynecologic and Obstetric Investigation
Gynecologic Oncology
Human Reproduction
International Journal of Cancer
Journal of Biological Chemistry
Journal of Cellular Biochemistry
Journal of Cellular Physiology
Journal of Clinical Investigation
Journal of the American Medical Association
Journal of Experimental Therapeutics and Oncology
Journal of Pathology
Journal of Postgraduate Medicine
Journal of Surgical Oncology
Lancet Oncology

Molecular and Cellular Endocrinology
 Nature Medicine
 Neoplasia
 New England Journal of Medicine
 Obstetrics and Gynecology
 Oncology
 Pathology Oncology Research
 Proceedings of the National Academy of Sciences
 Reproductive Sciences
 Science Translational Medicine
 Women's Cancer Network

EDITORIAL SERVICE

2003 – 2018	<i>Cancer</i> , Editorial Advisory Board
2004 – present	<i>Current Women's Health Reviews</i> , Editorial Board
2005 – 2019	<i>Cancer Biology and Therapy</i> , Editorial Board
2006	Editor, Prognostic and Predictive Factors in Gynecologic Cancers
2006 – 2008	<i>Gynecologic Oncology</i> , Editorial Board
2006 – 2010	<i>Obstetrics and Gynecology</i> , Editorial Board
2007 – 2014	<i>US Obstetrics & Gynecology</i> , Advisory Panel
2007 – present	<i>The Open Medicinal Chemistry Journal</i> , Editorial Board
2008 – 2015	<i>International Journal of Women's Health</i> , Editorial Board
2008 – 2016	<i>Obstetrics and Gynecology International</i> , Editorial Board
2008 – 2022	Deputy Editor, <i>Gynecologic Oncology</i>
2010 – present	<i>Ovarian Diseases</i> , Editorial Board
2010 – present	<i>Journal of Ovarian Research</i> (Associate Editor – 2010 – 2012; Editorial Board Member: 2012 – present)
2010 – present	<i>NanoLIFE</i> , Associate Editor
2010 – present	<i>American Journal of Cancer Research</i> , Editorial Board
2010 – 2012	<i>Journal of Clinical Oncology</i> , Editorial Board
2011 – present	<i>Frontiers in Non-Coding RNA</i> , Editorial Board
2011 – present	<i>Cancer Hallmarks</i> , Editorial Board
2014 – present	<i>Non-Coding RNA</i> , Editorial Board
2016 – present	<i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , Associate Editor
2017 – present	<i>Investigational New Drugs</i> , Editorial Board
2019 – present	<i>SN (Springer-Nature) Comprehensive Clinical Medicine</i> , Editorial Board

DIRECTION OF FELLOW, RESIDENT, AND STUDENT RESEARCH AND MENTORING:

Clinical Fellows:

2000 - 2002	Vikas Mahavni
2000 - 2002	David P. Bender
2002 - 2004	Premal H. Thaker (<u>Awards won</u> : J. G. Moore Award for best research presentation by a fellow, Annual Meeting of the Western Association of Gynecologic Oncologists, 2004; Best research presentation, Fellow's Forum, San Diego, CA, 2005; Fellow Award for Outstanding Paper (GCF/Eli Lilly and Carol's Cause), 36 th Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2005; Best Presentation, Annual Meeting of the Felix Rutledge Society, Berlin, Germany, 2006). *Participated in M.S. Committee.
2003 - 2005	Charles N. Landen (<u>Awards won</u> : J. G. Moore Award for best research presentation by a fellow at the 2004 Annual Meeting of the Western Association of Gynecologic Oncologists; the

- Bettyann Asche-Murray Fellowship Award, 2004; the 2005 Del and Dennis McCarthy Fellowship in Experimental Surgery, M. D. Anderson Cancer Center; AACR-AFLAC, Incorporated Scholar-in-Training Award, AACR 96th Annual Meeting, Anaheim, CA, 2005; M. D. Anderson Alumni and Faculty Association Trainee Excellence Award, 2005; Fellow Award for Outstanding Paper (Carol's Cause), 37th Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, 2006; The Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2007; The Bristol Myers-Squibb Poster Award in Clinical/Translational Research, Trainee Recognition Day, MDACC, 2007). *Chaired M.S. Committee.
- 2004 - 2006 Aparna A. Kamat (Awards won: The Bettyann Asche-Murray Fellowship Award, 2004; Virginia K. Pierce Award, Society of Memorial Gynecologic Oncologists, 2006; Bristol-Myers Squibb Award in Clinical/Translational Research, 10th Annual Trainee Recognition Day, M. D. Anderson Cancer Center, 2006; The Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2007). *Chaired M.S. Committee.
- 2004 - 2006 Liz Y. Han (Awards won: Virginia K. Pierce Award, Society of Memorial Gynecologic Oncologists, 2005; Linda K. Manning Fellowship in Ovarian Cancer for excellence in and unique contribution to cancer education, 2006; Best Oral Presentation by a Fellow, Society of Gynecologic Oncologists 2007 Meeting, Beaver Creek, CO; M. D. Anderson Alumni and Faculty Association Trainee Excellence Award, 2007; GCF/Eli Lilly and Company Award for the Outstanding paper, 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2007; Best Oral Presentation by a Fellow, Society of Gynecologic Oncologists 2008 Meeting, Park City, UT; Fellow Award for Outstanding Paper (Carol's Cause), 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL, 2008; Fulbright Scholarship, 2008). *Chaired M.P.H. Committee.
- 2005 - 2007 Yvonne Lin (Awards won: J. G. Moore Award for best research presentation by a fellow, Annual Meeting of the Western Association of Gynecologic Oncologists, 2006; The Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2008; Trainee of the Quarter, MDACC, 2008)
- 2005 - 2007 William Merritt (Awards won: Best Poster by a Fellow, Society of Gynecologic Oncologists 2007 Meeting, Beaver Creek, CO; M. D. Anderson Alumni and Faculty Association Trainee Excellence Award, 2007; GCF/Carol's Cause Fellow Award for Outstanding Paper, 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2007; Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2009; Trainee of the Quarter Award, M. D. Anderson Cancer Center, 2009). *Participated in M.S. Committee.
- 2006 - 2008 Whitney Spannuth. (Awards won: Jesse H. Jones Fellowship in Cancer Education, MDACC, 2008) *Chaired M.S. Committee.
- 2007 - 2009 Alpa M. Nick. (Awards won: J. G. Moore Award for best research presentation by a fellow, Annual Meeting of the Western Association of Gynecologic Oncologists, 2008; Trainee Excellence Award, MDACC, 2008; GCF/Ann Schreiber Ovarian Cancer Research Grant, 2009; AACR Scholar in Training Award, 2011; Trainee of the Quarter Award, M. D. Anderson Cancer Center, 2011) *Chaired M.S. Committee.
- 2008 - 2010 Rebecca L. Stone. (Awards won: GCF/Fail MacNeil KOH Research Grant for Early Detection of Ovarian Cancer, 2009; The Linda K. Manning Fellowship in Ovarian Cancer Research, MDACC, 2010; The Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2010; The Linda K. Manning Fellowship in Ovarian Cancer Research, 2011; Trainee of the Quarter Award, M. D. Anderson Cancer Center, 2012; The Lupe C. Garcia Fellowship in Cancer Research, 2012; The Diane Denson Tobola Fellowship in Ovarian Cancer Research, 2012) *Chaired M.S. Committee.
- 2009 - 2010 Amy R. Carroll (Awards won: M. D. Anderson Alumni and Faculty Association Trainee Excellence Award, 2010).
- 2009 - 2012 Chad V. Pecot (Awards won: The Jeffrey Lee Cousins Fellowship in Lung Cancer Research,

- MDACC, 2010; ASCO Young Investigator Award, 2011; The Ben F. Love Fellowship in Innovative Cancer Therapies, 2012; Achievement in Basic Science Award, MDACC, 2012).
- 2010 - 2012 Justin Bottsford-Miller. (Awards won: Ovarian Cancer National Alliance Ovarian Cancer Research Grant, 2012; The Thomas H. and Mayme P. Scott Fellowship in Cancer Research, 2012). *Chaired M.S. Committee.
- 2011 - 2013 Behrouz Zand. *Chaired M.S. Committee.
- 2012 - 2014 Heather J. Dalton. (Awards won: The Linda K. Manning Fellowship in Ovarian Cancer, 2013 and 2016; GSBS Student Travel Award, 2014). *Chaired M.S. Committee.
- 2013 – 2015 Rebecca A. Previs. (Awards won: The Linda K. Manning Fellowship in Ovarian Cancer, 2015 and 2017; The Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2016) *Chaired M.S. Committee
- 2014 – 2016 Jean M. Hansen. (Awards won: The Thomas H. and Mayme P. Scott Fellowship in Cancer Research, MDACC, 2015; The Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2017; The Linda K. Manning Fellowship in Ovarian Cancer, 2018). *Chaired M.S. Committee
- 2015 – 2017 Michael J. Wagner (Awards won: The Daniel Benedict Gazan Fellowship in Sarcoma Research, MDACC, 2016; QuadW Foundation-AACR Fellowship for Clinical/Translational Sarcoma Research, 2017; The Connie and Jim Walter Fellowship in Sarcoma Research, 2017)
- 2016 – 2018 Robert Dood (Awards won: The Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2017; 1st place in Cancer Survivorship Abstract Competition for Trainee Research Day, 2018; The Linda K. Manning Fellowship in Ovarian Cancer Research, 2018).
- 2017 – 2019 Chris LaFargue (Awards won: Caring Together, NY, Ovarian Cancer Research Grant from the Foundation for Women's Cancer, 2018; The Linda K. Manning Fellowship in Ovarian Cancer Research, 2018 and 2019) *Chaired M.S. Committee.
- 2020 – 2022 Deanna Glassman (Awards won: Linda K. Manning Fellowship in Ovarian Cancer Research, MDACC, 2021; Cancer Answers Scholarship, 2021-2022) *Chaired M.S. Committee.
- 2020 – 2022 Amma Asare (Awards won: Peggy A. Yates grant from the FWC, 2023; Trainee Grant Incentive Award, MDACC, 2023).

Post-doctoral Fellows:

- 2004 - 2006 Chunhua Lu (Awards won: AACR-Eli Lilly Scholar-in-Training Award, AACR 97th Annual Meeting, Washington, DC, 2006)
- 2005 - 2007 Lingegowda S. Mangala (Awards won: Young Scientist Award from the American Association of Indian Scientists in Cancer Research, 2008)
- 2007 - 2008 Seung W. Kim (Awards won: The Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2008)
- 2007 - 2010 Hee Dong Han (Awards won: The Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2009)
- 2007 - 2008 Juliana Benito
- 2008 - 2009 Christopher Danes (Awards won: Linda K. Manning Fellowship in Ovarian Cancer, MDACC, 2009)
- 2009 - 2010 Koji Matsuo (Awards won: GCF/OCRF Ann Schreiber Ovarian Cancer Research Grant, 2009)
- 2009 – 2012 Guillermo Armaiz-Pena (Awards won: The Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2010; M. D. Anderson Alumni and Faculty Association Trainee Excellence Award, 2010; AACR-Aflac, Inc. Scholar in Training Award, 2011; The Diane Denson Tobola Fellowship in Ovarian Cancer Research, 2011)
- 2010 – 2012 Jie Huang
- 2010 – 2015 Sherry Wu (Awards won: Ann Schreiber Research Training Program Award from the Ovarian Cancer Research Fund, 2011 - 2013; TRIUMPH Scholar, 2011-2014; The Linda K. Manning Fellowship in Ovarian Cancer Research, 2012; Computational Cancer Biology Training

- Program Fellowship, 2013; 1st place poster award, Keck Annual Research Conference, 2013; First Place Bayer HealthCare Pharmaceuticals, Inc. Award in Translational Research, MDACC Trainee Research Day, 2014)
- 2010 – 2013 Sunila Pradeep
- 2010 – 2014 Min-Soon Cho (Awards won: The Harold C. and Mary L. Daily Endowment Fellowship, 2013).
- 2012 – 2014 Morgan Taylor (Awards won: NLM Biomedical Informatics Training Program Fellowship, 2013)
- 2013 – 2014 Hyun Jin Choi (Awards won: Ann Schreiber Mentored Investigator Award from the Ovarian Cancer Research Fund, 2013).
- 2013 – 2015 Ashley Davis
- 2013 - 2014 Xiao-Yun Yang
- 2013 - 2016 Hiroto Hatakeyama (Awards won: Japan Society for the Promotion of Science (JSPS) fellowship, 2013 - 2015).
- 2013 - 2017 Justyna Filant (Awards won: Ann Schreiber Mentored Investigator Award from the Ovarian Cancer Research Fund, 2015 – 2016; The Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2016).
- 2014 - 2016 Monika Haemmerle (Awards won: Research Fellowship, German Science Fund; The Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2016, Ovarcome Award, 2016)
- 2014 - 2017 Piotr Lukasz Dorniak (Awards won: Computational Cancer Biology Training Program Fellowship, 2015; The Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2016; Ann Schreiber Mentored Investigator Award from the Ovarian Cancer Research Fund, 2016 – 2017)
- 2014 – 2016 Kyunghee Noh (Awards won: Ann Schreiber Mentored Investigator Award from the Ovarian Cancer Research Fund, 2014 – 2015; the Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2015 and 2016).
- 2015 – 2017 Sze Ling Mak
- 2015 – 2017 Yasmin Lyons (Awards won: NLM Biomedical Informatics Training Program Fellowship, 2015; The Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2017).
- 2017 – 2019 Karem Court
- 2017 – 2019 Olivia Lara (Awards won: GSBS/MDACC Travel Award, 2018)
- 2017 – 2018 Sara Corvigno (Awards won: The Diane Denson Tobola Fellowship in Ovarian Cancer Research, MDACC, 2018; FWC grant: Amy Krouse Rosenthal Foundation and Judy's Mission to End Ovarian Cancer Foundation Research Grant for Early Detection of Ovarian Cancer).
- 2017 – Yuan Liu
- 2018 – 2020 Akira Yokoi (Awards won: Japan Society for the Promotion of Science (JSPS) fellowship, 2018 - 2020).
- 2018 – 2022 Santosh Dasari
- 2018 – Elaine Stur (Awards won: Ann Schreiber Mentored Investigator Award from the Ovarian Cancer Research Fund, 2019 – 2020)
- 2018 – 2020 Mana Taki (Awards won: Japan Society for the Promotion of Science (JSPS) fellowship, 2019-2021).
- 2018 – 2019 Bach Duc-Hiep
- 2018 – 2020 Guy Katz (Awards won: Ann Schreiber Mentored Investigator Award from the Ovarian Cancer Research Fund, 2019 – 2020)
- 2019 – 2021 Katelyn Handley (Awards won: GCC/Keck Center's Computational Cancer Biology Training Program (CCBTP) postdoctoral fellowship; Linda K. Manning Fellowship in Ovarian Cancer Research, MDACC, 2021).
- 2019 – 2021 Shaolin Ma (Awards won: St. Louis Ovarian Cancer Awareness Research grant (SLOCA) from FWC, 2020 – 2021; Linda K. Manning Fellowship in Ovarian Cancer Research, MDACC, 2021)
- 2019 – 2021 Katherine Foster (Awards won: MDACC Endowed Fellowship Grant, 2022)

2023 - Nazende Bayram

Residents:

1996 - 1997 J. K. Olson (U. Iowa)
 1997 - 1999 Vatche Minassian (U. Iowa)
 1999 - 2000 Sunny Zhang (U. Iowa; Awards won: Won the Best Resident Presentation at the annual University of Iowa Research Day, 2000)
 1999 - 2002 Brian Cooper (U. Iowa; Awards won: Won the Best Resident Presentation at the Mid Atlantic Gynecologic Oncology Society, 2000)
 2000 - 2002 Amy Eichholz (U. Iowa)
 2008 Min Kyu Kim
 2010 - 2011 Antonio Saad (UTMB)
 2018 – Pres Sara Moufarrij (Baylor)
 2018 – Pres Amma Asare (Baylor; Awards won: Won first prize for presentation at annual resident research day; 1st place at the Annual Ralph J Anderson, MD, Texas Association of Obstetricians and Gynecologists Resident Research Day 2020)

Ph.D. Students:

2005 - 2009 Guillermo Armaiz-Pena (Awards won: Ruth L. Kirschstein National Research Service Award, 2006 - 2009; AACR Minority Scholar in Cancer Research Award, 2007; GSBS Student Travel Award for PNIRS meeting, 2008; Third Prize, Research Day, U. T. Health Science Center, Houston, 2008; First Prize – M. D. Anderson Alumni and Faculty Association Graduate Student Award in Clinical/Translational Research, 2009)
 2008 - 2012 Julie Allen (Awards won: The Smith Scholarship, 2008-2010; The Schissler Foundation Award; 2010)
 2010 - 2015 Rajesha Rupaimoole (Awards won: Hawkins Biomarker Discovery Group Fellowship, 2010 - 2013; GSBS Student Travel Award, 2012, 2013, 2014; 2nd Best Oral Presentation, Cancer Biology Program Retreat, 2014; First Place, MD Anderson Alumni & Faculty Association Award in Translational Research, MDACC Trainee Research Day, 2014; GSBS President's Research Scholarship, 2014-2015)
 2012 - 2017 Kshipra Gharpure (Awards won: Altman-Goldstein Discovery Fellowship, 2013; GSBS Student Travel Award, 2014, 2015; Andrew Sowell-Wade Huggins Scholarship in Cancer Research, 2015; 2nd prize for oral presentation, ETAP retreat, 2016)
 2012 - 2017 Archana Sidalaghatta Nagaraja (Awards won: CPRIT Graduate Scholar, 2013; GSBS Student Travel Award, 2014, 2015; Andrew Sowell-Wade Huggins Scholarship in Cancer Research, 2015; GSBS President's Research Scholarship, 2016-2017)
 2013 - 2018 Michael McGuire (Awards won: Cameron International Corporation Fellowship, 2015; Scholarship for Excellence in Biochemistry and Molecular Biology, 2016; Poster award winner, annual cancer biology program retreat, 2017; GSBS Travel Award, 2018)
 2015 - 2016 Merve Ozcan
 2015 - 2018 Alejandro Villar-Prados
 2016 - 2019 Shaolin Ma
 2018 - Qi-yu Yang
 2019 – 2021 Yutuan Wu
 2020 - Emine Bayraktar (Awards won: GSBS Travel Award, 2023)
 2021 - Pahul Hanjra (Awards won: TL1 Training Program grant, 2021-2023; American Legion Auxiliary Fellowship in Cancer Research, 2023; GSBS Travel Award for AACR meeting, 2023)
 2021 - Sujanitha Umamaheswaran

2022 - 2023 Nazende Bayram (Joint student from Abdullah Gul University, Kayseri, Turkey)

M.S. Students:

2012 - 2014 Nouara Sadaoui
 2015 - 2016 Swaminathan Kumar
 2017 - 2019 Sujanitha Umamaheswaran

Medical Students:

1997 - 1998 Yvonne Hsu (University of Iowa)
 1998 Sarah Pertzborn (University of Iowa)
 2003 Robert Bhatti (M. D. Anderson; student from University of Iowa)
 2004 - 2005 Navesh Sharma (M. D. Anderson)
 2005 - 2006 Elizabeth Nugent (M. D. Anderson; student from Baylor College of Medicine)
 2006 - 2008 Pooja R. Patel (M. D. Anderson; student from Baylor College of Medicine)
 2011 Danielle Herder (M. D. Anderson; student from Baylor College of Medicine)
 2012 Nicole Reusser (M. D. Anderson; student from U.T. Houston College of Medicine)
 2015 Zachary Jenner (M. D. Anderson; student from U.T. Houston College of Medicine)
 2015 Margaret Engelhardt (M. D. Anderson; student from U.T. Houston College of Medicine)
 2016 Rebecca K. Grace (M. D. Anderson; student from U.T. Houston College of Medicine)
 2016 Hannah McDonald (M. D. Anderson; student from U.T. Houston College of Medicine)
 2022 Panayiotis Kontoyiannis (MD Anderson; student from UT Houston College of Medicine)

College Students:

2008 Emily Barth (from the College of Wooster, Wooster, OH)
 2008 Andrea Gonzalez (from the University of Puerto Rico)
 2008 – 2009 Sean W. Sessel (from Rice University, Houston, TX)
 2011 Anshumaan Maharaj (from University of Texas, Austin, TX)
 2012 Chang Su (from Davidson College, Davidson, NC)
 2013 Hyang Ki Cho (from Washington University, St. Louis, MO)
 2013 James M. Seymour (from University of Houston, TX)
 2013 Stephanie Pool (from Davidson College, Davidson, NC)
 2014 Kyle Lewellen (from University of Notre Dame, South Bend, IN; funded by CPRIT)
 2015 Emily Nip (from Wellesley College, Wellesley, MA)
 2015 Margaret Stalker (from Davidson College, Davidson, NC)
 2015 Sarah Linesh (from University of Notre Dame, South Bend, IN; funded by CPRIT)
 2016 Ziyu Fan (from Carleton College, Northfield, MN; funded by CPRIT)
 2016 Tyler Pfister (from Davidson College, Davidson, NC)
 2016 Amy Wang (from University of Notre Dame, South Ben, IN; funded by CPRIT)
 2018 Lauren Redfern (from Davidson College, Davidson, NC)
 2019 – 2020 Paul Schwartz (From Tufts University, Boston, MA)
 2019 Anna Linzell (From Davidson College, Davidson, NC)
 2021 Yunah Han (From Davidson College, Davidson, NC)
 2022 Rhea A. Kamat (From University of Texas, Austin, TX)
 2022 Laura Nguyen (From Harvard University, Boston, MA)
 2022 William Gordon (From Halilton College, Clinton, NY)
 2022 Alvaro Goncalves (From Princeton University, Princeton, NJ)
 2022 Andrea Liu (From Davidson College, Davidson, NC)
 2023 Sisy Chen (From Notre Dame, Indiana; funded by University Outreach Summer Program; awards won: University Outreach Program Poster Exhibition Winner)
 2023 Veronica Cabeza de Vaca (From Tufts University, Boston, MA; funded by CPRIT)

2023 Khwahish Sharma (From Davidson College, Davidson, NC)
 2023 Samah Haidar (From Rice University, Houston, TX)

High School Students:

2009 – 2010 Shyon Haghpeykar
 2009 Hannah Gershenson
 2011, 2012 Chandra Kovvali
 2012 Nidhin Sam
 2012 Emily Nip
 2014, 2015 Mythri Ravoori
 2016 Ragini Kondetimmerahalli
 2016 Sunny Patil
 2018 Paul Schwartz
 2018 Jace Duhon
 2019 Puja Iyer
 2021 Abhay Iyer
 2021 Anjali Agrawal
 2021 Julia Williams
 2022 Vishnu Indukuri
 2022 Anjali Agrawal

Physician-Scientists in Laboratory (directly supervised):

2004 – 2006 Tae-Jin Kim (Gynecologic Oncologist from Seoul, South Korea)
 2006 – 2007 Jee-Young Hwang (Gynecologic Oncologist from Seoul, South Korea)
 2007 – 2009 Jeong-Won Lee (Gynecologic Oncologist from Seoul, South Korea)
 2007 – 2009 Charles N. Landen (Mentored under Reproductive Scientist Development Program Award; successfully obtained additional funding from the Ovarian Cancer SPORE (Career Development Award); GCF/Sarah Biedenharn Ovarian Cancer Research Grant, 2009)
 2007 – 2010 Mian Shahzad (Mentored under Women's Reproductive Health Research (WRHR) Career Development Program) (Awards won: GCF/Molly Cade Ovarian Cancer Research Grant, 2007; The SGO Basic Science Poster Award, 41st Annual Meeting on Women's Cancer, San Francisco, CA; J. G. Moore Award for best basic science presentation by a fellow, Annual Meeting of the Western Association of Gynecologic Oncologists, Park City, Utah, 2011)
 2007 – 2010 Edna Mora (Breast Cancer Surgeon from University of Puerto Rico; mentored under Department of Defense Career Development Grant)
 2008 – 2009 Hye Sun Kim (Gynecologic Pathologist from Seoul, South Korea)
 2008 – 2010 Aparna Kamat (Mentored under Women's Reproductive Health Research (WRHR) Career Development Program)
 2008 – 2009 Eun Ji Nam (Gynecologic Oncologist from S. Korea)
 2009 – 2010 Quan Hao (Gynecologic Oncologist from Tianjin Medical University Cancer Institute and Hospital, China)
 2009 – 2011 Masato Nishimura (Gynecologic Oncologist from the University of Tokushima, Japan)
 2009 – 2010 Sun-Joo Lee (Gynecologic Oncologist from the Konkuk University Hospital, South Korea)
 2009 – 2010 Padmavathi Jaladurgam
 2009 – 2010 Ju-Won Roh (Gynecologic Oncologist from Dongguk University Ilsan Hospital, Goyang, Gyeonggi, Republic of Korea)
 2009 – 2010 Duangmani Thanappapasr (Gynecologic Oncologist from Ramathibodi Hospital, Mahidol University, Bangkok, Thailand)
 2010 – 2011 Xudong Liang (Gynecologist from People's Hospital, Peking University, Beijing, China)
 2011 – 2012 Yu Kang (Gynecologist from Fudan University, Shanghai, China)

- 2011 – 2013 Tao Liu (Hepato-biliary surgeon from Wuhan, China)
 2011 – 2012 Jin Hwa Hong (Gynecologic Oncologist from Kangbuk Samsung Hospital, Seoul, Korea)
 2011 – 2014 Takahito Miyake (Gynecologic Oncologist from Osaka University Graduate School of Medicine, Osaka, Japan)
 2014 – 2016 Takeshi Hisamatsu (Osaka University, Osaka, Japan)
 2014 – 2016 Takashi Mitamura (Hokkaido University, Sapporo, Japan)
 2014 – 2016 Yan Huang (Fudan University Shanghai Cancer Center, Shanghai, China)
 2014 – 2016 Fangrong Shen (The First Affiliated Hospital of Soochow University, Suzhou, China)
 2015 – 2016 Ciprian P. Gheorghe (University of Texas, Houston)
 2016 – 2017 Hyun Park (CHA Bundang Medical Center, Korea)
 2016 – 2017 Xiuhui Chen (Harbin Medical University, China)
 2017 – Tomoyuki Sasano (Osaka University Graduate School of Medicine, Osaka, Japan)
 2017 – 2018 Shanshan Yang (Harbin Medical University, China)
 2017 – 2018 Graziela Zibetti Dal Molin (Sao Jose Hospital, Sao Paulo, Brazil)
 2018 – 2020 Yang Li (Zhejiang University, China)

Thesis Committees (for graduate students not listed above):

- 2004 - 2005 Nancy Seibert (M.S.)
 2005 - 2008 Ran Xie (Ph.D. Supervisory Committee)
 2005 - 2007 Bahareh Tavara (M.S.)
 2005 - 2007 Joseph Hernandez (M.S.)
 2006 - 2008 Jennifer M. Brannan (Ph.D. Supervisory Committee)
 2007 - 2008 Sarah Myers (M.S. Committee)
 2007 - 2009 Gabriel J. Villares (Ph.D. Supervisory Committee)
 2007 - 2010 Pavel Levin (Ph.D. Supervisory Committee)
 2009 - 2010 Aman Mann (Ph.D. Examination Committee)
 2009 - 2011 Stephanie Erzinger (M.S.)
 2009 - 2011 Meredith L. Rees (Ph.D. Advisory Committee)
 2010 - 2012 Xue Zhang (Ph.D. Advisory Committee)
 2010 - 2015 Sanchaika Gaur (Ph.D. Advisory Committee)
 2011 - 2015 Sze L. Leung (Ph.D. Advisory Committee)
 2012 - 2015 Suet Yan Kwan (Ph.D. Supervisory Committee)
 2014 - 2018 Xingtong Liu (Ph.D. Advisory Committee)
 2016 - 2019 Neeraj K. Aryal (Ph.D. Advisory Committee)
 2016 - 2019 Estefania Labanca (Ph.D. Advisory Committee)
 2018 - 2020 Kerri Wolf-Dennen (Ph.D. Advisory Committee)
 2018 - Oluwadara Coker (Ph.D. Advisory Committee)

Faculty mentoring:

- 2009 – 2013 Kathleen Schmeler, M.D., MDACC
 2009 – 2012 Wei Hu, M.D., Ph.D., MDACC
 2009 – 2012 Madeline Torres-Lugo, Ph.D., University of Puerto Rico, Mayaguez Campus (Awards funded: U54 Full Project)
 2010 – Yunfei Wen, Ph.D., MDACC (Awards funded: Breast SPORE and Ovarian SPORE Career Developmental Project Awards, 2011, 2012; DOD, 2019 - 2022)
 2010 – 2012 Hee Dong Han, Ph.D., MDACC
 2010 – Xinna Zhang, Ph.D., MDACC
 2010 – 2015 Jung Hae Suh, Ph.D., Rice University (Awards funded: R21, 2015; CPRIT, 2015)
 2011 – 2016 Alpa M. Nick, M.D., MDACC
 2012 – 2013 Chad V. Pecot, M.D., MDACC

- 2013 – 2015 Guillermo Armaiz-Pena, Ph.D., MDACC (Awards funded: Caring Together, NY Ovarian Cancer Research Grant, 2015)
- 2014 – 2017 Sunila Pradeep, Ph.D., MDACC (Awards: AACR Scholar-in-Training Award, 2015; The Liz Tilberis Early Career Award, OCRFA, 2016 – 2019)
- 2015 – 2017 Sherry Wu, Ph.D., MDACC (Awards funded: The Liz Tilberis Early Career Award, OCRF, 2015 – 2018)
- 2014 – 2016 Pradeep C. Raghavan, Ph.D., MDACC (Awards funded: The Liz Tilberis Early Career Award, OCRF, 2015 – 2018)
- 2015 – Mark Seungwook Kim, Ph.D., MDACC (Awards funded: SPORE Career Development Project, 2018)
- 2016 – Sanghoon Lee, Ph.D., MDACC

Faculty mentoring Committee (for faculty not listed above):

- 2011 – 2014 Qiang Shen, M.D., Ph.D., Assistant Professor, Department of Clinical Cancer Prevention
- 2013 – 2015 Ivan Uray, M.D., Ph.D., Assistant Professor, Department of Clinical Cancer Prevention
- 2014 – 2016 Carolyn Hall, Ph.D., Assistant Professor, Department of Surgical Oncology
- 2015 – 2017 Aung Naing, M.D., Assistant Professor, Department of Investigational Cancer Therapeutics

COMMITTEE SERVICE:

University of Iowa

- 1998 – 2000 Task force to review the prescribing, preparation and administration of chemotherapy
- 2000 – 2002 Research Review Committee, Holden Comprehensive Cancer Center
- 2001 – 2002 Grand Rounds Committee, Department of Obstetrics and Gynecology

University of Texas M. D. Anderson Cancer Center

- 2002 – present Tumor Bank Committee, Department of Gynecologic Oncology
- 2003 – present Fellowship Planning Committee, Department of Gynecologic Oncology
- 2003 – 2004 Chairman, Ovarian Cancer Working Group, Department of Gynecologic Oncology
- 2003 – 2004 Member, Multidisciplinary Program Steering Committee, Department of Gynecologic Oncology
- 2003 – 2006 Member, Faculty Senate
- 2003 – 2008 Research Committee, Division of Surgery
- 2004 – present Fellowship Admissions Committee
- 2004 – 2009 Research Affairs Committee
- 2004 – present Executive Committee, Blanton-Davis Ovarian Cancer Research Program
- 2005 Clinical Research Subcommittee of the Faculty Senate
- 2005 – 2006 User Committee for the Analytical Core
- 2006 Judge for Clinical/Translational Research, Trainee Recognition Day
- 2006 – 2008 Grand Rounds Committee, Department of Gynecologic Oncology
- 2005 – present Steering Committee, T32 Training Grant in Gynecologic Oncology
- 2006 – 2010 Office of Academic Affairs' Odyssey Committee
- 2007 – 2009 GOG Operations Committee
- 2007 – 2008 Institutional Biosafety Committee
- 2009 – 2013 Research Council, MDACC
- 2009 – 2013 ASCI/AAP Nomination Committee, MDACC
- 2010 – 2013 The Multidisciplinary Research Advisory Committee (MRAC), MDACC
- 2010 – 2011 Institutional Expense Analysis Research Subcommittee
- 2011 – 2014 Research Laboratory Space Subcommittee

2011 – Present	IAB, CCSG Flow Cytometry/Confocal Microscopy Core Laboratory
2012 – 2016	Advisory Board, CCTS T32
2013	Faculty Achievement Awards Committee
2014 – Present	M.D./Ph.D. Program Board, UTHealth and MD Anderson Cancer Center Graduate School of Biomedical Sciences (GSBS)
2014 – 2017	Institutional Research Executive Committee (IREC), MDACC
2014 – 2019	Technology Task Force, MDACC
2013 – 2016	Endowment Positions and Awards Committee, MDACC
2015 – 2018	Vice Provost Advisory Council (VPAC) on Clinical Research, MDACC
2015 – Present	Sabin Family Foundation Fellow Award Committee, MDACC
2016 – 2017	Search Committee (Vice President, Therapeutics Discovery), MDACC
2016 – 2017	Search Committee (Chair of Department of Symptom Research), MDACC
2017 – Present	Steering Committee, Cancer Biology Program, UT MD Anderson UTHealth Graduate School of Biomedical Sciences
2017 – 2018	MDACC Cancer Symposium Committee (2018)
2020 –	Faculty Grievance Oversight Committee
2022 –	Executive Oversight Committee for the Advanced Microscopy Core facility, MDACC

PROFESSIONAL AND SCIENTIFIC ACTIVITY

1999	Scientific Program Committee, Western Association of Gynecologic Oncologists
1999 – 2002	Candidates Task Force, Society of Gynecologic Oncologists
1999 – present	Gynecologic Oncology Group, Committee on Experimental Medicine
2001 – 2002	Candidate member, Education Committee, Society of Gynecologic Oncologists
2001	Scientific Program Committee, Western Association of Gynecologic Oncologists
2002 – 2010	Member, Education Committee, Society of Gynecologic Oncologists
2003 – 2005	Member-at-Large, Western Association of Gynecologic Oncologists
2004	Scientific Program Committee, Combined meeting of the Western Association of Gynecologic Oncologists and the Felix Rutledge Society
2002 – present	Member, Women's Cancer Network (WCN) Editorial Committee, Gynecologic Cancer Foundation
2005 - 2009	Committee on preparation of the 2006 Gynecologic Oncology (GO) written examination, American Board of Obstetrics and Gynecology, Dallas, TX
2005 – 2008	Task Force on Behavioral Science and Cancer, American Association for Cancer Research
2006	Scientific Program Committee, Society of Gynecologic Oncologists (Chair, Ovarian Section)
2006 – present	Executive Committee, Reproductive Scientist Development Program
2006	Scientific Program Committee, 11 th Biennial Meeting of the International Gynecologic Cancer Society, Santa Monica, CA
2006 – 2010	Member, Gynecologic Cancer Scientific Steering Committee (GCSC) of the National Cancer Institute (NCI)
2006 – 2007	Program Steering Committee, U54 Puerto Rico Cancer Center/M. D. Anderson Cancer Center Partnership for Excellence in Cancer Research
2006 – 2008	Chair, Reproductive Scientist Development Program Scholars' Fund Committee
2007 – 2012	Awards Committee, Gynecologic Cancer Foundation
2007	Organizing Committee, the 37 th Annual Meeting of the Felix Rutledge Society, Houston, TX
2007 – 2012	Chairman, Internal Advisory Committee, U54 Puerto Rico Cancer Center/M. D. Anderson Cancer Center Partnership for Excellence in Cancer Research
2008 – 2012	External Advisory Board, Ovarian cancer SPORE, Fox Chase Cancer Center
2009	Scientific Program Committee, American Association for Cancer Research (100 th meeting;

- Experimental and Molecular Therapeutics Section), Denver, CO
- 2009 Invited Judge for Resident Research Day, Medical University of South Carolina, Charleston, SC.
- 2009 – 2010 External Advisory Board, Ovarian cancer SPORE Application, Memorial Sloan-Kettering Cancer Center
- 2009 – 2015 Faculty, Vail Methods in Clinical Cancer Research Workshop sponsored by ASCO and AACR, Vail, CO
- 2010 – 2014 Member, Membership Committee, Society of Gynecologic Oncologists
- 2009 – 2012 External Advisory Board, Ovarian cancer SPORE, Mayo Clinic, Rochester, MN
- 2010 – 2015 Internal Advisory Board, Breast Cancer SPORE, M. D. Anderson Cancer Center
- 2010 – 2017 Co-Organizer, Biobehavioral Research Network, NCI
- 2010 – 2013 Member, Ovarian Task Force for the Gynecologic Cancer Scientific Steering Committee (GCSC) of the National Cancer Institute (NCI)
- 2010 – 2011 Chairman, Ovarian Cancer Section - Research Summit, Society of Gynecologic Oncologists
- 2011 Faculty Leadership Academy, M. D. Anderson Cancer Center
- 2012 Clinical Trials Committee, 2012 Annual meeting of the American Association for Cancer Research
- 2012 – 2021 Chairman, Awards Committee, Foundation for Women's Cancer
- 2012 - 2013 Scientific Program Committee and Steering Committee, 44th Annual Meeting on Women's Cancer (SGO, 2013)
- 2013 – 2016 Scientific and Medical Advisory Board, Ovarian Cancer National Alliance
- 2013 Chair, Education Session: Pathways in Gynecologic Malignancies, 2013 Annual Meeting of the American Society of Clinical Oncology
- 2013 - 2015 AACR Surgical Oncology Task Force
- 2014 - 2016 External Advisory Committee, Department of Biomedical Engineering, Rice University
- 2014 – 2015 Institute of Medicine Committee on the State of the Science in Ovarian Cancer Research
- 2015 – 2016 Scientific Program Committee, 47th Annual Meeting on Women's Cancer (SGO, 2016)
- 2015 Session Chairman: Metastatic Cell Plasticity, An AACR Special Conference on Tumor Metastasis
- 2015 – 2016 Search Committee for Vice President, Therapeutics Discovery
- 2015 – Judy's Mission Advisory Committee, The Judith Liebenthal Robinson Ovarian Cancer Foundation
- 2015 – 2019 Member, External Advisory Board, Carolina Center of Cancer Nanotechnology Excellence, University of North Carolina
- 2016 NCI GCSC Clinical Trials Planning Meeting on Moving Forward in Endometrial Cancer: Designing Targeted Trials for Targeted Endometrial Cancer Populations using Targeted Agents, Rockville, MD
- 2016 – 2018 Program Committee and Executive Advisory Board Member, The Nano/Molecular Medicine and Engineering Conference
- 2016 Panel on Opportunities for Cancer Prevention during Early Adulthood: Putting Scientific Evidence into Public Health Practice. Centers for Disease Control (CDC) and the National Association of Chronic Disease Directors (NACDD), Atlanta, GA
- 2016 – Scientific Advisory Committee, Ovarian Cancer Research Fund Alliance (OCRFA)
- 2016 – 2018 Member, Fellowship Committee, American Gynecological & Obstetrical Society
- 2017 Ad hoc reviewer, External Advisory Board (EAB), Dana Farber/Harvard Cancer Center
- 2018 – 2020 Nominating Committee, Society of Gynecologic Oncology
- 2018 Member, FDA-AACR-SGO Workshop on Drug Development in Gynecologic Malignancies
- 2019 – 2022 Member, Conquer Cancer Foundation Grants Selection Committee, ASCO
- 2019 – 2020 Member, Research Task Force, SGO

2019	Workshop on “Difficult questions in ovarian cancer research”, IARC and NCI, Lyon, France
2020 – 2022	Member, Honors & Awards Committee, SGO
2020 – present	Chair, Executive Committee, Reproductive Scientist Development Program
2020 – 2021	Research Management Task Force, SGO
2021 – 2024	Board of Directors, Society of Gynecologic Oncology (SGO)
2021 – 2022	Scientific Program Committee, and Co-Chair of Master Session on Ovarian Cancer, International Gynecologic Cancer Society (IGCS) 2022 Annual Global Meeting
2022 – 2025	Pelotonia-AACR Women’s Cancer Initiative Scientific Advisory Committee (SAC), AACR
2022 – present	NCI NCTN Core Correlative Sciences Committee (NCTN-CCSC)
2023 – present	Gynecologic Oncology Group (GOG) Partners Investigators Council (IC), Translational Research (TR) Sub-Committee

GRANT REVIEW SERVICE

2000 – 2002	The University of Iowa Holden Comprehensive Cancer Center Grant Review Committee
2004 – 2007	Member, Veterans Affairs Medical Research Service Merit Review Study Section (Endocrinology-A)
2005	Sheffield Hospitals Charitable Trust, UK (Ad hoc reviewer)
2006	National Institutes of Health, Small Grants in Behavioral Research in Cancer Control (ZCA1 SRRB-D; Ad hoc reviewer)
2004 – 2006	National Institutes of Health, MESH study section (Temporary Member)
2006	United States-Israel Binational Science Foundation (Ad hoc reviewer)
2006	National Institute of Allergy and Infectious Diseases Special Emphasis Panel (ZAI1 QV-I (M1; Ad hoc reviewer)
2007	Breakthrough Breast Cancer (United Kingdom)
2007	Ovarian Cancer Action (United Kingdom)
2007	Center for Targeted Therapy (M. D. Anderson Cancer Center)
2008	National Institutes of Health, Cancer Biomarkers Study Section (CBSS; Ad hoc reviewer)
2009	National Institutes of Health, RC1 Challenge Grants (OTC-K (58) R; BBBP-J (58) R; BDA-A (58) R; BBBP-L (58) R; Ad hoc reviewer)
2009 – 2015	National Institutes of Health, Cancer Biomarkers Study Section (CBSS; Permanent member)
2010	National Institutes of Health, ZRG1 DTCS-A (81) – CSR Special Emphasis Panel
2011	Ovarian Cancer Research Fund
2011 – Present	The Marsha Rivkin Center for Ovarian Cancer Research Grant Review Panel
2016	National Institutes of Health, Tumor Progression and Metastasis Study Section (TPM)
2018	Co-Chair, National Cancer Institute, ZCA1 RPRB-J (M1) SPORE III study section
2019	NIH ZRG1 BCMB-N (50) R – Pioneer Award Review
2020	NIH Cancer Diagnostics and Treatments (CDT) SBIR/STTR Special Emphasis Panel (ZRG1 OTC-H13)
2022	NCI Outstanding Investigator Award (R35) Study Section
2022	AACR Diversity, Equity, and Inclusion Grants Scientific Review Committee
2023	Chair; The Terry Fox Research Institute (TFRI) Program Project Grant (PPG) Site Visit, Sunnybrook Research Institute, Toronto, ON
2023	Co-Chair; NCI SEP-9: NCI Clinical and Translational Cancer Research review meeting (R03/R21) (ZCA1 RTRB-S (O1) S)

ORGANIZER OR CO-ORGANIZER OF NATIONAL/INTERNATIONAL MEETINGS

2004	“Advanced Laparoscopy for the Gynecologic Oncologist”, The 35 th Annual Meeting, Society
------	---

- of Gynecologic Oncologists, San Diego, CA
- 2004 “Reconstructive Surgery”, The 35th Annual Meeting, Society of Gynecologic Oncologists, San Diego, CA
- 2004 Chairman, the Fifth Annual International Conference on Ovarian Cancer, Houston, TX
- 2005 Chairman, Scholars’ Research Conference, Reproductive Scientist Development Program, Santa Fe, NM
- 2006 Postgraduate Course Director, “‘Targeting’ Targeted Therapy in Gynecologic Cancers”, The 37th Annual Meeting, Society of Gynecologic Oncologists, New Orleans, LA.
- 2006 Planning Committee, The 7th Annual International Conference on Ovarian Cancer, Houston, TX
- 2007 Mini-symposium Director, “Vascular Targeting for Gynecologic Malignancies and other Gynecologic Disorders”, The 54th Annual Meeting, Society for Gynecologic Investigation, Reno, NV.
- 2008 Co-Organizer, “Biobehavioral influences on tumor biology: Preclinical models of neuroendocrine regulation”. A Think Tank Sponsored by the National Cancer Institute Division of Cancer Control and Population Sciences and the Division of Cancer Biology. Bethesda, MD.
- 2009 Co-Course Director, the Eighth Annual International Conference on Ovarian Cancer, Memorial Sloan-Kettering Cancer Center, New York, NY.
- 2010 Co-Chair, “PNI at the Translational Interface”, The 17th Annual Meeting of the Psychoneuroimmunology Research Society, Dublin, Ireland.
- 2011 Chairman, Major Symposium, “Neuroendocrine Influences on Cancer Progression”, the 102nd Annual Meeting of the American Society for Cancer Research, Orlando, FL.
- 2011 Chairman, Educational Symposium, “What is individualized medicine”, the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), Vancouver, Canada.
- 2013 Chair, Panel on “Social origins of adverse health outcomes”. The American Gynecological and Obstetrical Society, Chicago, IL.
- 2014 Co-Chair, Session on “Role of platelet, tumor, and vascular biology in cancer-related thrombosis”. NHLBI and NCI Strategic Working Group: Cancer and Thrombosis, Bethesda, MD.
- 2014 Chair, Symposia on Cancer Research 2014. “Illuminating Genomic Dark Matter: ncRNA in Disease and Cancer”. MD Anderson Cancer Center, Houston, TX.
- 2017 Co-Chair, An AACR Special Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment. Pittsburgh, PA.

CLASSES TAUGHT:

- 2004 – Present Cancer Cell Signaling (GS04 0133), University of Texas, Houston, Graduate School of Biomedical Sciences
- 2010 – Present Bio-behavioral research methods in cancer prevention and addiction (GS219921/PH), University of Texas, Houston, Graduate School of Biomedical Sciences
- 2019 “Metabolism in cancer”, BIOC-302, Rice University

GRANTS AND FUNDING:

Past funding:

1. Type Specific Detection of Human Papillomavirus (HPV) in Cervical Neoplasia. Southern Medical Association Research Project Grant
\$2,400 1988 – 1989
Principal Investigator (Mentor – Jay Stoerker, Ph.D.)

2. Human Papillomavirus (HPV) DNA in LEEP Plume
Southern Medical Association Research Project Grant
\$2,400 1992 – 1993
Principal Investigator (Mentor – I. Keith Stone, M.D.)
3. Genomic Instability: Why the Guardian Fails in Ovarian Cancer
ACOG/Ortho Academic Training Fellowship Grant
\$30,000 1997 – 1998
Principal Investigator (Mentor – Richard E. Buller, M.D., Ph.D.)
4. The Use of Anorectal Manometry to Assess Rectal Dysfunction in Patients following Radical Hysterectomy
American Cancer Society Seed Grant to Dr. Ingrid Nygaard
\$20,000 1997 - 1998
Co-Principal Investigator with Ingrid Nygaard, M.D.
5. Distant Metastases in Ovarian Cancer
American Cancer Society Seed Grant
\$20,000 1998 – 1999
Principal Investigator
6. A Randomized, Double-Blind, Placebo-Controlled, Phase IIB Study of the Safety and Efficacy of OVAREX™ Mab-B43.13 in Ovarian Cancer Patients with an Elevated Serum CA 125 but without Other Evidence of Disease
ALTAREX Corporation
\$50,000 1999 – 2001
Principal Investigator
7. Phase II Trial of Intraperitoneal Topotecan/Oral Etoposide in Ovarian Cancer
SmithKline Beecham, Inc.
\$50,000 1999 – 2001
Principal Investigator
8. Molecular Mechanisms Resulting in Distant Metastases in Ovarian Cancer
Reproductive Scientist Development Program
\$200,000 1999 - 2001
Principal Investigator (Mentor – Mary J. C. Hendrix, Ph.D.)
9. ON-Q Pain Management System in Patients Undergoing Abdominal Surgery for Gynecologic malignancies
Ethicon Endo-Surgical (EES)
\$45,000 2000
Co-Principal Investigator with Mark Shahin, M.D.
10. Biobehavioral-immune interactions in ovarian cancer
NIH R21 CA88293-01 Grant 2000 - 02
Co-Investigator – 5% effort
Principal Investigator: Susan Lutgendorf, Ph.D.
11. Role of FAK expression in invasion and cisplatin resistance in ovarian cancer.

Gynecologic Cancer Foundation/National Ovarian Cancer Coalition Award.
\$50,000 2001
Principal Investigator

12. Development of teaching materials regarding operative dictations for residents and medical students.

Council on Teaching, University of Iowa
\$850 2002
Principal Investigator

13. Hormonal stimulation of tumor angiogenesis in ovarian cancer
Obermann Center for Advanced Studies Interdisciplinary Research Grant
\$12,000 2002
Co-Principal Investigator with Susan Lutgendorf, Ph.D.

14. Functional role of MMPs in ovarian tumor cell plasticity properties
U. T. M. D. Anderson Cancer Center Ovarian Cancer SPORE
Career Development Award
\$75,000/year 2002 - 2004
Principal Investigator

15. Neuroendocrine Regulation of VEGF and IL-6 in Ovarian Carcinoma
The Donna Marie Cimitile Fotheringham Award for Ovarian Cancer Research
\$50,000 2002 – 2004
Principal Investigator

16. Role of Focal Adhesion Kinase on Taxotere activity in ovarian cancer
Aventis, Inc.
\$67,584.00 (total cost) 08/01/03 – 08/31/04
Principal Investigator

17. Molecular Mechanisms of Ovarian Cancer Plasticity
Reproductive Scientist Development Program
\$240,000 2001 - 2005
Principal Investigator

18. Biobehavioral-cytokine interactions in ovarian cancer
NIH R01-CA1045-01 (Supplement)
\$152,116 (direct cost) 10/1/04 - 9/30/06
Co-Investigator, 5% effort (PI - Susan Lutgendorf, Ph.D.)

19. Anti-vascular effects of AVE8062 in ovarian carcinoma
Sanofi-Aventis, Inc.
\$123,006.00 (total cost) 11/01/04 – 12/30/06
Principal Investigator

20. Role of EphA2 in ovarian cancer development and progression
Department of Defense (W81XWH-04-1-0227)
\$375,000 (direct cost) 2004 – 2008
Principal Investigator, 15% effort

21. Novel siRNA based therapeutic approaches for ovarian carcinoma
Program Project Development Grant, Ovarian Cancer Research Fund, Inc.
\$900,000 (direct cost) 12/31/05 – 12/30/08
Overall Principal Investigator and PI of Project 1
22. Cell-specific targeting of ovarian cancer vasculature (Project 2 – UT MDACC SPORE in Ovarian Cancer)
NIH 2 P50 CA083639-06A1
\$688,227 (direct cost) 09/01/05 – 08/31/10
Principal Investigator
23. Tumor metastasis: Biobehavioral mechanisms
NIH R01-CA110793-01
\$1,485,575 (direct cost) 9/30/04 - 9/30/11
Principal Investigator
24. Synergistic effects of CXCR4 and FAK in ovarian cancer progression and metastases
DOD OC073399 (Grant 00325350)
\$300,000 (direct cost) 05/09/2008 – 05/08/2011
Mentor for Edna Mora (PI)
25. Novel siRNA based therapeutic approaches for ovarian carcinoma
Program Project Development Grant, Ovarian Cancer Research Fund, Inc.
\$900,000 (direct cost) 03/01/09 – 02/28/13
Overall Principal Investigator and PI of Project 2
26. Identification and Validation of Biomarkers for Predicting Therapeutic Response to VEGF.
DOD W81XWH-10-1-0158
05/01/10-04/30/13
Role: Principal Investigator
27. Nanovectors for characterization and destruction of breast tumor vasculature
NIH R01-CA128797
\$100,000 (annual direct costs for subcontract) 08/30/2008 – 07/31/2012
Co-Investigator (PI: Mauro Ferrari)
28. Toward individualized breast cancer therapy: leveraging molecular medicine with multistage vector technology.
DOD Innovator Award BC085265 (W81XWH-08-BCRP-INNOV)
\$458,040 (direct cost) 03/01/2009 – 02/28/2014
Co-Investigator (PI: Mauro Ferrari)
29. R44 GM084442-03
09/01/10-08/31/13
Title: New Reagents for Synthesis of High Potency siRNAs
Role: Co-Investigator
Yang (PI)
30. BCM/MDACC MRP
01/01/11-12/31/13
Wah and Sood (MPI)

Title: Role of platelets in ovarian cancer pathogenesis
 Role: Principal Investigator

31. OC100237/DOD S. Izraeli (PI) 09/01/2011-08/31/2013
 Title: Disrupting BRCA1/2 DNA Damage Response by Blocking the Centrosomal Protein STIL(SIL): A novel strategy for treatment of ovarian cancer
 Role: Co-Investigator

32. Anti-vascular therapy for ovarian cancer
 The Marcus Foundation
 \$1,387,040 (direct cost) 8/1/06 – 9/15/15
 Principal Investigator

33. R01 CA142969-01A1 Shureiqi (PI) 07/01/10-08/30/15
 Title: Molecular Targeting of PPAR-delta in colon cancer
 Goal: The goal is to improve understanding of the molecular mechanisms by which PPAR-d contributes to aspects of colon cancer development, especially the ability of tumors to make new blood vessels.
 Role: Co-Investigator

34. OC12054707/01/13 – 08/30/16
 Consortium to study long-term survivors of ovarian cancer (Development of Ovarian Cancer Outcome Consortium)
 \$620,669.66 (overall cost)
 Role: Principal Investigator

35. Targeting Dll4-Notch signaling in ovarian cancer (Project 2 - UT MDACC SPORE in Ovarian Cancer)
 NIH 2 P50 CA083639-11
 \$1,365,921 (direct cost) 09/01/10 – 08/31/16
 Principal Investigator

36. RP110595-P2 (Multi-PI) Bast, Sood, White 06/01/11 – 05/31/17
 Title: Circumventing Platinum Resistance Using siRNA Transfer
 Goals: Improving the primary therapy for ovarian cancer- by testing methods for “Circumventing Primary Carboplatin Resistance using siRNA and miRNA Transfer” by knocking down copper transporters (ATP7, ATP11B) to reverse cisplatin resistance.
 Role: Principal Investigator – Project 2

37. Power of platelets in ovarian cancer
 Program Project Development Grant, Ovarian Cancer Research Fund, Inc.
 \$900,000 (direct cost) 03/01/13 – 02/28/17
 Overall Principal Investigator and PI of Project 2

38. Texas Center for Cancer Nanomedicine
 NIH 1U54 CA151668-01
 \$15,961,171 (total direct costs) 09/01/2010 – 08/31/2017
 Principal Investigator (MPI) and Project 2 Leader

39. Ovarian Cancer: Mechanisms of neuroendocrine regulation

NIH R01-CA109298
 \$1,124,626 (direct cost) 4/1/14 – 8/30/17
 Principal Investigator, 25% effort

40. Microenvironmental control of premalignant lesions in ovarian cancer
 Program Project Development Grant, Ovarian Cancer Research Fund Alliance, Inc.
 \$900,000 (direct cost) 03/01/15 – 02/28/18
 PI of Project 2

41. RP120214 (Coleman) 12/1/2011 – 11/30/2018 (NCE)
 CPRIT \$165,000 (annual direct costs)
 Title: Clinical Translation of Therapeutic siRNA in Solid Malignancies
 The major goal of this project is to demonstrate the ability to therapeutically silence EphA2 in human tumor via a systematically delivered siRNA-based nanovector

42. UH3 TR000943 07/15/13 – 07/14/19
 Novel Extra Cellular RNA-Based Combinatorial RNA Inhibition Therapy
 \$3,997,494 (total award)
 Role: Principal Investigator (Contact) (MPI: Sood, Calin, Lopez)

43. DP 150091 (Lacko) 12/1/2014 – 8/30/2018 (NCE)
 CPRIT \$120,160 (annual direct costs)
 Title: *Selective Tumor Delivery of Anti-Cancer Agents in Ovarian Cancer Therapy*
 The major goal is to use rHDL nanoparticles for cancer therapy.

44. R01 CA177909 07/24/13 – 06/30/18
 Platelets promote growth of ovarian cancer
 \$1,975,000 (total award)
 Role: Multiple PI (Afshar-Kharghan and Sood)

Active Funding:

R35 CA209904 08/02/2017 – 07/31/2024
 NCI \$600,000 (annual direct costs)
 Title: Harnessing the power of exosomes for non-coding RNA delivery
 Role: PI

American Cancer Society Research Professor Award (RP-16-240-01-TBG) 1/1/17 – 12/31/21
 Non-coding RNA cancer therapeutics
 \$400,000 (Annual direct costs)
 Role: PI

The role of macrophages in resistance to anti-VEGF drugs in ovarian cancer (Project 3 - UT MDACC
 SPORE in Ovarian Cancer)
 NIH P50 CA217685
 \$231,000 (annual direct costs) 09/01/17 – 08/31/22
 Overall MPIs (Bast and Sood) and PI of Project 3

EphA2 targeting in uterine carcinoma (Project 3 - UT MDACC SPORE in Uterine Cancer)
 NIH 2 P50 CA098258-06A2

\$1,104,876 (direct cost) 09/01/16 – 08/31/21
Role: PI of Project 3

R01 CA177909 12/01/18 – 11/30/23
Platelets promote growth of ovarian cancer
\$80,000 (annual direct costs)
Role: Multiple PI (Afshar-Kharghan and Sood)

Gateway Foundation (Grant No. G-16-100) 07/01/16 – 6/30/19
Targeting adaptive changes following anti-angiogenesis therapy in ovarian cancer
\$800,000 (total award)
Role: Co-PI (PI: Westin)

V-Foundation Award
Adaptation to anti-angiogenesis therapy
\$600,000 (total award)
Role: Co-PI (PI: Rob Coleman)

Biobehavioral-cytokine interactions in ovarian cancer
NIH R01-CA1045
\$1,266,373 (direct cost) 6/01/16 - 5/30/21
Role: Co-Investigator, 5% effort (PI - Susan Lutgendorf, Ph.D.)

U01 CA213759 06/01/2017 – 05/31/2022
NIH \$373,498 (annual direct costs)
Title: Targeted Therapeutics for Ovarian Cancer and Its Microenvironment - treatment and theoretical modeling
Role: MPI (Lopez, Sood)

R01 CA227622
\$50,125 (Annual direct costs) 08/01/2018 – 07/31/2023
Title: Targeting Stromal Influences on Glutamine Addiction in Ovarian Cancer.
Role: Co-I (PI: Nagrath)

RP180381
\$119,795 (annual direct costs) 03/01/2018 – 02/28/2021 (NCE till 2022)
Title: Mass Spectrometry Imaging to Uncover Predictive Metabolic Markers of Ovarian Cancer Surgical Outcome and Treatment Response.
Role: Co-I (PI: Eberlin)

R01 CA229907 7/1/2019 – 06/30/2024
NCI
\$117,740 (Direct costs)
Title: Role of RNA activation in Tumor Progression and Metastasis
Role: Co-I (PI: Chaluvally-Raghavan)

PATENTS AND TECHNOLOGY LICENSES

- Delivery of siRNA by neutral lipid compositions, M. D. Anderson Cancer Center, U. S. Provisional Patent Application No. 60/671,641 (filing date: April 15, 2005). (Australian patent number 2006236453)

- issued February 23, 2012; U.S. patent number 8,895,717 issued November 25, 2014).
- Methods for treating cancer targeting transglutaminase (filed October 5, 2007; Issued: October 30, 2012; Patent number 8299040).
 - Pro-angiogenic gene in ovarian tumor endothelial cell isolates (filed: December, 2006; Issued: May 14, 2013; Patent number 8440393).
 - Therapeutic targeting of Interleukins using siRNA in neutral liposomes (Issued November 29, 2011; Patent number: US 8,067,390 B2)
 - HDL nanoparticles for delivery of nucleic acids (filed: December, 2007; Issued: May 27, 2014; U.S. Patent Number 8,734,853)
 - Methods and Composition of Matter Related to Wrapping of Dehydrons (filed: October, 2007; Issued: June 18, 2013; U.S. Patent Number 8,466,154 B2)
 - Assessment of platelet ultrastructure for cancer diagnosis (MDA11-012; filed: November, 2010)
 - Novel tissue protective erythropoietin receptor (NEPOR) and methods of use (European patent number 2 109 690; issued March 22, 2012)
 - Multifunctional CuS nanoparticles with efficient renal clearance and low liver retention (filed: May, 2014)
 - EGFL6 specific monoclonal antibodies and methods of their use (filed: February 2017; issued December 29, 2020; U.S. Patent Number 10,875,912)
 - Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer (Inventors: Pablo E. Vivas-Mejia, Jeyshka M. Reyes Gonzalez, Anil K. Sood); U.S. Patent Number 11090266 (Filed February 3, 2020; issued August 17, 2021)
 - Hybrid exosomal-polymeric (HEXPO) nano-platform for delivery of RNAi therapeutics (filed: February, 2017)
 - Nuclear-derived exosomes and methods of use thereof (provisional filed: April, 2019)
 - Dual assembly nanoparticles (Issued December 29, 2020; U.S. Patent Number 10,874,622 B2)
 - CD5L aptamer S76.T blocks tumor angiogenesis (Filed: April 1, 2021)
 - Antibodies against CD5L for therapeutic and diagnostic uses (Filed: April 2, 2020)

BOOK CHAPTERS:

1. Sorosky JI, Sood AK, Buekers TE (1997). The use of chemotherapeutic agents during pregnancy. *Obstetrics and Gynecology Clinics of North America* 24(3):591-9.
2. Sood AK, Sorosky JI (1998). Invasive cervical cancer complicating pregnancy: How to manage the dilemma. *Obstetrics and Gynecology Clinics of North America* 25(2):343-352, 1998.
3. Sood AK, Buller RE (2000). SSCP and sequence analysis of p53 mutation in ovarian tumors. *Methods in Molecular Medicine: Ovarian Cancer Methods and Protocols*, pp 323-328, Humana Press, New Jersey.
4. Sood AK (2002). Genetics and Cancer. *Women's Cancer Network Website* chapter.
5. Sood AK, Gershenson DM (2006). Management of early-stage ovarian cancer (Chapter 3). *Surgery for ovarian cancer: Principles and practice*, Parthenon Publishing. Pages 57 - 86.
6. Sood AK, Lutgendorf SK, Cole SW (2006). Neuroendocrine regulation of cancer progression: I. Biological Mechanisms and Clinical Relevance. *Psychoneuroimmunology (Fourth Edition)*: Chapter 11, 233-249.

7. Lin YG, Jaffe RB, Sood AK (2007). Prognostic and predictive implications of angiogenesis in ovarian carcinoma. *Prognostic and Predictive Factors in Gynecologic Cancers*, Taylor & Francis Group. Chapter 6, 83-100.
8. Lu C, Sood AK (2007). Role of pericytes in angiogenesis. *Angiogenesis Agents in Cancer Therapy (Second Edition)*, The Humana Press, Inc., New Jersey. Chapter 7, 117-132.
9. Mangala LS, Han HD, Lopez-Berestein G, Sood AK (2009). Liposomal siRNA for ovarian cancer. *Methods in Molecular Biology: Therapeutic Applications of RNAi*. Humana Press, New Jersey, https://doi.org/10.1007/978-1-60327-295-7_3; 555:29-42.
10. Nick AM, Coleman RL, Sood AK (2009). Molecular therapeutics in ovarian carcinoma. *Ovarian Cancer: State of the Art*. Remedica Medical Education and Publishing Limited, London, UK. Chapter 5, pages 109-160.
11. Maxwell GL, Berchuck A, Sood AK (2009). Biology and Genetics. *Practical Gynecologic Oncology (5th edition)*. Editors: Jonathan S. Berek and Neville F. Hacker. Lippincott Williams & Wilkins, Philadelphia, PA. Chapter 1, pages 2 - 40.
12. Stone RL, Sood AK. Status of targeted/molecular therapy for ovarian cancer. *Ovarian Cancer: Ask the Experts*. Humana Press, Inc., Totowa, NJ, In Press.
13. Allen JK, Armaiz-Pena G, Sood AK (2010). Stress and Cancer. In: *The M. D. Anderson Manual of Psychosocial Oncology*. Editors: James D. Duffy, Alan D. Valentine. McGraw Hill, Syracuse, NY. Chapter 2, pages 17-34.
14. Han LY, Sood AK (2011). Inhibition of the Src oncogene: Therapeutic potential in ovarian carcinoma. *Emerging Therapeutics in Cancer*, Chapter 5; DOI:10.1007/978-1-4419-7216-3_5 (Print ISBN 978-1-4419-7215-6)
15. Mora EM, Mangala LS, Lopez-Berestein G, Sood AK. RNAi: A new paradigm in cancer gene therapy. In: *Gene based therapies for Cancer*, Springer, Chapter 1; DOI:10.1007/978-1-4419-6102-0_1 (Print ISBN 978-1-4419-6101-3).
16. Matsuo K, Lu C, Shahzad MMK, Coleman RL, Sood AK (2010). Role of pericytes in resistance to antiangiogenic therapy. In: *"The Tumor Microenvironment"*, Springer, New York, NY. Editors: Beverly A. Teicher and Rebecca G. Bagley. Chapter 15, pages 311-324.
17. Sood AK, Matsuo K, Gershenson DM. Management of early-stage ovarian cancer – 2nd Edition. *Surgery for ovarian cancer: Principles and practice*, Parthenon Publishing. *In Press*.
18. Thaker PH, Sood AK (2012). Chapter 26 – Immunology and Molecular Oncology in Gynecologic Cancer: Immunologic Response, Cytokines, Oncogenes, and Tumor Suppressor Genes. In: *Comprehensive Gynecology (6th edition)*. Editors: Lentz, Lobo, Gershenson, and Katz. Elsevier, Philadelphia, PA. Pages 623-634.
19. Costanzo E, Sood AK, Lutgendorf SK (2010). Biobehavioral influences on cancer progression. Editor: Gailen D. Marshall. In: *Stress and Inflammatory Diseases in Immunology and Allergy Clinics of North America*. 31(1):109-132.

20. Lutgendorf SK, Costanzo E, Sood AK. Psychoneuroimmunology and cancer: Biobehavioral influences on tumor progression. *The Oxford Handbook of Psychoneuroimmunology*. In Press
21. Ahmed AA, Knapp S, Sood AK, Bast RC (2011). Targeting therapies in cancer: Opportunities in Ovarian cancer. In: *Gynecological Cancers: Biology and Therapeutics*, RCOG Press, London, UK. Editors: Sean Kehoe, Richard J. Edmondson, Martin Gore, Iain McNeish. Chapter 13, pages 167-182.
22. Westin SN, Sood AK, Coleman RL (2012). Targeted therapy and molecular genetics (Chapter 18). In: *Clinical Gynecologic Oncology* (8th edition). Editors: Philip J. DiSaia, William T. Creasman, Robert S. Mannel, D. Scott McMeekin, and David G. Mutch. Elsevier, Philadelphia, PA. Pages 539 - 560.
23. Aslan B, Han HD, Lopez-Berestein G, Sood AK (2012). Chitosan nanoparticles. In: *Encyclopedia of Nanotechnology*. Editor: Bharat Bhushan. Springer, Dordrecht. DOI: 10.1007/978-90-481-9751-4_71 (Print ISBN 978-90-481-9750-7)
24. Chen A, Zhaoxia D, Sood AK, Hu W (2011). Ovarian cancer hormonal therapy. In: *Encyclopedia of Cancer*. Editor: Manfred Schwab. Springer, Berlin, Heidelberg. DOI: 10.1007/978-3-642-16483-5_6991 (Print ISBN 978-3-642-16482-8)
25. Alpay SN, Ozpolat B, Han HD, Lopez-Berestein G, Sood AK, Pan HL (2012). Delivering siRNA using nanoparticles to the central nervous system. In: *Nanomedicine and the Nervous System*. Editors: Colin R. Martin, Victor R. Preedy, Ross J. Hunter. Science Publishers, Enfield, pages 228 – 249.
26. Fleming ND, Coleman RL, Sood AK. Targeted therapies in ovarian cancer. Clinical Decisions Support Project. In Press
27. Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK (2013). RNAi in Cancer Therapy. In: *Advanced delivery and therapeutic applications of RNA interference* (Chapter 13). Editors: Kun Cheng and Ram I. Mahato. John Wiley & Sons, Inc. Pages 271-307.
28. Thaker PH, Sood AK. Molecular pathogenesis of ovarian cancer (Chapter 13). In: *Current Multidisciplinary Oncology: Gynecologic Cancer*. Editors: Tanja Pejovic and Kunle Odunsi. Demos Medical Publishing (New York), pages 95-104.
29. Taylor M, Coleman RL, Sood AK (2015). The role of angiogenesis in cancer. In: *Targeted Therapy in Translational Cancer Research*. Editors: Apostolia-Maria Tsimberidou, Razelle Kurzrock, and Kenneth C. Anderson. Publisher: JohnWiley & Sons, Pages 64 – 71.
30. Jiang D, Mangala LS, Rodriguez-Aguayo C, Gorenstein D, Lopez-Berestein G, Sood AK (2015). Targeting approaches for nanoparticles. In: *Nanoparticles for Delivery of Biotherapeutics*. Editors: Drs. Josh Ramsey and Laird Forrest. Future Science Group, London, UK. Pages 64-77.
31. Zhang X, Lopez-Berestein G, Sood AK, Calin GA (2016). Profiling long-non coding RNA expression using custom-designed microarray. *Methods in Molecular Biology* 1402:33-41.
32. Hatakeyama H, Wu SY, Mangala LS, Lopez-Berestein G, Sood AK (2016). Assessment of *in vivo* siRNA delivery in cancer mouse models. In: *Long non-coding RNA: Methods and protocols*. *Methods in Molecular Biology*. Editors: Yi Feng and Lin Zhang. Humana Press, New York, NY. Chapter 15,

pages 189 - 197.

33. Liang L, Mercado-Uribe I, Niu N, Jiang Y, Cheng W, Mills GB, Scott C, Sood AK, Liu J (2017). Patient-derived xenograft models of ovarian/gynecologic tumors. In: Patient Derived Tumor Xenograft Model. Editors: Drs. Raj Uthamanthil and Peggy Tinkey. Elsevier, Philadelphia, PA, pages: 257 – 272.
34. Menter DG, Davis JS, Tucker SC, Hawk E, Crissman JD, Sood AK, Kopetz S, Honn KV (2017). Platelets: “First responders” in cancer progression and metastasis. In: Platelets in Thrombotic and Non-thrombotic Disorders - Pathophysiology, Pharmacology and Therapeutics. Editors: P. Gresele, NS Kleiman, JA Lopez, CP Page. Cambridge University Press, pages 1111 – 1132.
35. Kanlikilicer P, Rashed M, Ozpolat B, Ivan C, Rodriguez-Aguayo C, Sood AK, Calin GA, Lopez-Berestein G (2014). The “EX” and the “SOMA”: How they communicate. In: Nano-Oncologicals: New Targeting and Delivery Approaches. Editors: Maria Jose Alonso and Marcos Garcia-Fuentes. Springer, New York, NY. Chapter 2: pages 47 – 66.
36. Denizli M, Aslan B, Rodriguez-Aguayo C, Mangala LS, Jiang D, Lopez-Berestein G, Sood AK (2017). Chitosan nanoparticles for miRNA delivery. In: RNA Nanostructures. Methods in Molecular Biology. Editors: Eckart Bindewald and Bruce A. Shapiro. Humana Press, New York, NY. Pages 219 – 230 (chapter 14).
37. Filant J, Nejad P, Paul A, Simonson B, Srinivasan S, Zhang X, Balaj L, Das S, Gandhi R, Laurent LC, Sood AK (2018). Isolation of extracellular RNA from serum/plasma. Methods in Molecular Biology, vol. 1740, pages 43-57. Publisher: Springer
38. Kondetimmerahalli R, Gharpure KM, Wu SY, Lopez-Berestein G, Sood AK (2018). Non-coding RNAs: Novel targets in anti-cancer drug development. Chapter 24; Pages 447-459; DOI: 10.1016/B978-0-12-811022-5.00024-3
39. Coleman RL, Liu JS, Matsuo K, Thaker PH, Westin SN, Sood AK (2020). Carcinoma of the ovaries and fallopian tubes. In Abeloff's Clinical Oncology, Sixth Edition. Editors: John E. Niederhuber, James O. Armitage, James H. Doroshow, Michael B. Kastan, Joel E. Tepper. Elsevier. Pages 1525 – 1543 (chapter 86).
40. Zhang J, Silva E, Sood AK, Liu J. Ovarian epithelial carcinogenesis. Chapter 4; *Gynecologic and Obstetric Pathology, Volume 2*, (https://doi.org/10.1007/978-981-13-3019-3_4) pages 121-139, 2019. Publisher: Science Press & Springer Nature, Singapore Pte Ltd.
41. Taki M, Rodriguez-Aguayo C, Mangala LS, Lopez-Berestein G, Sood AK. Avances in RNAi-based therapy for cancer.
42. Oncul S, Amero P, Rodriguez-Aguayo C, Sood AK, Calin GA, Lopez-Berestein G. RNA delivery for cancer gene therapy. In: RNA Therapeutics. Publisher: Elsevier.
43. Li Y, Yang S, Hu W, Sood AK (2021). The roles of anoikis in cervical cancer. In: Anoikis: How the extracellular matrix regulates life-or-death decisions. Editor: Steven M. Frisch. Pages 127 – 136, 2021. Publisher: Springer Nature, Switzerland.
44. Mangala LS, Rodriguez-Aguayo C, Bayraktar E, Jennings NB, Lopez-Berestein G, Sood AK (2021). Assessment of in vivo siRNA delivery in cancer mouse models. In: Long non-coding RNAs: Methods

and protocols, 2nd edition. Editors: Lin Zhang and Xiaowen Hu. Chapter 14, pages 157 – 168. Publisher: Humana Press, New York.

RESEARCH:

Publications:

1. Sood AK (1991). Cigarette smoking and cervical cancer: Meta-analysis and critical review of recent studies. *American Journal of Preventive Medicine* 7:208-213.
2. Sood AK, Stoerker J, Watts SL (1989). Type-specific detection of human papillomaviruses in archival cervical neoplasia samples using the polymerase chain reaction. *Fax* 4(1):5-9.
3. Sood AK, Bahrani-Mostafavi Z, Stoerker J, Stone IK (1994). Human papillomavirus DNA in LEEP plume. *Infectious Diseases in Obstetrics and Gynecology* 2(4):167-170.
4. Sood AK, Yancey M, Richards D (1995). Prediction of fetal macrosomia using humeral soft tissue thickness. *Obstetrics and Gynecology* 85:937-940.
5. Sood AK, Gelder MS, Huang SW, Morgan LS (1995). Anaphylaxis to carboplatin following multiple previous uncomplicated courses: A case report. *Gynecologic Oncology* 57:131-132.
6. Sood AK, Stone IK (1996). Myoglobinuric acute renal failure associated with the Maylard incision: A case report. *Journal of Pelvic Surgery* 2:42-43.
7. Skilling JS, Sood AK, Neiman T, Lager DJ, Buller RE (1996). An abundance of p53 null mutations in ovarian carcinoma. *Oncogene* 13:117-123.
8. Sood AK, Buller RE (1996). Genomic instability in ovarian cancer: A reassessment using arbitrarily primed polymerase chain reaction. *Oncogene* 13:2499-2504.
9. Sood AK, Sorosky J, Krogman S, Anderson B, Benda J, Buller RE (1996). Surgical management of cervical cancer complicating pregnancy: A case-control study. *Gynecologic Oncology* 64:294-299. (*Lead article published with comment).
10. Sood AK, Sorosky J (1996). Alternatives to estrogen replacement therapy in the menopausal patient. *Postgraduate Obstetrics and Gynecology* 16(21):1-6.
11. Sood AK, Skilling JS, Buller RE (1997). Ovarian cancer genomic instability correlates with p53 frameshift mutations. *Cancer Research* 57:1047-1049.
12. Buller RE, Sood AK, Fullenkamp C, Sorosky J, Powills K, Anderson B (1997). The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. *Cancer Gene Therapy* 4(4):239-245.
13. Skilling JS, Sood AK (1997). Molecular genetics: Implications for the practicing gynecologic oncologist. *CME Journal of Gynecologic Oncology*, 2(1):6-15.
14. Sood AK, Buller RE, Burger R, Dawson JD, Sorosky JI, and Berman M (1997). Measurement of a preoperative CA125 level facilitates optimal management of uterine cancer and predicts clinical

- outcome. *Obstetrics and Gynecology* 90(3):441-447.
15. Rasmussen CC, Sood AK, Sorosky JI, Anderson B (1997). Posterior exenteration through groin incision in a patient with stage III vulvar carcinoma. *Gynecologic Oncology* 66(2):331-334.
 16. Sood AK, Sorosky JI, Mayr N, Krogman S, Anderson B, Buller RE, Hussey DH (1997). Radiotherapeutic management of cervical carcinoma that complicates pregnancy. *Cancer* 80:1073-1078.
 17. Sood AK, Pardubsky PD, Gacuson M, Kumar GC, Sum Ping ST (1998). Nasoenteric tube complications: A case report of tip displacement. *Nutrition in Clinical Practice* 13:40-42.
 18. Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen R, Lager DJ (1998). Field cancerization: Why late recurrent ovarian cancer isn't recurrent. *American Journal of Obstetrics and Gynecology* 178:641-649.
 19. Sood AK, Sorosky JI, Gelder MS, Buller RE, Anderson B, Wilkinson EJ, Benda JA, Morgan LS (1998). Primary ovarian sarcoma: Analysis of prognostic variables and role of surgical cytoreduction. *Cancer* 82:1731-1737.
 20. Sood AK, Buller RE (1998). Drug resistance in ovarian cancer: From the laboratory to the clinic. *Obstetrics and Gynecology* 92:312-319.
 21. Shahin M, Sood AK, Buller RE (1998). The value of CA-125 levels in the management of endometrial cancer. *Contemporary Reviews in Obstetrics and Gynaecology* 135-140.
 22. Signore CC, Sood AK, Richards DS (1998). Second trimester vaginal bleeding: Correlation of ultrasound findings with perinatal outcome. *American Journal of Obstetrics and Gynecology* 178:336-40.
 23. Olson JK, Sood AK, Sorosky JI, Anderson B, Buller RE (1998). Taxol Hypersensitivity: Rapid retreatment is safe and cost effective. *Gynecologic Oncology* 68(1):25-28.
 24. Buller RE, Sood AK, Lallas T, Buekers T, Skilling JS.(1999) Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. *Journal of the National Cancer Institute* 91(4):339-346.
 25. Minassian V, Sood AK, Metcalf A, Anderson B, Mayr N, Buller RE (1999). Complications related to radiotherapy for cervical cancer in a patient with Crohn's disease. *Journal of Pelvic Surgery* 5:36-39.
 26. Sood AK, Sorosky JI, Dolan M, Anderson B, Buller RE (1999). Distant metastases in ovarian cancer: Association with p53 mutations. *Clinical Cancer Research* 5:2485-90.
 27. Sood AK, Sorosky, JI, Squatrito RC, Skilling JS, Anderson B, Buller RE (1999). Cyclosporin A: Role in reversal of chemoresistance in gynecologic malignancies. *Neoplasia* 1:118-122.
 28. Hsu Y, Lallas TA, Hodges K, Sood AK, Sorosky JI (1999). Primary ovarian leiomyoma: A case report and review of the literature. *Journal of Gynecologic Surgery* 15:55-59.
 29. Sood AK, Buller RE (1999). Loss of Heterozygosity (LOH) as a prognostic factor in ovarian cancer.

CME Journal of Gynecologic Oncology 4(2):189-191.

30. Sood AK, Sorosky, JI, Mayr N, Anderson B, Buller RE, Niebyl J (2000). Cervical cancer diagnosed shortly after pregnancy: Prognostic variables and delivery route. *Obstetrics and Gynecology* 95:832-838.
31. Pertzborn S, Buekers TE, Sood AK (2000). Hematogenous skin metastases from cervical cancer at primary presentation. *Gynecologic Oncology* 76(3):416-417.
32. Harms SA, Sood AK, Shahin M, Mayr N, Sorosky JI. (2000) Bowel surgery after intraperitoneal ³²P: Is it safe to perform low colorectal anastomosis? *Journal of Gynecologic Techniques*. 6(2):65-67.
33. Shahin MS, Hughes JM, Sood AK, Buller RE (2000). The prognostic significance of p53 tumor suppressor gene alterations in ovarian cancer. *Cancer*. 89(9):2006-2017, 2000.
34. Mayr NA, Yuh WTC, Arnholt JC, Ehrhardt JC, Sorosky JI, Magnotta VA, Berbaum KS, Zhen W, Paulino AC, Oberley LW, Sood AK, Buatti JM (2000). Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. *Journal of Magnetic Resonance Imaging*. 12:1027-1033.
35. Minassian VA, Sood AK, Lowe MP, Sorosky JI, Al-Jurf AS, Buller RE (2000). Long term central venous access in gynecologic cancer patients. *Journal of the American College of Surgeons* 191:403-409.
36. Lutgendorf SK, Anderson B, Rothrock N, Buller RE, Sood AK, Sorosky JI (2000). Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer. *Cancer* 89:1402-11.
37. Mayr NA, Sood AK (2000). Chemo-Radiation Therapy in Cervical Cancer: Where do we go from here? Invited commentary for "Combined chemo-radiation for locally advanced cancer of the cervix". *Oncology* 1336-1338.
38. Zhang SH, Sood AK, Sorosky JI, Anderson B, Buller RE (2000). Preservation of saphenous vein in inguinal lymphadenectomy decreases morbidity in vulvar cancer patients. *Cancer* 89:1520-1525.
39. Lowe MP, Ault KA, Sood AK (2001). Recurrent carcinoma *in situ* of neovagina. *Gynecologic Oncology* 80:403-4.
40. Buller RE, Shahin MS, Holmes R, Hatterman M, Kirby PA, Sood AK (2001). P53 mutations and microsatellite instability in ovarian cancer: Yin and Yang. *American Journal of Obstetrics and Gynecology*. 184:891-903.
41. Bender DP, Sood AK (2001). Chemoradiation for the treatment of cervical cancer: A new paradigm. *Postgraduate Obstetrics and Gynecology*. 21(19):1-5.
42. Sood AK, Hendrix MJC (2001). Angiogenesis and its implications for cancer treatment. *Cancer Matters* 7(3):2-3.
43. Buller RE, Lallas T, Shahin M, Sood AK, Hatterman-Zogg M, Anderson B, Sorosky J, Kirby P (2001). The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. *Clinical Cancer Research* 7:831-838.

44. Sood AK, Shahin MS, Sorosky JI (2001). Paclitaxel and platinum chemotherapy during pregnancy for ovarian carcinoma. *Gynecologic Oncology* 83(3):599-600.
45. Mahavni VM, Sood AK (2001). Hormone replacement and cancer risk. *Current Opinion in Oncology* 13:384-389, 2001.
46. Geisler JP, Sorosky JI, Duong HL, Buekers TE, Geisler MJ, Sood AK, Anderson B, Buller RE (2001). Papillary serous carcinoma of the uterus: Increased risk of subsequent or concurrent development of breast carcinoma. *Gynecologic Oncology* 83 (3):501-503.
47. Sood AK, Seftor EA, Fletcher M, Gardner LMG, Heidger PM, Buller RE, Seftor REB, Hendrix MJC (2001). Molecular determinants of ovarian cancer plasticity. *American Journal of Pathology* 158:1279-1288.
48. Sood AK, Holmes RW, Hendrix MJC, Buller RE (2001). Application of the NCI international criteria for determination of microsatellite instability in ovarian cancer. *Cancer Research* 61:4371-4374.
49. Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J (2002). Randomized trial of cisplatin and Ifosfamide versus cisplatin, Ifosfamide, and bleomycin in advanced squamous cell carcinoma of the uterine cervix: A Gynecologic Oncology Group study. *Journal of Clinical Oncology* 20:1832-1837.
50. Lutgendorf SK, Anderson B, Ullrich P, Johnsen E, Buller RE, Sood AK, Sorosky JI, Ritchie J (2002). Quality of life and mood in women with gynecologic cancer. *Cancer* 94:131-140.
51. Lowe MP, Bender D, Sood A, Davis W, Syrop CH, Sorosky J (2002). Two successful pregnancies after conservative treatment of endometrial cancer and assisted reproduction. *Fertility and Sterility* 77:188-189.
52. Cooper BC, Ritchie JM, Broghammer CLW, Coffin J, Sorosky JI, Anderson B, Buller RE, Sood AK (2002). Preoperative serum vascular endothelial growth factor (VEGF) levels: Significance in ovarian cancer. *Clinical Cancer Research* 8:3193-3197.
53. Goodheart MJ, Vasef MA, Sood AK, Davis CS, Buller RE (2002). Ovarian cancer p53 mutation is associated with tumor microvessel density. *Gynecologic Oncology* 86:85-90.
54. Sood AK, Nygaard I, Shahin MS, Sorosky JI, Lutgendorf SK, Rao SSC (2002). Anorectal dysfunction after surgical treatment for cervical cancer. *Journal of the American College of Surgeons* 195(4):513-519. (*Selected for the CME-1 program of the journal)
55. Lutgendorf SK, Johnsen EL, Cooper B, Anderson B, Sorosky JI, Buller RE, Sood AK (2002). Vascular endothelial growth factor and social support in patients with ovarian carcinoma. *Cancer* 95:808-815.
56. Eichholz A, Mahavni V, Sood AK (2002). Allopathic and complementary alternatives to hormone replacement therapy. *Expert Opinion on Pharmacotherapy* 3(7):949-955.
57. Sood AK, Fletcher MS, Hendrix MJC (2002). The embryonic properties of aggressive human tumor cells. *Journal of the Society for Gynecologic Investigation* 9:2-9. (*Lead article).
58. Sood AK, Buller RE, Coffin J, Jabbari S, Hendrix MJC, Klingelutz A (2002). p53 null mutations are

- associated with a telomerase negative phenotype in ovarian carcinoma. *Cancer Biology and Therapy* 1(5):511-517. (*Published with commentary by Dr. Mihaela Velicescu and Dr. Louis Dubeau).
59. Sood AK, Fletcher MS, Zahn CM, Lynn M, Gruman, Jeremy E, Coffin, Seftor EA, Hendrix MJC (2002). The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: Implications for anti-vasculogenic therapy. *Cancer Biology and Therapy* 1(6):661-664. (*Cover Illustration)
 60. Cooper BC, Sood AK, Davis C, Ritchie J, Sorosky JI, Anderson B, Buller RE (2002). Preoperative CA125 levels: An independent prognostic factor for epithelial ovarian cancer. *Obstetrics and Gynecology* 100:59-64.
 61. Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJC (2002). The paradoxical expression of maspin in ovarian carcinoma. *Clinical Cancer Research* 8:2924-2932.
 62. Eichholz AC, Geisler JP, Sood AK (2003). Metastatic breast cancer to the uterus and cervix. *Journal of Gynecologic Surgery* 19(3):145-148.
 63. Chun ML, Buekers TE, Sood AK, Sorosky, JI (2003). Postoperative wound infection with *Pasteurella multocida* from pet cats. *American Journal of Obstetrics and Gynecology* 188:1115-1116, 2003.
 64. Bender D, Sorosky, JI, Buller RE, Sood AK (2003). Serum CA-125 is an independent prognostic factor in cervical adenocarcinoma. *The American Journal of Obstetrics and Gynecology* 189:113-117.
 65. Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RE (2003). Mismatch repair gene expression defects contribute to microsatellite instability in ovarian cancer. *Cancer* 98:2199-2206. (*Published with commentary by Drs. C. Richard Boland and Ajay Goel)
 66. Sood AK, Hendrix MJC (2003). The complexity of tumor vascularity. Invited commentary for "Blood markers for vasculogenesis increase with tumor progression in patients with breast carcinoma". *Cancer Biology and Therapy* 2:257-258.
 67. Lowe MP, Cooper B, Sood AK, Davis WA, Syrop CH, Sorosky JI (2003). Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia. *Gynecologic Oncology* 91(3):569-72.
 68. Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman J (2003). Phase II study of oxaliplatin in recurrent, platinum resistant and refractory ovarian cancer: A gynecologic oncology group study. *Journal of Clinical Oncology* 21:2856-2859.
 69. Lutgendorf SK, Cole S, Costanzo E, Bradley S, Coffin J, Jabbari S, Sood AK (2003). Stress related mediators stimulate vascular endothelial growth factor secretion by ovarian cancer cells. *Clinical Cancer Research* 9:4514-4521.
 70. Frausto SD, Geisler JP, Fletcher MS, Sood AK (2004). Late Recurrence of Juvenile Granulosa Cell Tumor of the Ovary. *American Journal of Obstetrics and Gynecology* 191:366-367.
 71. Hsu Y, Sood AK, Sorosky JI (2004). Docetaxel versus Paclitaxel for adjuvant treatment of ovarian cancer: A case control analysis of toxicity. *American Journal of Clinical Oncology* 27:14-18.

72. Eichholz AC, VanVoorhis BJ, Sorosky JI, Smith BJ, Sood AK (2004). Operative note dictation: Should it be taught routinely in residency programs? *Obstetrics and Gynecology* 103(2):342-346.
73. Lowe MP, Sood AK (2004). Response to Letter-to-the-Editor by Guvendag Guven et al regarding "Recurrent carcinoma *in situ* of a neovagina". *Gynecologic Oncology* 92(2):728-729.
74. Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM, Hendrix MJC (2004). Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. *American Journal of Obstetrics and Gynecology* 190 (4):899-909.
75. Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Kinch MS, Kiener PA, Sood AK (2004). EphA2 expression is associated with aggressive features in ovarian carcinoma. *Clinical Cancer Research* 10:5145-5150.
76. Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI (2004). Sequential Intraperitoneal Topotecan and Oral Etoposide Chemotherapy in Recurrent Platinum-Resistant Ovarian Carcinoma: Results of a Phase II Trial. *Clinical Cancer Research* 10:6080-6085.
77. Landen CN, Klingelutz A, Coffin JE, Sorosky JI, Sood AK (2004). Genomic instability is associated with lack of telomerase activation in ovarian cancer. *Cancer Biology and Therapy* 3(12):1250-1253. (*Cover mention)
78. Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJC (2004). Biological significance of FAK in ovarian cancer: Role in migration and invasion. *American Journal of Pathology* 165:1087-1095.
79. Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM (2005). Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. *Cancer* 104:305-313.
80. Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, Sorosky JI, DeGeest K, Ritchie, J, Lubaroff DM (2005). Social support, psychological distress, and natural killer cell activity in ovarian cancer. *Journal of Clinical Oncology* 23:7105-7113.
81. Sood AK, Cooper BC, Sorosky JI, Ramirez PT, Levenback C (2005). Novel modification of the vertical rectus abdominis myocutaneous (VRAM) flap for neovagina creation. *Obstetrics and Gynecology* 105:514-518.
82. Sharma NK, Sorosky JI, Fletcher MS, Sood AK (2005). Malignant mixed mullerian tumor (MMMT) of the cervix. *Gynecologic Oncology* 97:442-445.
83. Sood AK, Abu-Rustum NR, Barakat RR, Bodurka DC, Brown J, Donato ML, Poynor EA, Wolf JK, Gershenson DM (2005). Fifth International Conference on Ovarian Cancer: Challenges and Opportunities. *Gynecologic Oncology* 97:916-923.
84. Rose SL, Bunt CE, Geisler JP, Sood AK, Sorosky JI (2006). Mesh erosion into the bowel and vagina following abdominal sacral colpopexy: A case-report. *Journal of Pelvic Medicine & Surgery* 12(1):45-48.
85. Sood AK, Coleman RL, Judith K. Wolf, Gershenson DM (2005). Selected Highlights from the 5th International Conference on Ovarian Cancer. *Expert Opinion on Pharmacotherapy* 6(7):1269-1275.

86. Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, Sood AK (2005). Antivascular therapy for human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. *Clinical Cancer Research* 11:4923-4933. (*Cover Illustration)
87. Thaker PH, Yokoi K, Jennings NB, Li Y, Rebhun RB, Rousseau DL, Fan D, Sood AK (2005). Inhibition of experimental colon cancer metastasis by the GABA-receptor agonist Nembutal. *Cancer Biology and Therapy* 4(7):753-758.
88. Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Coffey D, Sood AK, Agoulnik AI (2006). Relaxin promotes migration and invasion of endometrial cancer. *Cancer Biology & Therapy* 5(1):71-77. (*Highlighted on Cover)
89. Han LY, Landen CN, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM, Sood AK (2006). Preoperative serum tissue factor (TF) levels are an independent prognostic factor in patients with ovarian carcinoma. *Journal of Clinical Oncology* 24(5):755-761. (*Featured Article in Translational Oncology)
90. Landen CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK (2005). Therapeutic EphA2 gene targeting by *in vivo* liposomal siRNA delivery. *Cancer Research* 65 (15):6910-6918.
91. Bennett M, Clifford S, Thornton A, Jiang F, Broaddus R, Lu KH, Sood AK, Gershenson D, R Schmandt (2006). The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. *Cancer Biology and Therapy* 5(9):1136-1141.
92. Kamat AA, Fletcher MS, Gruman L, Mueller P, Lopez A, Landen CN, Han L, Gershenson DM, Sood AK (2006). The clinical relevance of stromal matrix metalloproteinase (MMP) expression in ovarian cancer. *Clinical Cancer Research* 12:1707-1714. (*Highlighted in *Nature Clinical Practice Oncology*). PMID: 16551853.
93. Halder JB, Landen CN, Lutgendorf SK, Li Y, Jennings NB, Fan D, Nelkin GM, Gershenson DM, Schaller MD, Sood AK (2005). FAK silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. *Clinical Cancer Research* 11(24):8829-8836. PMID: 16361572.
94. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB (2005). VEGF Trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. *Clinical Cancer Research* 11:6966-6971, 2005.
95. Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, Heinze G, Six L, Sliutz G, Tempfer CB, Reinthaller A (2006). The clinical value of preoperative vascular endothelial growth factor in ovarian cancer: A multicenter study. *Gynecologic Oncology* 103(2):512-517.
96. Kamat AA, Sood AK (2005). The Merits of Vascular Targeting for Gynecologic Malignancies. *Current Oncology Reports* 7(6):444-450. PMID: 16221381.
97. Milam MR, Sood AK, King S Bassett RL, Lu KH, Coleman RL, Ramirez PT (2007). Supracervical hysterectomy does not impact clinical outcome in patients with epithelial ovarian cancer: A case-control analysis. *Obstetrics and Gynecology* 109(3):641-6.

98. Landen CN, Kinch MS, Sood AK (2005). EphA2 as a target for ovarian cancer therapy. *Expert Opinion on Therapeutic Targets* 9(6):1179-1187.
99. Merritt WM, Thaker PH, Landen CN, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA, Schmandt R, Gershenson DM, Kinch MS, Sood AK (2006). Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. *Cancer Biology and Therapy* 5(10):1357-1360. (*Published with commentary by Linda Meade-Tollin and Jesse D. Martinez 6(2):288-289, 2007)
100. Bonome T, Lee J-Y, Park D-C, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ (2005). Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. *Cancer Research* 65:10602-10612.
101. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC (2006). The clinical course of stage II-IV low-grade serous carcinoma of the ovary. *Obstetrics and Gynecology* 108 (2):361-368.
102. Frumovitz M, Bodurka DC, Coleman RL, Sood AK, Gershenson DM, Burke TW, Levenback CF (2007). Lymphatic mapping and sentinel node biopsies in women with high-risk endometrial cancer. *Gynecologic Oncology* 104(1):100-103.
103. Sood AK, Bhatta R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf SK, Cole SW (2006). Stress hormone mediated invasion of ovarian cancer cells. *Clinical Cancer Research* 12(2):369-375. PMID: 16428474.
104. Kamat AA, Sood AK, Dang D, Gershenson DM, Simpson JL, Bischoff FZ (2006). Quantification of total plasma cell-free DNA in ovarian cancer using real time PCR. *Annals of the New York Academy of Sciences* 1075: 230-234.
105. Sood AK (2006). Location matters. Editorial for articles by Solomon et al., Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer; Alvarez-Secord et al., Maspin expression in epithelial ovarian cancer and associations with poor prognosis: A Gynecologic Oncology Group study. *Gynecologic Oncology* 101:378-379.
106. Antoni MH, Lutgendorf SK, Cole S, Dhabhar F, Sephton S, McDonald PG, Stefanek M, Sood AK (2006). The Influence of Biobehavioral Factors on Tumor Biology: Pathways and Mechanisms. *Nature Reviews Cancer* 6:240-248. PMID: 16498446.
107. McDonald PG, Antoni MH, Lutgendorf SK, Cole S, Dhabhar F, Sephton S, Stefanek M, Sood AK (2005). A biobehavioral perspective of tumor biology. *Discovery Medicine* 5(30):520-526. PMID: 20704834.
108. Halder JB, Kamat AA, Landen CN, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK (2006). Focal adhesion kinase targeting for therapy of ovarian carcinoma using *in vivo* siRNA delivery in neutral liposomes. *Clinical Cancer Research* 12:4916-4924. (*Cover Illustration). PMID: 16914580.
109. Sood AK, Landen CN, Sanguino A, Lopez-Berestein G (2006). Therapeutic gene silencing *in vivo* using RNA interference. *AACR Education Book* 353-357.

110. Han LY, Landen CN, Trevino JG, Kamat AA, Kim T-J, Merritt WM, Lin YG, Sawyer TK, Shakespeare WC, Coleman RL, Gershenson DM, Gallick GE, Sood AK(2006). Anti-angiogenic and anti-tumor effects of Src inhibition in ovarian carcinoma. *Cancer Research* 66(17):8633-8639. NIHMSID: 312788.
111. Landen CN, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker PH, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK (2006). Efficacy and anti-vascular mechanisms of EphA2 downregulation with agonistic antibodies in ovarian cancer. *Journal of the National Cancer Institute* 98(21):1558-1570.
112. Thaker PH, Han LY, Kamat AA, Arevalo J, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Angela M. Sanguino, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK (2006). Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. *Nature Medicine* 12(8):939-944. Advance Online Publication, 23 July 2006 (doi: 10.1038/nm1447). PMID: 16862152.
113. Landen CN, Merritt WM, Sanguino AM, Bucana C, Lu C, Lin Y, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK (2007). Intraperitoneal delivery of siRNA in neutral liposomes for therapy of advanced ovarian cancer. *Cancer Biology and Therapy* 5(12):1708-1713. (*Cover Illustration)
114. Kamat AA, Bischoff FZ, Dang D, Han LY, Lin YG, Merritt WM, Landen CN, Lu C, Gershenson DM, Simpson JL, Sood AK (2006). Circulating cell-free DNA: A novel biomarker for response to therapy in ovarian carcinoma. *Cancer Biology and Therapy* 5(10):1369-1374. (*Cover Mention)
115. Spannuth WA, Thaker PH, Sood AK (2007). Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer. *American Journal of Obstetrics and Gynecology* 196(4):e6-e9.
116. Coleman RL, Sood AK (2006). Historical progress in the initial management of ovarian cancer: Intraperitoneal therapy. *Current Oncology Reports* Nov;8(6):455-64.
117. Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt W, Jennings N, Spannuth WA, Langley R, Gershenson DM, Coleman RL, Kundra V, Sood AK. Anti-tumor and anti-vascular effects of AVE8062 in ovarian carcinoma (2007). *Cancer Research* 67(19):9337-45. PMID: 17909042.
118. Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Li Y, Marsh CB, Jewell S, Flavahan NA, Morrison C, Peir-En Y, Lemeshow S, Glaser R (2006). Norepinephrine up-regulates the expression of VEGF, MMP-2 and MMP-9 in nasopharyngeal carcinoma tumor cells. *Cancer Research* 66(21):10357-10364. PMID: 17079456.
119. Kamat AA, Kim TJ, Landen CN, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK (2007). Metronomic chemotherapy enhances the efficacy of anti-vascular therapy in ovarian cancer. *Cancer Research* 67(1):281-288.
120. Merritt WM, Sood AK (2007). Markers of angiogenesis in ovarian cancer. *Disease Markers* 23(5,6):419-431.

121. Sood AK (2006). Second look laparotomy for ovarian germ cell tumors: To do or not to do? Editorial for article by George et al., Laparotomy for post chemotherapy residue in ovarian germ cell tumours. *Journal of Postgraduate Medicine* 52(4): 246-247.
122. Frumovitz M, Sood AK (2007). Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. *Gynecologic Oncology* 104:768-778.
123. Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, Fletcher MS, Urbauer DL, Kinch MS, Sood AK (2007). EphA2 Overexpression is Associated with Angiogenesis in Ovarian Cancer. *Cancer* 109(2): 332-340.
124. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS (2007). The receptor tyrosine kinase EphB4 is over-expressed in ovarian cancer, provides survival signals and predicts poor outcome. *British Journal of Cancer* 96:1083-1091. *Advance on line publication, March 13, 2007*
125. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Kamat AA, Armaiz-Pena GN, Spannuth WA, Gershenson DM, Aggarwal BB, Sood AK (2007). Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the NF- κ B pathway. *Clinical Cancer Research* 13(11):3423-3430. (*Cover Illustration). PMID: 17545551.
126. Thaker PH, Lutgendorf SK, Sood AK. The neuroendocrine impact of chronic stress on cancer. *Cell Cycle*. (2007) Feb;6(4):430-3. PMID: 17312398.
127. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK (2007). Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. *Cancer Research* 67(4):757-768. PMID: 17308118.
128. Lu C, Kamat AA, Landen CN, Kim TJ, Arumugam T, Han LY, Jennings NB, Merritt WM, Logsdon C, Spannuth W, Jaffe RB, Coleman RL, Sood AK (2007). Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. *Clinical Cancer Research* 13(14):4209-4217. PMID: 17634550.
129. Sood AK (2007). Cancer in surgical scar: insights and clinical challenges. Editorial for articles by Neumann et al., Cervical adenosquamous carcinoma: Tumor implantation in an episiotomy scar; Harry et al., Isolated clear cell adenocarcinoma in scar endometriosis mimicking an incisional hernia. *Obstetrics and Gynecology* 110(2 Pt 2):453-4.
130. Landen CN, Lin YG, Das P, Arevalo JMG, Kamat AA, Han LY, Jennings NB, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK (2007). Neuroendocrine modulation of STAT3 in ovarian cancer. *Cancer Research* 67(21):10389-10396. PMID: 17974982.
131. Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Arevalo J, Lutgendorf SK, Gallick GG, Lopez-Berestein G, Cole SW, Sood AK (2007). Stress hormones regulate IL-6 expression by ovarian carcinoma cells through a Src-dependent mechanism. *The Journal of Biological Chemistry* 282(41):29919-29926. Advance online publication August 23, 2007 (<http://www.jbc.org/cgi/doi/10.1074/jbc.M611539200>). PMID: 17716980.
132. Landen CN, Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA, Bodurka DC, Gershenson

- DM, Brinkley WR, Sood AK (2007). Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. *Clinical Cancer Research* 13(14):4098-4104.
133. Fernandez A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Shavrin A, Qin C, Maxwell D, Ma J, Trent J, Lin YG, Gelovani J, Bornmann W, Sood AK, Lopez-Berestein G (2007). Curbing cardiotoxicity of anti-cancer drug imatinib through rational molecular re-engineering: From *in silico* design to animal model. *Journal of Clinical Investigation* 117;4044-4054. (*Published with commentary by George D. Demetri)
134. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK (2007). Therapeutic efficacy of a novel FAK inhibitor TAE226 in ovarian carcinoma. *Cancer Research* 67(22):10976-10983. (*Highlighted in *Nature Reviews Cancer*). PMID: 18006843.
135. Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley R, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK (2008). Impact of vessel maturation on anti-angiogenic therapy in ovarian cancer. *American Journal of Obstetrics and Gynecology* 198:477.e1-744.e10. PMID: 18395047.
136. Han LY, Fletcher MS, Deavers MT, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth W, DeGeest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK (2008). HLA class I antigen processing machinery component expression and intratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma. *Clinical Cancer Research* 14(11):3372-3379. PMID: 18519766.
137. Lutgendorf SK, Lamkin DM, DeGeest K, Anderson B, McGinn S, Zimmerman B, Maseri H, Sood AK, Lubaroff DM (2008). Depressed and anxious mood and T-Cell cytokine expressing populations in ovarian cancer patients. *Brain, Behavior, and Immunity* 22:890-900.
138. Landen CN, Birrer MJ, Sood AK (2008). Early genetic events in the pathogenesis of epithelial ovarian cancer. *Journal of Clinical Oncology* 26(6):995-1005. PMID: 18195328.
139. Sanguino AM, Lopez-Berestein G, Sood AK (2008). Strategies for *in vivo* siRNA delivery in cancer treatment. *Mini Reviews in Medicinal Chemistry* 8:248-255.
140. Spannuth WA, Sood AK, Coleman RL (2008). Angiogenesis as a strategic target for ovarian cancer therapy. *Nature Clinical Practice Oncology* 5(4):194-204. PMID: 18268546.
141. Gray MJ, Van Buren G, Dallas NA, Xia L, Yang AD, Somcio RJ, Lin YG, Lim S, Fan F, Mangala LS, Arumugam T, Logsdon CL, Lopez-Berestein G, Sood AK, Ellis LM (2008). Therapeutic targeting of neuropilin-2 by siRNA reduces *in vivo* tumor progression in colorectal carcinoma cells in a murine orthotopic model. *Journal of the National Cancer Institute* 100:109-120. (*Published with commentary by M. Narazake, M. Segarra, and G. Tosato)
142. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, DeGeest K, Langley R, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AK (2008). Effects of IL-8 targeted therapy with liposome incorporated siRNA on ovarian cancer growth. *Journal of the National Cancer Institute* 100:359-372.

143. Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, Sood AK, Aggarwal BB, Krishnan S, Mehta K (2008). Inhibition of tissue transglutaminase promotes gemcitabine efficacy and blocks pancreatic cancer growth and metastasis in mice. *Clinical Cancer Research* 14(8):2476-2483.
144. Lutgendorf SK, Weinrib A, Penedo F, Russell D, DeGeest K, Costanzo E, Henderson P, Sephton S, Rohleder N, Lucci J, Cole S, Sood AK, Lubaroff DM (2008). Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. *Journal of Clinical Oncology* 26:4820-4827.
145. Kamat AA, Merritt WM, Coffey D, Lin YG, Broaddus R, Nugent E, Han LY, Patel PR, Landen CN, Spannuth W, Coleman RL, Gershenson DM, Sood AK (2007). Clinical and biological significance of vascular endothelial growth factor (VEGF) in endometrial cancer. *Clinical Cancer Research* 13(24):7487-7495.
146. Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LM (2008). *In vivo* therapeutic targeting of the transcriptional regulator inhibitor of DNA-binding (Id2) by siRNA reduces tumor growth and survival of human colorectal carcinoma cells in the liver. *Oncogene* 27:7192-7200.
147. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK (2008). Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. *Cancer Research* 68 (14):5849-5858. PMID: 18632639.
148. Thaker PH, Sood AK (2008). Neuroendocrine influences on cancer biology. *Seminars in Cancer Biology* 18:164-170, 2008. [Epub ahead of print 2007 Dec 8]. PMID: 18201896.
149. Lamkin DM, Lutgendorf SK, McGinn S, Dao M, Maseri H, DeGeest K, Sood AK, Lubaroff DM (2008). Positive psychosocial factors and NKT cell percentages in ovarian cancer patients. *Brain, Behavior, and Immunity* 22:65-73.
150. Lin YG, Immaneni A, Merritt WM, Mangala SL, Kim SW, Armaiz-Pena GN, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK (2008). Aurora kinase targeting inhibits tumor growth in ovarian cancer. *Clinical Cancer Research* 14(17):5437-5446. (*Selected for Highlights). PMID: 18765535.
151. Guan H, Zhou Z, Gallick GE, Jia SF, Morales J, Sood AK, Corey SJ, Kleinerman ES (2008). Lyn activation contributes to the growth and metastasis of Ewing's sarcoma. *Molecular Cancer Therapeutics* 7(7):1807-16.
152. Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennings NB, Kinch MS, Tice D, Sood AK (2008). Tumor-selective response to antibody-mediated targeting of the alphavbeta3 integrin in ovarian cancer. *Neoplasia* 10(11):1259-1267.
153. Ren W, Korchin B, Lahat G, Wei, C, Bolshakov S, Nguyen T, Merritt WM, Dicker A, Lazar A, Sood AK, Pollock RE, Lev D (2008). Combined VEGFR/EGFR blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. *Clinical Cancer Research* 14(17):5466-5475.
154. Spannuth WA, Nick AM, Jennings NB, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK (2009). Functional significance of VEGFR-2 on ovarian cancer cells.

International Journal of Cancer 124:1045-1053. PMID: 19058181.

155. Lu C, Shahzad MMK, Wang H, Landen CN, Kim SW, Allen J, Nick AM, Jennings N, Bar-Eli M, Sood AK (2008). EphA2 overexpression promotes ovarian cancer growth. *Cancer Biology and Therapy* 7(7):1098-1103. [Epub ahead of print] (*Highlighted on cover)
156. Villares GJ, Zigler M, Wang H, Wu H, Melnikova VO, Friedman R, Leslie MC, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Bar-Eli (2008). Targeting melanoma growth and metastasis with liposomal incorporated PAR-1 siRNA. *Cancer Research* 68(21):9078-9086.
157. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MMK, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK (2009). Therapeutic targeting of ATP7B in ovarian carcinoma. *Clinical Cancer Research* 15(11):3770-3780.
158. Armaiz-Pena GN, Mangala LS, Spannuth WA, Lin YG, Jennings N, Nick AM, Schmandt R, Lutgendorf SK, Cole SW, Sood AK (2009). Estrous cycle modulates ovarian carcinoma growth. *Clinical Cancer Research* 15(9):2971-2978. PMID: 19383821.
159. Yang L, Hamilton SR, Sood A, Kuwai T, Ellis L, Sanguino A, Lopez-Berestein G, Boyd DD (2008). The previously un-described ZKSCAN3 (ZNF306) is a novel “driver” of colorectal cancer progression. *Cancer Research* 68(11):4321-30.
160. Lamkin DM, Spitz DR, Zimmerman B, Lenihan, DeGeest K, Lubaroff DM, Shinn EH, Sood AK, Lutgendorf SK (2009). Glucose as a prognostic factor in ovarian carcinoma. *Cancer* 115(5):1021-1027. (*Cover mention; *Published with editorial by Richard T. Penson)
161. Shinn EH, Taylor C, Kilgore K, Valentine A, Bodurka DC, Kavanagh J, Sood A, Li Y, Basen-Engquist K (2009). Associations with worry about dying and hopelessness in ambulatory ovarian cancer patients. *Palliative and Supportive Care* 7(3):299-306.
162. Sood AK, Birrer MJ (2008). Highlights from the 2008 Annual Meeting of the American Association for Cancer Research. *Gynecologic Oncology* 110:5-6.
163. Armaiz-Pena GN, Lutgendorf SK, Cole SW, Sood AK (2009). Neuroendocrine modulation of cancer progression. *Brain, Behavior, and Immunity* 23(1):10-15. (*Cover Illustration). PMID: 18638541.
164. Nick AM, Sood AK (2008). The ROC n’ Role of the Multiplex Assay for Early Detection of Ovarian Cancer. *Nature Clinical Practice Oncology* 5(10):568-569. [Commentary on article by Visintin I, et al. Diagnostic markers for early detection of ovarian cancer. *Clinical Cancer Research* 14(4):1065-72, 2008].
165. Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Bassett R, Landen CN, Han LY, Lin YG, Spannuth W, Agoulnik AI, Edwards C, Broaddus R, Gershenson DM, Coleman RL, Sood AK (2009). EphA2 Overexpression is Associated with Lack of Hormone Receptor Expression and Poor Outcome in Endometrial Cancer. *Cancer* 115(12):2684-2692.
166. Le X-F, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC (2008). Specific blockade of VEGF and HER2 pathways results in additive inhibition of breast cancer xenografts that overexpress HER2. *Cell Cycle* 7(23):3747-3758.

167. Stany MP, Bonome T, Wamunyokoli F, Zorn K, Ozburn L, Park DC, Hao K, Boyd J, Sood AK, Gershenson DM, Berkowitz RS, Mok SC, Birrer MJ (2008). Classification of ovarian cancer: a genomic analysis. *Advances in Experimental Biology* 622:23-33.
168. Brown J, Sood AK, Deavers MT, Milojevic L, Gershenson DM (2009). Patterns of metastasis in sex cord-stromal tumors of the ovary: Can routine staging lymphadenectomy be omitted? *Gynecologic Oncology* 111:86-90.
169. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ (2009). Recurrent low-grade serous carcinoma of the ovary is relatively chemoresistant. *Gynecologic Oncology* 114(1):48-52.
170. Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia P, Sood A, McConkey DJ, Logsdon CD (2008). NFkB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. *Clinical Cancer Research* 14(24):8143-8151.
171. Lutgendorf SK, Lamkin DM, Jennings NB, Penedo F, DeGeest K, Langley RR, Lucci JA, Cole S, Lubaroff DM, Sood AK (2008). Behavioral influences on MMP expression in ovarian cancer. *Clinical Cancer Research* 14(21):6839-6846. (*Cover Illustration). PMID: 18980978.
172. Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Sood AK (2009). Combined anti-angiogenic therapy against VEGF and integrin $\alpha_v\beta_3$ in ovarian carcinoma. *Cancer Biology and Therapy* 8(23):2261-2270. (*Published with commentary by Drs. Amir A. Jazaeri and Jill K. Slack-Davis). (*Cover Illustration). PMID: 19829059.
173. Lee J-W, Shahzad MMK, Lin YG, Armaiz-Pena G, Han HD, Kim HS, Nam EJ, Jennings NB, Halder JB, Mangala LS, Nick AM, Stone RL, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK (2009). Surgical stress promotes tumor growth in ovarian carcinoma. *Clinical Cancer Research* 15(8):2695-2702. PMID: 19351748.
174. Shahzad MMK, Lu C, Lee J-W, Mangala LS, Danes CG, Halder J, Nick AM, Stone RL, Kim H-S, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL*, Sood AK* (2009). Dual targeting of EphA2 and FAK in ovarian Carcinoma. *Cancer Biology and Therapy* 8(11):1027-1034. (*Joint senior authors)
175. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng J-F, Nick AM, Deavers MT, Zeidan AM, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK (2008). Dicer, Drosha, and outcomes in patients with Ovarian Cancer. *The New England Journal of Medicine* 359(25):2641-2650. (*Accompanying editorial by FJ Slack and JB Weidhaas). (*Highlighted in *Nature Reviews Clinical Oncology, Nature*) PMID: 19092150.
176. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, Brown J (2009). Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. *Gynecologic Oncology* 114(3):431-436. (*Highlighted on Cover)
177. Lutgendorf SK, McGinn S, Sung CY, Arevalo JM, DeGeest K, Penedo F, Lucci J, Lubaroff, Sood AK, Cole SW (2009). Depression, social support, and beta-adrenergic transcription control in human

- ovarian cancer. *Brain, Behavior, and Immunity* 23(2):176-183. PMID: 18550328.
178. Matsuo K, Eno ML, Im DD, Rosenshein NB, Sood AK (2010). Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. *Gynecologic Oncology* 116(1):61-65. (*Cover mention)
 179. Merritt WM, Danes CG, Shahzad MMK, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma (2009). *Cancer Biology and Therapy* 8(16):1597-1604. (*Cover mention)
 180. Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, , Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BTJ, Sanguino A, Peng Z, Sood AK*, Lopez-Berestein* (2010). JNK-1 inhibition leads to antitumor activity in ovarian cancer. *Clinical Cancer Research* 16(1):184-194. (*Joint senior authors). PMID: 20028751.
 181. Merritt WM, Urbauer DL, Sood AK (2009). Dicer and Drosha in ovarian cancer. Response to Correspondence from Kobel M, Gilks CB, Huntsman DG. *The New England Journal of Medicine* 360(11):1150-1151.
 182. Moroney J, Sood AK, Coleman RL (2009). Aflibercept in epithelial ovarian carcinoma. *Future Oncology* 5(5):591-600.
 183. Cai YQ, Shao-Rui C, Han HD, Sood AK, Lopez-Berestein G, Pan HL (2009). Role of M2, M3, and M4 muscarinic receptor subtypes in the spinal cholinergic control of nociception revealed using siRNA in rats. *Journal of Neurochemistry* 111:1000-1010.
 184. Ramachandran V, Arumugam T, Langley R, Hwang RF, Vivas-Mejia P, Sood AK, Lopez-Berestein G, Logsdon CD (2009). The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cell of the tumor microenvironment. *PLoS One* 4(10):e7502; 1-12.
 185. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan B, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK (2010). Plasma cell-free DNA in ovarian cancer: An independent predictive biomarker of clinical outcome. *Cancer* 116:1918-1925.
 186. Stone RL, Sood AK, Coleman RL (2010). Ovarian Cancer: Collateral damage of targeted therapy. *Lancet Oncology* 11:465-475. PMID: 20226736.
 187. Shahzad MMK, Lopez-Berestein G, Sood AK (2009). Novel strategies for reversing platinum resistance. *Drug Resistance Updates* 12:148-152. PMID: 19805003.
 188. Lee JW, Han HD, Shahzad MMK, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK (2009). Molecularly targeted chemotherapy using a novel EphA2 immunoconjugate in ovarian carcinoma. *Journal of the National Cancer Institute* 101:1193-1205.
 189. Spannuth WA, Sood AK, Coleman RL (2010). Farletuzumab in epithelial ovarian carcinoma. *Expert Opinion on Biological Therapy* 10(3):431-437.
 190. Lu C, Shahzad MMK, Moreno-Smith M, Lin Y, Jennings NB, Allen JK, Landen CN, Mangala LS,

- Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK (2010). Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. *Cancer Biology and Therapy* 9(3):1-7. (Published with Commentary by Barbara Sennino)
191. Fu S, Hu W, Iyer R, Kavanagh J, Coleman R, Levenback C, Sood AK, Wolf J, Gershenson D, Markman M, Hennessy B, Kurzrock R, Bast R (2011). Phase Ib-IIa study to reverse platinum resistance by the use of a hypomethylating agent azacitidine in platinum-resistant or refractory epithelial ovarian cancer. *Cancer* 117(8):1661-1669.
192. Lee JW, Nam EJ, Nick AM, Stone RL, Han HD, Shahzad MMK, Kim HS, Mangala LS, Jennings NB, Carroll AR, Matsuo K, Hao Q, Mao S, Gooya J, Fazenbaker C, Tice D, Jackson D, Coleman RL, Sood AK (2010). EphA2 targeted chemotherapy using an immunoconjugate in endometrial carcinoma. *Clinical Cancer Research* 16(9):2562-2570.
193. Merritt WM, Bar-Eli M, Sood AK (2010). The dicey role of Dicer: Implications for RNAi therapy. *Cancer Research* 70(7):2571-2574. PMID: 20179193.
194. Merritt WM, Nick AM, Dumble M, Jennings N, Zhang SY, Lin YG, Spannuth WA, Kamat AA, Stone RL, Coleman RL, Kumar R, Sood AK (2010). Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. *Molecular Cancer Therapeutics* 9(4):985-995. (*Selected for "Highlights of the Issue")
195. Ozpolat B, Sood AK, Lopez-Berestein G (2009). Nanoparticle based systemic siRNA therapy for cancer. *Journal of Internal Medicine* 267(1):44-53.
196. Weinrib AZ, Sephton SE, DeGeest K, Penedo F, Bender D, Zimmerman B, Kirschbaum C, Sood AK, Lubaroff DM, Lutgendorf SK. Diurnal cortisol dysregulation, functional disability, and depression in women with cancer (2010). *Cancer* 116:4410-4419.
197. Corney DC, Hwang C, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, Nikitin AY (2010). Frequent downregulation of miR-34 family in human ovarian cancers. *Clinical Cancer Research* 16:1119-1128.
198. Sood AK, Coleman RL (2010). Targeted therapy in gynecologic oncology: Biology, strategy, and assessment. *Gynecologic Oncology* 116:155-156.
199. Lutgendorf SK, Sood AK, Antoni MH (2010). Host factors and cancer progression: Biobehavioral signaling pathways and interventions. *Journal of Clinical Oncology* 28(26):4094-4099. PMID: 20644093.
200. Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DM (2010). Unmasking the complexities of mucinous ovarian carcinoma. *Gynecologic Oncology* 117:491-496.
201. Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves RA, Mann AP, Mora E, Han H-D, Shahzad MMK, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin, Stone RL, Nick AM, Lopez-Berestein G*, Sood AK*, Ferrari M* (2010). Sustained siRNA delivery by porous silicon particles for cancer treatment. *Cancer Research* 70(9):3687-3696. (*Joint Senior Authors).
202. Cole SW, Arevalo JM, Sung CY, Takahashi R, Sloan EK, Lutgendorf SK, Sood AK, Sheridan JF, Seeman TE (2010). Computational modeling of gene-environment interaction identifies the human IL6

- locus as a genetic moderator of socio-environmental mortality risk. *Proceedings of the National Academy of Sciences* 107(12):5681-5686.
203. Sood AK, Armaiz-Pena G, Halder JB, Nick AM, Stone R, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MMK, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK (2010). Beta-adrenergic modulation of anoikis. *Journal of Clinical Investigation* 120(5):1515-1523.
 204. Moreno-Smith M, Lutgendorf SK, Sood AK (2010). Impact of stress on cancer metastasis. *Future Oncology* 6(12):1863-1881. PMID: 21142861.
 205. Matsuo K, Lin YG, Roman LD, Sood AK (2010). Overcoming platinum resistance in ovarian carcinoma. *Expert Opinion on Investigational Drugs* 19(11):1339-1354.
 206. Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PT, Ramirez PT, Frumovitz M, Bodurka DC, Sood AK (2010). Pelvic fractures following radiation therapy for cervical cancer: Implications for survivors. *Cancer* 116(3):625-630.
 207. Carroll AR, Coleman RL, Sood AK (2011). Therapeutic advances in women's cancers. *Frontiers in Bioscience* S3:82-97. PMID: 21196359.
 208. Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, Brown J, Gershenson DM, Ramirez PT (2010). Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. *Obstetrics and Gynecology* 116(2):269-274.
 209. Brown J, Smith JA, Ramondetta LM, Sood AK, Ramirez PT, Coleman RL, Levenback CF, Munsell M, Jung M, Wolf JK (2010). Combination gemcitabine and cisplatin are highly active in endometrial carcinoma: Results of a prospective phase 2 trial. *Cancer* 116:4973-4979.
 210. Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad M, Lee S-J, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK (2010). Converging evidence for efficacy from paralled EphB4 targeted approaches in ovarian carcinoma. *Molecular Cancer Therapeutics* 9(8):2377-2388. PMID 20682653. PMCID: PMC2933364.
 211. Matsuo K, Ahn EH, Bond VK, Im DD, Rosenshein NB, Sood AK (2011). Multi-drug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian, and peritoneal cancer. *American Journal of Clinical Oncology* 34:488-493.
 212. Lutgendorf SK, Mullen-Houser EA, Russell D, DeGeest K, Jacobson GM, Hart L, Bender D, Buekers T, Goodheart M, Antoni MH, Sood AK, Lubaroff DM (2010). Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. *Brain Behavior and Immunity* 24(8):1231-1240.
 213. Han HD, Mangala LS, Lee JW, Kim HS, Shahzad MMK, Nam EJ, Mora EM, Stone RL, Lu C, Nick AM, Lopez-Berestein G, Sood AK (2010). Targeted gene silencing using RGD-labeled chitosan nanoparticles. *Clinical Cancer Research* 16(15):3910-3922. PMID: 20538762. PMCID: PMC2912984.
 214. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel M, Arevalo JM, Morizono, Wu L, Sood AK, Cole SW

- (2010). Sympathetic nervous system induces a metastatic switch in primary breast cancer. *Cancer Research* 70(18):7042-7052. (*Cover Illustration). PMID: 20823155. PMCID: PMC2940980.
215. Lee JS, Rodriguez-Luccioni H, Mendez J, Sood AK, Lopez-Berestein G, Rinaldi C, Torres-Lugo M (2011). Hyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis-diamminedichloroplatinum. *Journal of Nanoscience and Nanotechnology* 11(5):4153-4157.
216. Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya E, Pereira R, Han HD, Lopez-Berestein G, Klonisch T, Ittmann MM, Sood AK, Agoulnik AI (2010). Suppression of relaxin receptor decreases prostate cancer growth and metastasis. *Endocrine Related Cancer* 17:1021-1033.
217. Saad AF, Hu W, Sood AK (2010). Microenvironment and pathogenesis of epithelial ovarian cancer. *Hormones & Cancer* 1(6):277-290.
218. Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth W, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman KT, Bruckheimer E, Broaddus R, Gershenson DM, Coleman RL, Sood AK (2010). Clinical and Biological Impact of EphA2 Overexpression and Angiogenesis in Endometrial Cancer. *Cancer Biology and Therapy* 10(12):1306-1314.
219. Liggett T, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, Kamat A, Sood AK, Levenson V (2011). Unique cell-free plasma DNA methylation patterns in women with malignant ovarian tumors. *Gynecologic Oncology* 120:113-120.
220. Mann A, Somasunderam A, Nieves-Alicea R, Li X, Hu A, Sood AK, Ferrari M, Gorenstein D, Tanaka T (2010). A novel antagonistic thioaptamer ligand against E-selectin. *PLoS One* 5(9):e13050. Doi:10.1371/journal.pone.0013050
221. Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Vivas Mejia P, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK (2010). Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. *Molecular Cancer Therapeutics* 9(12):3186-3199. (*Cover Illustration). PMID 20889728.
222. Lutgendorf SK, DeGeest K, Dahmouh L, Farley D, Penedo F, Lucci JA, Bender D, Buekers T, Goodheart M, Mendez L, Krueger G, Clevenger L, Lubaroff DM, Sood AK, Cole SW (2011). Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. *Brain Behavior and Immunity* 25(2):250-255. PMID: 20955777. PMCID: PMC3103818.
223. Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Ahmed KA, Le XF, Australian Ovarian Cancer Study Group, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RC (2010). The centrosome kinase SIK2 is required for bipolar mitotic spindle formation and is a target for therapy in ovarian cancer. *Cancer Cell* 18:109-121.
224. Shahzad MMK, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK (2010). Stress effects on FosB and interleukin-8 (IL-8) driven ovarian cancer growth and metastasis. *The Journal of Biological Chemistry* 285 (46):35462-35470. PMID: 20826776. PMCID: PMC2975170.
225. Lamkin DM, Lutgendorf SK, Lubaroff DM, Sood AK, Beltz TG, Johnson AK (2011). Cancer induces

- inflammation and depressive-like behavior in the mouse: Modulation by social housing. *Brain, Behavior, & Immunity* 25(3):555-564.
226. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton C, Ozbun L, Armaiz-Pena G, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MMK, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbass EB, Lee J-S, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK (2010). Regulation of tumor angiogenesis by EZH2. *Cancer Cell* 18:185-197. PMID: 20708159.
227. Sood AK, Wilson MT, Herzog TJ (2011). Supporting gynecologic cancer research: The last 20 years and beyond. *Gynecologic Oncology* 120:319-320.
228. Huang J, Hu W, Sood AK (2011). Prognostic biomarkers in ovarian cancer. *Cancer Biomarkers* 8:231-251.
229. Shahzad M, Mangala L, Han HD, Lu C, Bottsford-Miller J, Mora EM, Lee JW, Stone RL, Thanappasr D, Roh JW, Gaur P, Nair MP, Park YY, Sabnis N, Deavers MT, Lee SJ, Ellis LM, Lopez-Berestein G, McConathy W, Prokai L, Lacko A, Sood AK (2011). Targeted delivery of small interfering RNA using rHDL nanoparticles. *Neoplasia* 13(4):309-319. PMID: 21472135. PMCID: PMC3071079.
230. Pecot C, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK (2011). RNA interference in the clinic: Challenges and future directions. *Nature Reviews Cancer* 11:59-67. (*Cover Illustration). PMID: 21160526.
231. Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MMK, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK (2011). Functional and biological roles of Src and Fgr in ovarian carcinoma. *Clinical Cancer Research* 17(7):1713-1721.
232. Wang E, Bhattacharya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK, Bhattacharya R (2011). Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. *PLoS One* 6(3):1-9.
233. Chakravarty D, Roy SS, Babu CR, Dandamudi R, Vivas-Mejia P, Curiel TJ, Lopez-Berestein G, Sood AK, Vadlamudi RK (2011). Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. *Clinical Cancer Research* 17(8):2250-2259.
234. Han HD, Mora EM, Roh JW, Nishimura M, Lee SJ, Stone RL, Bar-Eli M, Lopez-Berestein G, Sood AK (2011). Chitosan hydrogel for localized gene silencing. *Cancer Biology & Therapy* 11(9):839-845. (*Commentary by Sundaram Ramakrishnan)
235. Lutgendorf SK, Sood AK (2011). Biobehavioral factors and cancer progression: Physiological pathways and mechanisms. *Psychosomatic Medicine* 73:724-730.
236. Schauer IG, Sood AK, Mok S, Liu J (2011). The functional role of activated fibroblasts in ovarian cancer development. *Neoplasia* 13(5):393-405.
237. Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK,

- Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM (2011). Beta-blocker use is associated with improved relapse-free survival in patients with triple negative breast cancer. *Journal of Clinical Oncology* 29(19):2645-2652. (*Accompanying editorial by Patricia Ganz and Steven W. Cole)
238. Sood AK, Lutgendorf SK (2011). Stress influences on anoikis. *Cancer Prevention Research* 4:481-485. (*Cover illustration)
239. Moreno-Smith M, Lu C, Shahzad MMK, Armaiz-Pena GN, Allen JK, Stone RL, Mangala LS, Han HD, Kim HS, Farley D, Lopez-Berestein G, Cole SW, Lutgendorf SK, Sood AK (2011). Dopamine blocks stress mediated tumor growth in ovarian carcinoma. *Clinical Cancer Research* 17(11):3649-3659. (*Cover illustration). PMID: 21531818. PMCID: PMC3107884.
240. Thanappapasr D, Hu W, Sood AK, Coleman RL (2012). Moving beyond VEGF for anti-angiogenesis strategies. *Current Pharmaceutical Design* 18:2713-2719.
241. Samuel S, Gaur P, Fan F, Xia L, Gray MJ, Dallas NA, Bose D, Lopez-Berestein G, Plowman G, Bagri A, Sood AK, Ellis LM (2011). Neuropilin-2 mediated β -catenin signaling and survival in human gastrointestinal cancer cell lines. *PLoS One* 6(10):e23208. doi:10.1371/journal.pone.0023208
242. Rupaimoole R, Han HD, Lopez-Berestein G, Sood AK. MiRNA therapeutics: Principles, expectations and challenges (2011). *Chinese Journal of Cancer* 30(6):368-370. (*Cover illustration)
243. Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MMK, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK*, Lopez-Berestein G* (2011). Silencing surviving splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer. *Clinical Cancer Research* 17(11):3716-3726. (*Joint Senior Authors)
244. Stany M, Ozbun L, Vathipadiekal V, Stone RL, Mok S, Xue H, Kagami T, Wang Y, McAlpine JN, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang Y-Z, Vivas Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ (2011). Genomic analysis of microdissected ovarian clear cell cancers identifies histotype specific therapeutic targets. *PLoS One* 6(7): e21121. doi:10.1371/journal.pone.0021121 (1-13).
245. The Cancer Genome Atlas Research Network (Sood AK – Co-Author; Spellman PT – Corresponding Author) (2011). Integrated genomic analyses of ovarian carcinoma. *Nature* 474:609-615.
246. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA (2011). MicroRNAs in body fluids – the mix of hormones and biomarkers. *Nature Reviews Clinical Oncology* 8:467-477.
247. Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MMK, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshein NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK (2011). Targeting Src in mucinous ovarian carcinoma. *Clinical Cancer Research* 17(16):5367-5378. PMID: 21737505.
248. Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez R, Lopez-Berestein G, Sood AK, Landen CN (2011). Targeting the Notch ligand Jagged1 in both tumor cell and stroma in ovarian cancer. *Clinical Cancer Research* 17(17):5674-5685.
249. Hu W, Lu C, Han HD, Huang J, Shen D-Y, Stone RL, Nick AM, Shahzad MMK, Mora E, Jennings NB,

- Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AK (2011). Biological roles of tumor and endothelial delta-like ligand 4 in ovarian cancer. *Cancer Research* 71(18):6030-6039.
250. Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming JB, Abdalla EK, Curley SA, Vauthey JN, Sood AK, Yao JC, Ellis LM (2011). Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. *Gastroenterology* 141(5):1728-1737.
251. Kang Y, Lutgendorf SK, Hu W, Cole SW, Sood AK (2012). Stress related neuroendocrine influences in ovarian cancer. *Current Cancer Therapy Reviews* 8:100-109, 2012.
252. Vaughan S, Coward J, Bast R, Berchuck A, Berek J, Brenton J, Coukos G, Crum C, Drapkin R, Etemadmoghadam D, Freidlander M, Gabra H, Kaye S, Lord C, Lengyel E, Levine D, McNeish I, Menon U, Mills G, Nephew K, Oza A, Sood A, Stronach E, Walczak H, Bowtell D, Balkwill F (2011). Rethinking ovarian cancer: Recommendations for improving outcomes. *Nature Reviews Cancer* 11:719-725.
253. Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM (2012). Reclassification of serous carcinoma of the ovary using a two-tier grading system: A Gynecologic Oncology Group study. *Cancer* 118:3087-94.
254. Melhem-Bertrandt A, Sood AK (2012). New directions in combating stress effects on cancer. *Cancer Prevention Research* 5(2):147-149.
255. Coleman RL, Duska L, Ramirez PT, Kamat AA, Modesitt SC, Schmeler KM, Iyer R, Garcia M, Miller D, Kundra V, Jaffe R, Sood AK (2011). Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. *Lancet Oncology* 12:1109-1117. (*Published with editorial by Dr. Gordon Jayson)
256. Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein, Sood AK (2011). Silencing of p130Cas in ovarian carcinoma: A novel mechanism for tumor cell death. *Journal of the National Cancer Institute* 103:1-17, 2011.
257. Sood AK, Coleman RL, Ellis LM (2012). Moving beyond anti-VEGF therapy in ovarian cancer. *Journal of Clinical Oncology* 30(4):345-347.
258. Zand B, Coleman RL, Sood AK (2012). Targeting angiogenesis in gynecologic cancers. *Hematology Oncology Clinics* 26(3):543-563.
259. Jackson DB, Sood AK (2011). Personalized cancer medicine: Advances and socioeconomic challenges. *Nature Reviews Clinical Oncology* 8:735-741.
260. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora M, Patel C, Orina JN, Eliseeva T, Singal V, Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Seiden MV, Rueda BR, Ambudkar SV, Gottesman MM (2011). Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. *Proceedings of the National Academy of Sciences* 108(46):18708-18713.

261. Frumovitz M, Kriseman ML, Sun CC, Blumenthal-Barby J, Bodurka DC, Sood AK, Soliman PT (2012). Unverifiable academic accomplishments and publications on applications for gynecologic oncology fellowships. *Obstetrics & Gynecology* 119(3):504-508. (*Editorial by Lee A. Learman, M.D., Ph.D.)
262. Berger JL, Westin SN, Fellman B, Rallapali V, Frumovitz M, Ramirez PT, Sood AK, Soliman PT. Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction: An analysis of surgical outcomes (2012). *Gynecologic Oncology* 125(1):252-255.
263. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W (2011). Association of BRCA2 but not BRCA1 mutations with beneficial survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. *Journal of the American Medical Association* 306(14):1557-1565. (*Accompanying Editorial by Grann VR and Parsons RE)
264. Pecot CV, Bischoff FZ, Mayer JA, Wong K, Pham T, Bottsford-Miller J, Stone RL, Lin YG, Jaladurgam P, Roh JW, Goodman BW, Merritt WM, Pircher TJ, Mikolajczyk SD, Nick AM, Celestino J, Eng C, Ellis LM, Deavers MT, Sood AK (2011). Novel platform for detection of CK+ and CK-CTCs. *Cancer Discovery* 1(7):580-586.
265. Zhang W, Yang D, Sood AK (2012). Exploring clinical and molecular differences between BRCA1 and BRCA2 mutations in serous ovarian carcinoma. Reply to correspondence. *Journal of the American Medical Association* 307(4):360-361.
266. Hussein YR, Sood AK, Bandyopadhyay S, Albashiti B, Semaan A, Nahleh Z, Bitar BS, Roh J, Han HD, Lopez-Berestein G, Ali-Fehmi R (2012). Clinical and biological relevance of EZH2 in triple negative breast cancer. *Human Pathology* 43(10):1638-1644.
267. Cole SW, Sood AK. Beta-adrenergic signaling in cancer (2012). *Clinical Cancer Research* 18(5):1201-1216.
268. Li L, Cao X-H, Chen S-R, Han H-D, Lopez-Berestein G, Sood AK, Pan H-L. Upregulation of Cav α_3 Subunit in Primary Sensory Neurons Increases Voltage-Activated Ca $^{2+}$ Channel Activity and Nociceptive Input in Neuropathic Pain (2012). *The Journal of Biological Chemistry* 287(5):1201-1206.
269. Wu S, Sood AK (2012). New roles opined for OPCML. *Cancer Discovery* 2(2):115-116.
270. Schmeler KM, Sood AK, Bell-McGuinn KM, Coleman RL, Frumovitz M, Sonoda Y, Ramirez PT, Gershenson DM, Barakat RR, Gardner GJ (2012). Proceedings from the 9th International Conference on Ovarian Cancer. *Gynecologic Oncology* 125(1):5-7.
271. Romero Noguera I, Sun CC, Broaddus RR, Branham D, Levenback C, Ramirez PT, Sood AK, Coleman RL, Gershenson DM (2012). Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum or fallopian tube. *Gynecologic Oncology* 125:640-645.
272. Gillet J-P, Calcagno AM, Varma S, Davidson B, Elstrand MB, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM (2012). Multidrug resistance-linked gene signature predicts overall survival of patients with ovarian primary serous carcinoma. *Clinical Cancer Research* 18(11):3197-3206.

273. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes K, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC, Mills GB (2012). Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory epithelial ovarian cancer. *Gynecologic Oncology* 126:47-53.
274. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupaimoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MMK, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Collins K, Gushiken F, Lamkin D, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK (2012). Paraneoplastic thrombocytosis in ovarian cancer. *The New England Journal of Medicine* 366(7):610-618. (Covered in: *Cancer Discovery*; selected for Faculty of 1000) (*Selected by the Columbia Hospital for Women Research Foundation for the best overall publication in 2012)
275. Stone RL, Afshar-Kharghan V, Sood AK (2012). Paraneoplastic thrombocytosis in ovarian cancer. Response to Naina HV, Harris S. *The New England Journal of Medicine* 366(19):1840.
276. Liu Y, Sun Y, Broaddus R, Liu J, Sood AK, Shmulevich I, Zhang W. Integrated analysis of gene expression profile and tumor nuclear images associated with chemotherapy response in serous ovarian adenocarcinoma (2012). *PLoS One* 7(5):e36383.
277. Klionsky DJ, et al. (Sood AK – Co-Author) (2012). Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* 8(4):445-544.
278. Clevenger L, Schrepf A, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart MJ, Penedo F, Lubaroff DM, Sood AK, Lutgendorf SK (2012). Sleep disturbance, cytokines, and fatigue in women with ovarian cancer. *Brain Behavior and Immunity* 26:1037-1044.
279. Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK, Hu W (2012). Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. *Cancer Biology and Therapy* 13(11):1034-1041.
280. Lutgendorf SK, DeGeest K, Bender D, Ahmed A, Goodheart MJ, Dahmouch L, Zimmerman MB, Penedo FJ, Lucci JA, Ganjei-Azar P, Thaker PH, Mendez L, Lubaroff DM, Slavich GM, Cole S, Sood AK (2012). Social influences on clinical outcome of ovarian cancer patients. *Journal of Clinical Oncology* 30(23):2885-2890.
281. Lee SJ, Ghosh SC, Han HD, Stone RL, Bottsford-Miller J, Shen DY, Auzenne EJ, Lopdz-Araujo A, Lu C, Nishimura M, Pecot CV, Zand B, Thanappapasr D, Jennings NB, Kang Y, Huang J, Hu W, Klostergaard J, Sood AK (2012). Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. *Clinical Cancer Research* 18(15):4114-4121.
282. Shahzad MMK, Shin YH, Matsuo K, Lu C, Nishimura M, Stone RL, Mora EM, Rodriguez-Aguayo C, Bottsford-Miller J, Lopez-Berestein G, Rajkovic A, *Sood AK* (2013). Biological significance of HORM-A domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. *Cancer Letters* 330(2):123-129. *Joint senior authors
283. Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JMG, Jennings NB, Scott S, Vence

- L, Wei Q, Kentor D, Radvanyi L, Tannir N, Jonasch E, Tamboli P, Pisters L (2012). Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: Role of inflammatory signaling. *PLoS One* 7(8):e42324. Doi:10.1371/journal.pone.0042324 (1-8).
284. Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK (2012). Targeting PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. *Breast Cancer Research* 14:R108 (1-15).
285. Armaiz-Pena GN, Cole SW, Lutgendorf SK, Sood AK (2013). Neuroendocrine influences on cancer progression. *Brain, Behavior, and Immunity* 30 (SUPPL.):S19-S25.
286. Zhou J, Roh J-W, Bandyopadhyay S, Chen Z, Munkarah A, Hussein Y, Alesh B, Jazaerly T, Sood AK, Ali-Fehmi R. Overexpression of enhancer of zeste 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma (2013). *Gynecologic Oncology* 128:344-348.
287. Wu CC, Yang TY, Yu CTR, Phan L, Ivan C, Sood AK, Hsu SL, Lee MH (2012). P53 negatively regulates Aurora-A *via* transcriptional and post-translational regulation. *Cell Cycle* 11(18):3433-3442.
288. Bottsford-Miller JN, Coleman RL, Sood AK (2012). Resistance and escape from anti-angiogenesis therapy: Clinical implications and future strategies. *Journal of Clinical Oncology* 30(32):4026-4034.
289. Zhou HY, Chen SR, Byun HS, Chen H, Li L, Han HD, Lopez-Berestein G, Sood AK, Pan HL (2012). N-methyl-D-aspartate receptor- and calpain-mediated proteolytic cleavage of K⁺ Cl⁻ cotransporter-2 impairs spinal chloride homeostasis in neuropathic pain. *Journal of Biological Chemistry* 287(40):33853-33864.
290. Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, Zhang W (2012). BRCAness in ovarian cancer: Different characteristics of BRCA1 and BRCA2 mutations. *Pharmacogenomics* 13(13):1523-1535.
291. Kloc M, Tejpal N, Sidhu J, Ganachari M, Flores-Villanueva P, Jennings NB, Sood AK, Kubiak JZ, Ghobrial RM. Inverse relationship between TCTP/RhoA and p53/cyclin A/actin expression in ovarian cancer cells (2012). *Folia Histochemica Et Cytobiologica* 50(3):358-367.
292. Matsuo K, Sheridan TB, Yoshiro K, Miyake T, Hew KE, Im DD, Rosenshein NB, Mabuchi S, Enomoto T, Kimura T, Sood AK, Roman LD (2012). Significance of lymphovascular invasion in epithelial ovarian cancer. *Cancer Medicine* 1(2):156-164.
293. Cho MS, Bottsford-Miller J, Vasquez HG, Stone RL, Zand B, Kroll M, Sood AK, Afshar-Kharghan V (2012). Platelets increase the proliferation of ovarian cancer cells *in vitro* and *in vivo*. *Blood* 120 (2):4869-4872.
294. Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK (2012). Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group Study. *Gynecologic Oncology* 127(1):70-74.
295. Wang Y, Hu X, Greshock J, Shen L, Yang X, Shao Z, Shun L, Tanyi J, Sood AK, Zhang L (2012). Genomic DNA copy-number alterations of the let-7 family in human cancers. *PLoS One* 7(9):e44399. Doi:10.1371/journal.pone.0044399.

296. You J, Zhang R, Xiong C, Zhong M, Melancon M, Gupta S, Nick AM, Sood AK, Li C (2012). Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. *Cancer Research* 72(18):4777-4786.
297. Tekedereli I, Alpay SN, Tavares CDJ, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, Ozpolat B (2012). Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. *PLoS One* 7(7):e41171. Doi:10.1371/journal.pone (1-12).
298. Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A, Lopez-Berestein G, Ozpolat B, Ittmann M. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors (2012). *Clinical Cancer Research* 18(24):6648-6657.
299. Miyake T, Sood AK, Coleman RL (2013). Contemporary use of bevacizumab in ovarian cancer. *Expert Opinion on Biological Therapy* 13(2):283-294.
300. You J, Zhang R, Zhang G, Zhong M, Liu Y, Van Pelt CS, Liang D, Wei W, Sood AK, Li C (2012). Photothermal-chemotherapy with doxorubicin-loaded hollow gold nanospheres: A platform for near-infrared light-triggered drug release. *Journal of Controlled Release* 158:319-328.
301. Ziebarth AJ, Newshean S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Connor M, Yang ES, Landen CN (2013). Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. *Clinical Cancer Research* 19(1):170-182.
302. Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK (2013). Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. *Gynecologic Oncology* 128:506-511.
303. Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh K, Sood AK (2012). A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group (GOG) study. *Gynecologic Oncology* 127:538-543.
304. Nagaraja AS, Armaiz-Pena GN, Lutgendorf SK, Sood AK (2013). Why stress is BAD for cancer patients. *Journal of Clinical Investigation* 123(2):558-560.
305. Park Y-Y, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem S-H, Lin SY, Lopez-Berestein G, Sood AK, Lee J-S (2012). FOXM1 mediates doxorubicin resistance in breast cancer by enhancing DNA repair. *Carcinogenesis* 33(10):1843-1853.
306. Coleman RL, Monk BJ, Sood AK, Herzog TJ (2013). Latest research and clinical treatment of advanced-stage epithelial ovarian cancer. *Nature Reviews Clinical Oncology* 10(4):211-224.
307. Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt R, Kwan SY, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC (2013). Identification of fibroblast growth factor receptor 4 (FGFR4) as a potential therapeutic target for advanced-stage high-grade serous ovarian cancer. *Clinical Cancer Research* 19(4):809-820.
308. Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, Liu J (2013). Interleukin-

- 1 β promotes ovarian tumorigenesis through a p53/NF- κ B-mediated inflammatory response in stromal fibroblasts. *Neoplasia* 15(4):409-20.
309. Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G (2013). Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. *Clinical Cancer Research* 19(7):1806-1815. *Co-corresponding authors
310. Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, Lu Y, Rodriguez-Aguayo C, Lopez-Berestein G, Mills GB, Sood AK, Lee JS (2013). Tat-activation regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. *Hepatology* 58(1):182-191.
311. Yang D, Sun Y, Hu L, Ji P, Pecot CV, Zheng H, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, Shmulevich I, Sood AK*, Chen K*, Zhang W* (2013). Integrated analysis reveals a poor prognostic mesenchymal subtype driven by a key microRNA network in serous ovarian cancer. *Cancer Cell* 23:186-199. *Co-corresponding authors (*Cover Illustration)
312. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas Mejia P, Zand B, Schmandt R, Wang H, Langley RR, Jennings JB, Ivan C, Coffin JE, Armaiz-Pena GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJC, Bornmann W, Bar-Eli M, Lee JS, Siddik AH, Lopez-Berestein G, Sood AK (2013). ATP11B mediates platinum resistance in ovarian cancer. *Journal of Clinical Investigation* 125(3):2119-2130.
313. Schrepf A, Clevenger L, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart MJ, Dahmouch L, Penedo F, Lucci JA, Ganjei-Azar P, Mendez L, Markon K, Lubaroff DM, Thaker PH, Slavich GM, Sood AK, Lutgendorf SK. Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: Relationships with depression, fatigue, and disability. *Brain, Behavior, and Immunity* 30 (SUPPL.):S126-S134.
314. Clevenger L, Schrepf A, DeGeest K, Bender D, Goodheart M, Ahmed A, Dahmouch L, Penedo F, Lucci J, Thaker P, Mendez L, Sood AK, Slavich GM, Lutgendorf SK (2013). Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year post diagnosis. *Cancer* 119(17):3234-3241.
315. Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MMK, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK (2013). Src activation by β -adrenoreceptors is a key switch for tumor metastasis. *Nature Communications* 4:1403 doi: 10.1038/ncomms2413; 1-11.
316. Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS, He G, Rupaimoole R, Han HD, Jennings NB, Roh JW, Nishimura M, Kang Y, Allen JK, Armaiz GN, Matsuo K, Shahzad MMK, Bottsford-Miller J, Langley RR, Cole SW, Lutgendorf SK, Siddik ZH, Sood AK (2013). Biological effects of dopamine on tumor vasculature in ovarian carcinoma. *Neoplasia* 5(15):502-10.
317. Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AK (2013). Synergistic effects of combined valproic acid and the Aurora kinase inhibitor VE465 on gynecologic

- cancer cells. *Frontiers in Women's Cancer* 3:58. doi:10.3389/fonc.3013.00058.
318. Miller DFB, Yan PS, Buechlein A, Rodriguez BA, Yilmaz AS, Goel S, Lin H, Collins-Burow B, Rhodes LV, Braun C, Pradeep S, Rupaimoole R, Dalkilic M, Sood AK, Burow ME, Tang H, Huang TH, Liu Y, Rusch DB, Nephew KP (2013). A new method for stranded whole transcriptome RNA-seq. *Methods* 63:126-134.
319. Thaker PH, Melhem-Bertrandt A, Sood AK, Ramondetta LM (2013). Importance of adrenergic pathways in women's cancers. *Cancer Biomarkers* 13(3):145-154.
320. Jin Y, Qu S, Teslkova M, Wang L, Kristian A, Maelandsmo GM, Kong H, Zhang T, Jeronimo C, Teixeira MR, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Danielsen HE, Ozpolat B, Danielsen HE, Saatcioglu F (2013). A molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. *Proceedings of the National Academy of Sciences* 110(28):E2572-E2581.
321. Nagaraja AS, Sadaoui NC, Lutgendorf SK, Ramondetta LM, Sood AK (2013). Beta blockers: A new role in chemotherapy. *Expert Opinion on Investigational Drugs* 22(11):1359-1363.
322. Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Alpaugh K (2013). A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomas: A Gynecologic Oncology Group (GOG) study. *Gynecologic Oncology* 129(1):86-91.
323. Masiero M, Simoes FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, Li JL, Patient R, Sood AK, Banham AH, Harris AL, Buffa FM (2013). A core primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. *Cancer Cell* 24:229-241. (*Cover Illustration)
324. Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AK (2013). Role of focal adhesion kinase in regulating Y-box binding protein 1-mediated paclitaxel resistance in ovarian cancer. *Journal of the National Cancer Institute* 105(19):1485-1495.
325. Wong KK, Izaguirre D, Kwan S, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM (2013). Poor survival with wild-type TP53 in ovarian cancer. *Gynecologic Oncology* 130(3):565-569.
326. Gharpure KM, Sood AK (2013). Neighborhood matters: Response to EZH2 methyltransferase inhibitors. *Cell Cycle* 12(15):245-2347.
327. Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst K, Kurzrock AK (2013). Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. *Investigational New Drugs* 31(5):1192-1200.
328. Zhang X, Lu X, Lopez G, Sood AK, Calin G (2013). *In situ* hybridization-based detection of microRNAs in human diseases. *MicroRNA Diagnostics and Therapeutics* doi: 10.2478/micmat-2013-0002.MICRNAT.2013.12-23.

329. Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G (2013). Nanotechnology in cancer therapy. *Journal of Drug Targeting* 21(10):904-913.
330. Cata JP, Villarreal J, Keerty D, Thakar DR, Liu DD, Sood AK, Gottumukkala V (2014). Perioperative beta-blocker use and survival in lung cancer patients. *Journal of Clinical Anesthesia* 26(2):106-117.
331. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee J-S, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AK (2013). Tumor angiogenesis regulation by the miR-200 family. *Nature Communications* 4:2427 | doi: 10.1038/ncomms3427, pages 1-14.
332. Wan G, Hu X, Liu Y, Han C, Sood AK, Calin GA, Zhang X, Lu X (2013). A novel noncoding RNA lncRNA-JADE connects DNA damage signaling to histone H4 acetylation. *The EMBO Journal* 32:2833-2847.
333. Wang H, Heijnen CJ, van Velthoven CTJ, Willems HLDM, Ishikawa Y, Zhang X, Sood AK, Vroon A, Eijkelkamp N, Kavelaars A (2013). Balancing GRK2 and Epac1 levels prevents and relieves chronic pain. *Journal of Clinical Investigation* 123(12):5023-5034.
334. Shinn EH, Lenihan DJ, Urbauer D, Basen-Engquist K, Valentine A, Palmero L, Woods M, Patel P, Nick AM, Shahzad MMK, Stone RL, Golden A, Atkinson E, Lutgendorf SK, Sood AK. Impact of cardiovascular comorbidity on ovarian cancer mortality (2013). *Cancer Epidemiology, Biomarkers & Prevention* 22:2102-2109.
335. Lutgendorf SK, Slavich GM, DeGeest K, Goodheart M, Bender D, Thaker PH, Penedo F, Zimmerman B, Lucci J, Mendez L, Collins K, Sood AK (2013). Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients. *Gynecologic Oncology* 131:667-673.
336. Liu T, Hu W, Dalton HJ, Choi JH, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer D, Coleman RL, Frumovitz M, Sood AK (2013). Targeting Src and tubulin in mucinous ovarian carcinoma. *Clinical Cancer Research* 19(23):6532-6543.
337. Matsuo K, Nishimura M, Komurov K, Shahzad MMK, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK (2014). Platelet-derived growth factor receptor alpha (PDGFR α) targeting and relevant biomarkers in ovarian carcinoma. *Gynecologic Oncology* 132:166-175.
338. Zhaorigetu S, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G, Walton BL (2014). Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. *Journal of Liposome Research* 24(3):182-190.
339. Nishimura M, Jung E-J, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK*, Calin GA* (2013). Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. *Cancer Discovery* 3:1302-1315.
*Joint Senior Authors (*Accompanying editorial by A. Kasinski and Frank J. Slack: Small RNAs deliver a blow to ovarian cancer)

340. Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee P. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. *PLoS ONE* 8(11): e79167. doi:10.1371/journal.pone.0079167; pages 1-12.
341. Tekedereli I, Alpay SN, Akar U, Yuca E, Aguayo-Rodriguez C, Han HD, Sood AK, Lopez-Berestein G, Ozpolat B. Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (-) and ER (+) breast cancer. *Molecular Therapy Nucleic Acids*. 2013 Sep 10;2:e121. doi: 10.1038/mtna.2013.45. PMID: 24022053
342. Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, Seo BY, Kim J, Eskiocak B, Chung H, McMillan E, Wu S, De Brabander J, Komurov K, Rodriguez-Aguayo C, Lopez-Berestein G, Toombs JE, Wei S, Peyton M, Williams N, Gazdar AF, Posner BA, Brekken RA, Sood AK, Deberardinis RJ, Roth MG, Minna JD, White MA (2013). Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. *Cell* 155:552-566.
343. Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC, Liu J (2013). CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. *International Journal of Gynecological Cancer* 23(5):815-822.
344. Dalton HJ, Armaiz-Pena G, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M, Sood AK (2014). Monocyte subpopulations in angiogenesis. *Cancer Research* 74(5):1-7.
345. Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer J, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen C, Eblen ST (2014). EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. *Carcinogenesis* 35(5):1100-1109.
346. Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh J, Thanappapras D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings JB, Huang L, Deavers MT, Broaddus R, Coleman RL, Sood AK (2014). Crosstalk between EphA2 and BRaf/CRaf is a key determinant of response to dasatinib. *Clinical Cancer Research* 20(7):1846-1855. *Selected for Highlights
347. Wu SY, Yang X, Gharpure K, Hatakeyama H, Egli M, McGuire M, Nagaraja AS, Miyake T, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena G, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhanian R, Han HD, Su C, Kim JH, Dalton H, Kowali C, Keyomarsi K, McMillan NAJ, Overwijk WW, Liu J, Lee JS, Baggerly K, Lopez-Berestein G, Ram P, Nawrot B, Sood AK (2014). 2'-OMe-phosphorodithioate siRNAs show increased loading into the RISC complex and enhanced anti-tumor activity. *Nature Communications* 5:3459 doi: 10.1038/ncomms4459.
348. Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton H, Ivan C, Baggerly K, Lopez-Berestein G, Sood AK*, Afshar-Kharghan V* (2014). Autocrine effects of tumor-derived complement. *Cell Reports* 6:1085-1095. *Joint senior authors
349. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK,

- Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK (2014). Antagonism of tumoral prolactin receptor promotes autophagy related cell death. *Cell Reports* 7:488-500.
350. Matsuo K, Yoshino K, Hiramatsu K, Banzai C, Hasegawa K, Yasuda M, Nishimura M, Sheridan TB, Ideda Y, Shiki Y, Mabuchi S, Enomoto T, Kimura T, Fujiwara K, Roman LD, Sood AK (2014). Impact of lymphovascular space invasion on survival of stage I epithelial ovarian cancer patients. *Obstetrics and Gynecology* 123(5):957-965.
351. Joshi HP, Subramanian IV, Schnettler EK, Ghosh G, Rupaimoole R, Evans C, Saluja M, Jing YW, Ivan C, Zeng Y, Shah VH, Sood AK, Ramakrishnan S. Dynamin 2 along with miR-199a reciprocally regulate HIF and ovarian cancer metastasis (2014). *Proceedings of the National Academy of Sciences* 111(14):5331-5336.
352. Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D, Kerrigan BCP, Shmulevich I, Chen K, Sood AK, Xue F, Zhang W (2014). MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. *The Journal of Pathology* 233:308-318. *Cover Illustration
353. Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV (2014). Platelets and cancer: A casual or causal relationship revisited. *Cancer and Metastasis Reviews* 33:231-269.
354. Jeong W, Kim S-B, Sohn BH, Park YY, Park ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DSL, Mills GB, Sood A, Lee J-S (2014). Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. *Anticancer Research* 34:811-818.
355. Guo F, Parker B, Yang D, Hu L, Shmulevich I, Sood AK, Xue F, Zhang W (2014). Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions. *Journal of Hematology & Oncology* 7(1).
356. Roh JW, Huang J, Hu W, Yang XY, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapparasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee JS, Ram P, Coleman RL, Sood AK (2014). Biological effects of platelet-derived growth factor receptor α blockade in uterine cancer. *Clinical Cancer Research* 20 (10):2740-2750.
357. Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M (2014). Randomized phase II study of docetaxel plus vandetanib vs. docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. *European Journal of Cancer* 50:1638-1648.
358. Matsuo K, Sheridan TB, Mabuchi S, Yoshino K, Hasegawa K, Studeman KD, Im DD, Rosenshein NB, Roman LD, Sood AK (2014). Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. *Gynecologic Oncology* 133(3):473-479.
359. Yang L, Moss T, Lingegowda S. Mangala, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Rupaimoole R, Rodriguez-Aguayo C, Mercado-Urbe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT, Nagrath D (2014). Metabolic shifts toward glutamine regulates aggressive tumor growth, invasion and bioenergetics in ovarian cancer. *Molecular Systems Biology* 10(5):728.
360. Guo F, Cogdell D, Hu L, Yang D, Sood AK, Xue F, Zhang W (2014). Mir-101 suppresses the epithelial-

- to-mesenchymal transition by targeting *ZEB1* and *ZEB2* in ovarian carcinoma. *Oncology Reports* 31:2021-2028.
361. Stone RL, Baggerly KA, Armaiz-Pena G, Sanguino AM, Thanappapas D, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, Lutgendorf SK, Sood AK. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. *Cancer Biology & Therapy* 15(7):919-929.
362. Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han Hee HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK (2014). Notch3 pathway alterations in ovarian cancer. *Cancer Research* 74(12):3282-3293.
363. Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK (2014). Molecular predictors of residual disease after cytoreductive surgery in patients with high-grade serous ovarian cancer. *Clinical Cancer Research* 20(12):3280-3288.
364. Abu-Rustum N, Chi D, Coleman RL, del Campo JM, Fotopoulou C, Frumovitz M, Gershenson DM, Gonzalez A, Jhingran A, Ledermann J, Mariani A, Mirza M, Oaknin A, Ramirez PT, Schmeler KM, Sood AK (2014). Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: Emerging Therapies in Gynecologic Cancer. *Gynecologic Oncology* 134(1):6-9.
365. Davis A, Afshar-Kharghan V, Sood AK (2014). Platelet effects on ovarian cancer. *Seminars in Oncology* 41(3):378-384.
366. Gharpure KM, Chu KS, Bowerman C, Miyake T, Pradeep S, Mangala LS, Han HD, Rupaimoole R, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AK (2014). Metronomic docetaxel in PRINT® nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. *Molecular Cancer Therapeutics* 13(7):1750-1757. *Cover Illustration
367. Choi HJ, Armaiz-Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK (2015). Anti-vascular therapies in ovarian cancer: Moving beyond anti-VEGF approaches. *Cancer and Metastasis Reviews* 34(1):19-40.
368. Reusser NM, Dalton HJ, Pradeep S, Gonzalez-Villasana V, Jennings NB, Vasquez HG, Wen Y, Rupaimoole R, Pecot CV, Nagaraja AS, Gharpure K, Miyake T, Huang J, Hu W, Lopez-Berestein G, Sood AK (2014). Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. *Cancer Biology & Therapy* 15(8):1061-1067.
369. Rytelewski M, Tong J, Buensuceso A, Leong HS, Vareki SM, Figueredo R, Di Cresce C, Herbrich SM, Baggerly KA, Romanow L, Shepherd T, Deroo BJ, Sood AK, Chambers A, Vincent M, Ferguson PJ, Koropatnick J (2014). BRCA2 inhibition modulates tumor proliferation, metabolic response and metastatic frequency following cisplatin treatment. *Molecular Oncology* 8(8):1429-1440.
370. Liu Y, Patel L, Mills G, Lu K, Sood AK, Li D, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, Broaddus R, Zhang W (2014). Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. *Journal of the National Cancer Institute* 106(9): dju245 doi:10.1093/jnci/dju245

371. Menter DG, Swank MW, Patterson SL, Logsdon C, Kopetz S, Sood AK, Hawk ET (2014). Convergence of nanotechnology and cancer prevention: Are we there yet? *Cancer Prevention Research* 7(10); 973–92. *Cover Illustration
372. Wu SY, Lopez-Berestein G, Calin GA, Sood AK (2014). Targeting the undruggable: Advances and obstacles in current RNAi therapy. *Science Translational Medicine* 6(240):240ps7.
373. Han C, Liu Y, Wan G, Choi HJ, He X, Ivan C, Sood AK*, Zhang X*, Lu X* (2014). The RNA-binding protein DDX1 promotes microRNA maturation and inhibits ovarian tumor progression. *Cell Reports* 8:1447-1460. *Co-corresponding authors
374. Leung CS, Yeung T-L, Yip K-P, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena G, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC (2014). Calcium Dependent FAK/CREB/TNNC1 Signaling Mediates the Effect of Stromal MFAP5 on Ovarian Cancer Metastatic Potential. *Nature Communications* 5:5092 doi: 10.1038/ncomms6092.
375. Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Deng D, Fuentes-Mattei E, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Aslan B, Gutierrez-Puente Y, Ozpolat B, Reuben JM, Sood AK, Logsdon C, Lopez-Berestein G (2014). Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin Bound-Paclitaxel in Pancreatic Ductal Adenocarcinoma. *Molecular Cancer Therapeutics* 13 (11):2583-2594.
376. Gizzatov A, Stigliano C, Ananta JS, Sethi R, Xu R, Guven A, Ramirez M, Shen H, Sood A, Ferrari M, Wilson LJ, Liu X, Decuzzi P (2014). Geometrical confinement of Gd(DOTA) molecules in mesoporous silicon nanoconstructs for cancer imaging. *Cancer Letters* 352:97-101.
377. Tamir A, Jag UR, Schindewolf CD, Tanaka T, Gharbaran R, Sarojini S, Paten HA, Sood AK, Hu W, Patwa R, Blake PM, Lim H, Goy AH, Pecora AH, Suh KS (2014). Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous subtypes of ovarian cancer. *The Journal of Ovarian Research* 7:109 doi:10.1186/s13048-014-0109-z
378. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvaly-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Jeong LH, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK (2014). Hematogenous metastasis of ovarian cancer: Rethinking mode of spread. *Cancer Cell* 26:77-91.
379. Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Bottsford-Miller J, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AK (2014). Hypoxia mediated downregulation of miRNA biogenesis leads to increased tumor progression. *Nature Communications* 5:5202 doi: 10.1038/ncomms6202.
380. Van den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, Voncken JW, Harris AL, Buffa FM, Haider S, Starmans MHW, Yao CQ, Ivan M, Ivan C, Pecot CV, Boutros PC, Sood AK, Koritzinsky M, Wouters BG (2014). Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. *Nature Communications* 5:5203 doi: 10.1038/ncomms6203.

381. Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang W (2015). MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. *The Journal of Pathology* 235(1):25-36.
382. Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Hazam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK (2014). Therapeutic silencing of KRAS using systemically delivered siRNAs. *Molecular Cancer Therapeutics* 13(12):2876-2885.
383. Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, Woodward WA, Liang H, Yang X, Lopez-Berestein G, Sood AK, Hu Y, Ang KH, Chen J, Ma L (2014). MiR-205 acts as a tumor radiosensitizer by targeting ZEB1 and Ubc13. *Nature Communications* 5:5671 doi: 10.1038/ncomms6671, pages 1-10.
384. Chaoul A, Milbury K, Sood AK, Prinsloo S, Cohen L (2014). Mind-body practices in cancer care. *Current Oncology Reports* 16(12):417.
385. Yang X, Shen F, Hu W, Coleman RL, Sood AK (2015). New ways to successfully target tumor vasculature in ovarian cancer. *Current Opinion in Obstetrics and Gynecology* 27(1):58-65.
386. Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton M, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peugeot S, Rodriguez-Aguayo C, Han HD, Zhang D, Liu W, Venkatanarayan A, Krohn M, Lopez-Berestein G, Kristensen VN, Gagea M, Ram P, Lorenzi PL, Borresen-Dale A-L, Chin K, Gray J, Duseti NJ, McGuire SE, Flores ER, Sood AK, Mills GB (2014). Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. *Cancer Cell* 26(6):863-879.
387. Previs RA, Coleman RL, Harris AL, Sood AK (2015). Molecular pathways: Translational and therapeutic implications of the Notch signaling pathway in cancer. *Clinical Cancer Research* 21(5):955-961.
388. Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Sehgal V, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK (2015). Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. *Clinical Cancer Research* 21(2):488-459.
389. Bottsford-Miller J, Choi HJ, Dalton HJ, Stone RL, Cho M, Haemmerle M, Nick AM, Pradeep S, Zand B, Previs R, Pecot CV, Crane EK, Hu W, Lutgendorf S, Afshar-Kharghan V, Sood AK (2015). Differential platelet levels affect response to taxane-based therapy in ovarian cancer. *Clinical Cancer Research* 21(3):602-610.
390. Sun Y, Guo F, Bognoli M, Xue F, Sun B, Shmulevich I, Mezzanzanica D, Chen K, Sood AK, Yang D, Zhang W (2015). The key nodes of a microRNA network associated with integrated mesenchymal subtype of high-grade serous ovarian cancer. *Chinese Journal of Cancer* 34(1):28-40.
391. Matsuo K, Yoshino K, Hasegawa K, Murakami R, Ikeda Y, Adachi S, Hiramatsu K, Yokoyama T, Nishimura M, Sheridan TB, Enomoto T, Fujiwara K, Matsumura N, Konishi I, Fotopoulou C, Roman LD, Sood AK (2015). Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular

- space invasion. *Gynecologic Oncology* 136:198-204.
392. Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Lutgendorf SK, Sood AK, Lopez-Berestein G (2014). Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. *Oncotarget* 6(6): 4266-4273.
393. Noh KH, Kim SH, Kim JH, Song KH, Lee YH, Kang TH, Han HD, Sood AK, Ng J, Kim K, Sonn CH, Kumar V, Yee C, Lee KM, Kim TW (2014). API5 confers tumor immune escape through FEF2-dependent cell survival pathway. *Cancer Research* 74(13):3556-3566.
394. Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, Sahin AA, Sood A, Mills GB, Yu D, Hortobagyi GN, Hung MC (2014). Definition of PKC- α , CDK6, and MET as therapeutic targets in triple-negative breast cancer. *Cancer Research* 74(17):4822-4835.
395. Schrepf A, Goodheart MJ, Bender D, Dahmouh L, Penedo F, Lucci JA, Thaker PT, Mendez L, Slavich G, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK (2015). Diurnal cortisol and survival in epithelial ovarian cancer. *Psychoneuroendocrinology* 53:256-267.
396. Gonzalez-Villasana V, Fuentes-Mattei E, Dalton H, Rodriguez-Aguayo C, Aslan B, Valazquez-Torres G, Previs R, Pradeep S, Ivan C, Kahraman N, Kanlikilicer P, Sood AK, Lopez-Berestein G (2015). Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer. *Clinical Cancer Research* 21(9):2127-37.
397. Jin Y, Wang L, Qu S, Kristian A, Maeldandsmo GM, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood AK, Lopez-Berestein G, Fazil L, Rennie PS, Risberg B, Waehre H, Dalielsen HE, Ozpolat B, Saatcioglu F (2015). STAMP2 increases oxidative stress and is critical for prostate cancer. *EMBO Molecular Medicine* 7:315-331.
398. Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, Velazquez-Torres G, Nip KM, Zhu K, Brooks D, Jones SJM, Birol I, Mosqueda M, Wen YY, Eterovic AK, Sood AK, Hwu P, Gershenwald JE, Robertson AG, Calin GA, Markel G, Fidler IJ, Bar-Eli M (2015). Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. *Nature Cell Biology* 17(3):311-321.
399. Nick AM, Coleman RL, Ramirez PT, Sood AK (2015). A framework for personalized surgical approach to ovarian cancer. *Nature Reviews Clinical Oncology* 12:239-245.
400. Thanappapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena G, Dorniak PL, Hansen JM, Rupaimoole R, Huang J, Dalton HJ, Ali R, Coleman RL, Sood AK (2015). PTEN expression as a predictor of response to focal adhesion kinase inhibition in uterine cancer. *Molecular Cancer Therapeutics* 14(6):1466-1475.
401. Bullock MD, Silva AM, Kanlikilicer P, Filant J, Rashed MH, Sood AK, Lopez-Berestein G, Calin GA (2015). Exosomal non-coding RNAs: Diagnostic, prognostic and therapeutic applications in cancer. *Non-Coding RNA* 1(1):53-68.
402. Aslan B, Monroig P, Hsu MC, Armaiz-Pena G, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala LS, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang

- H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein G (2015). The ZNF304-integrin axis protects against anoikis. *Nature Communications* 6:7351 doi: 10.1038/ncomms8351, pages 1-12.
403. Rodriguez Gomez-Hidalgo N, Martinez-Cannon BA, Nick AM, Sood AK, Coleman RL, Ramirez PT (2015). Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. *Gynecologic Oncology* 137(3):553-558.
404. Gharpure KM, Wu SY, Li C, Lopez-Berestein G, Sood AK (2015). Nanotechnology: Future of oncotherapy. *Clinical Cancer Research* 21(14):3121-3130.
405. Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MC, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AK (2015). XPO1/CRM1 inhibition causes anti-tumor effects by mitochondrial accumulation of eIF5A. *Clinical Cancer Research* 21(14):3286-3297.
406. Graybill W, Sood AK, Monk BJ, Coleman RL (2015). State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. *Gynecologic Oncology* 138:223-226.
407. Ozcan G, Ozpolat B, Coleman R, Sood AK, Lopez-Berestein G (2015). Preclinical and clinical development of siRNA-based therapeutics. *Advanced Drug Delivery Reviews* 87:108-119.
408. Matsuo K, Hom MS, Moeini A, Machida H, Takeshima N, Roman LD, Sood AK (2015). Significance of monocyte counts on tumor characteristics and survival outcome of women with endometrial cancer. *Gynecologic Oncology* 138(2):332-338.
409. Liu Y, Sato M, Zhao Y, Hu L, Cogdell D, Zheng H, Broaddus R, Gharpure KM, Pradeep S, Nagaraja AS, Shmulevich I, Chen K, Sood AK, Zhang W (2015). Association of somatic mutations of ADAMTS family genes with improved chemotherapy sensitivity and survival in serous ovarian carcinoma. *Journal of the American Medical Association Oncology* 1(4):486-494.
410. Moss TJ, Luo Z, Seviour EG, Sehgal V, Lu Y, Hill S, Rupaimoole R, Lee JS, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Azencott R, Gray JW, Mukerjee S, Mills GB, Ram PT (2015). Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. *Systems Biology and Applications* 1, 15001; doi:10.1038/npjsba.2015.1.
411. Davis LZ, Slavich GM, Thaker PH, Goodheart MJ, Bender D, Lubaroff DM, Dahmouch L, Farley D, Markon KE, Cole SW, Sood AK, Lutgendorf SK (2015). Eudaimonic well-being is associated with lower tumor norepinephrine in epithelial ovarian cancer patients. *Cancer* 121(19):3543-3550.
412. Matsuo K, Hasegawa K, Yoshino K, Murakami R, Hisamatsu T, Ikeda Y, Miyara A, Hiramatsu K, Enomoto T, Fujiwara K, Matsumura N, Konishi I, Roman LD, Gabra H, Fotopoulou C, Sood AK (2015). Venous thromboembolism, interleukin-6, and survival outcomes in patients with advanced ovarian clear cell carcinoma. *European Journal of Cancer* 51(14):1978-1988.
413. Zhou M, Li J, Liang S, Sood AK, Li C (2015). CuS nanodots with ultrahigh efficient renal clearance for positron emission tomography imaging and image-guided photothermal therapy. *ACS Nano* 9(7):7085-7096.

414. Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer D, Matsuo K, Squires K, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK (2015). Clinical impact of selective and non-selective beta-blockers on survival in ovarian cancer patients. *Cancer* 121(19):3444-3451.
415. Cole SW, Nagaraja AS, Lutgendorf SK, McDonald PG, Sood AK (2015). Sympathetic nervous system regulation of the tumour microenvironment. *Nature Reviews Cancer* 15(9):563-572.
416. Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, Le XF, Bast RC (2015). CDK5 regulates paclitaxel sensitivity in ovarian cancer cells by regulation of activation of AKT, p21Cip1- and p27Kip1-mediated G1 cell cycle arrest and apoptosis. *PLoS One* 10(7): <http://dx.doi.org/10.1371/journal.pone.0131833>.
417. Ravoori M, Singh S, Lu C, Han L, Pradeep S, Choi HJ, Bankson J, Sood AK, Kundra V (2015). Tumor T1 relaxation time for assessing response to bevacizumab anti-angiogenic therapy in a mouse ovarian cancer model. *PLoS One* 10(6):e0131095.
418. Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X (2015). TP53 loss creates therapeutic vulnerability in colorectal cancer. *Nature* 520:697-701.
419. Timsah Z, Ahmed Z, Ivan C, Gagea M, Berrout J, Gagea M, Zhou Y, Armaiz-Pena GN, Hu X, Vallien C, Kingsley CV, Lu Y, Hancock JF, Liu J, Gladden AB, Mills G, Lopez-Berestein G, Hung MC, Sood AK, Bogdanov M, Ladbury JE (2016). Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumour formation and contributes to poor prognosis in ovarian cancer. *Oncogene* 35:2186-2196.
420. Nagaraja AS, Dorniak PL, Sadaoui NC, Kang Y, Armaiz-Pena G, Wu SY, Rupaimoole R, Allen JK, Pradeep S, Zand B, Previs R, Hansen JM, Yang P, Rodriguez-Aguayo C, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK (2016). Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. *Oncogene* 35:2390-2397.
421. Jiang L, Nick AM,* Sood AK.* (2015) Fundamental principles of cancer biology: Does it have relevance to the postoperative period? *Current Anesthesiology Reports* 5(3):250-256 *Co-corresponding authors
422. Shinn EH, Valentine A, Jethanandani A, Basen-Engquist K, Fellman B, Urbauer D, Adkinson E, Yusuf SW, Lenihan D, Woods ML, Kies MS, Sood AK, Carmack C, Morrison WH, Gillenwater A, Sturgis EM, Garden AS (2016). Depression and oropharynx cancer outcome. *Psychosomatic Medicine* 78(1):38-48.
423. Srivastava A, Babu A, Filant J, Moxley KM, Ruskin R, Dhanasekaran D, Sood AK, McMeekin S, Ramesh R (2016). Exploitation of exosomes as nanocarriers for gene-, cemo-, and immune-therapy of cancer. *Journal of Biomedical Nanotechnology* 12(6):1159-1173.
424. Gaur S, Wen Y, Song JH, Mangala LS, Blessing A, Ivan C, Wu SY, Varkaris A, Shi Y, Parikh NU, Frigo DE, Sood AK, Gallick GE (2015). Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. *Oncotarget* 6(30): 29161-29177.

425. Reyes-Gonzalez JM, Armaiz-Pena G, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarria-Vargas I, Rivera A, Sood AK, Vivas-Mejia PE (2015). Targeting c-MYC in platinum-resistant ovarian cancer. *Molecular Cancer Therapeutics* 14(10):2260-2269.
426. Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, Pradeep S, Hwang JE, Jang HJ, Lee HS, Rupaimoole R, Lopez-Berestein G, Jeong W, Park IS, Park YN, Sood AK, Mills GB, Lee JS (2016). Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. *Hepatology* 63(1):159-172.
427. Klionsky DJ, et al. (Sood AK – Co-Author) (2016). Guidelines for the use and interpretation of assays for monitoring autophagy (2nd edition). *Autophagy* 12(1):1-222.
428. Bowtell D, Boehm S, Ahmed A, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer B, Blagden S, Bookman MA, Brenton J, Chiappinelli KB, Correia Martins F, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman, Iwanicki M, Karlan B, Kaye A, Lengyel E, Levine DA, Lu K, McNeish I, Menon U, Narod S, Nelson BH, Nephew K, Pharoah P, Powell D, Ramos P, Romero I, Scott C, Sood AK, Stronach EA, Balkwill F (2015). Rethinking ovarian cancer II: A roadmap for reducing mortality from high-grade serous ovarian cancer. *Nature Reviews Cancer* 15:668-679.
429. Previs RA*, Armaiz-Pena GN*, Lin YG*, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK (2015). Dual metronomic chemotherapy with Nab-paclitaxel and topotecan has potent anti-angiogenic activity in ovarian cancer. *Molecular Cancer Therapeutics* 14(12):2677-2786. *Co-first authors
430. Kendrick A, Pigeon LR, Craig SL, Wen Y, Sood AK, Lockworth CR (2016). Severe polyarthritis with implanted ovarian carcinoma cells in a mouse. *Journal of the American Veterinary Medical Association* 249(10):1149 – 1151.
431. Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, Fan L, Kandalaft LE, Tanyi JL, Li C, Yuan CX, Zhang D, Yuan H, Hua K, Lu Y, Katsaros D, Huang Q, Montone K, Fan Y, Coukos G, Boyd J, Sood AK, Rebbeck T, Mills GB, Dang CV, Zhang L (2015). Comprehensive genomic characterization of long non-coding RNAs across human cancers. *Cancer Cell* 28:529-540.
432. Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu S, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK (2015). Erythropoietin stimulates tumor growth via EphB4. *Cancer Cell* 28(5):610-622. (*Cover illustration) (*Highlighted in *Cancer Discovery*; selected by Faculty of 1000)
433. Shields BB, Pecot CV, Gao H, McMillan E, Potts M, Nagel C, Purinton S, Wang Y, Ivan C, Kim HS, Borkowski RJ, Khan S, Rodriguez-Aguayo C, Lopez-Berestein G, Lea J, Gazdar AF, Baggerly KA, Sood AK, White MA (2015). A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. *Molecular Systems Biology* 11(12):842.
434. Kang Y, Nagaraja AS, Armaiz-Pena G, Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA, Hansen JM, Rodriguez-Aguayo C, Ivan C, Ram P, Lopez-Berestein G, Lutgendorf SK, Cole SW,

- Sood AK (2016). Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer. *Clinical Cancer Research* 22(7):1713-1724.
435. Huang T, Poole EM, Okereke OI, Kubzansky LD, Eliassen AH, Sood AK, Wang M, Tworoger SS (2015). Depression and risk of epithelial cancer: Results from two large prospective cohort studies. *Gynecologic Oncology* 139:481 – 486.
436. Wang R, Stone RL, Rochat RH, Nick AM, Vijayan V, Afshar-Kharghan V, Schmid MF, Dong JF, Sood AK,* Chiu* (2015). Electron cryo-tomography reveals ultrastructure alterations in platelets from ovarian cancer patients. *Proceedings of the National Academy of Sciences* 112(46):14266-14271.
437. Rupaimoole R, Calin GA, Lopez-Berestein, Sood AK (2016). MicroRNA deregulation in cancer cells and the tumor microenvironment. *Cancer Discovery* 6(3):235-246.
438. Sercombe L, Veerati T, Mohemani F, Wu SY, Sood AK, Hua S (2015). Advances and challenges of liposome assisted drug delivery. *Frontiers in Pharmacology* 6:286.
439. Rupaimoole R, Previs RA, Lee J, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Zacharias Millward NM, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Mills GB, Zhang W, Lopez-Berestein G, Bhattacharya PK, Sood AK (2015). Novel long noncoding RNA ceruloplasmin promotes cancer growth by altering glycolysis pathway. *Cell Reports* 13:2395-2402.
440. Di Guilmi J, Salvo G, Nick A, Sood AK, Coleman RL, Lu KH, Mehran R, Vaporciyan A, Ramirez PT (2016). Role of video-assisted thoracoscopy in advanced ovarian cancer. A literature review. *International Journal of Gynecologic Cancer* 26(4):801-806.
441. Rupaimoole R, Ivan C, Yang D, Wu SY, Pecot CV, Previs RA, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Zhang W, Lopez-Berestein G, Calin GA, Sood AK (2016). Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. *Oncogene* 1-9.
442. Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo, Lopez-Berestein G, Sood AK, Hung MC, Beretta L (2016). Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor development, growth and phenotype and liver fibrosis. *Hepatology* 63(3):864-879.
443. Pu T, Xiong L, Liu Q, Zhang M, Cai Q, Liu H, Sood AK, Kang Y, Li G, Xu C (2017). Delineation of retroperitoneal metastatic lymph nodes in ovarian cancer with near-infrared fluorescence imaging. *Oncology Letters* 14:2869 – 2877.
444. Liu G, Yang D, Pecot CV, Sun Y, Li X, Ji P, Cogdell D, Hu L, De Cecco L, Mezzanzanica D, Rodriguez-Aguayo C, Lopez-Berestein G, Xue F, Sood AK, Zhang W (2015). Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. *Journal of the National Cancer Institute* 107(7):djh108; doi:10.1093/jnci/djh108
445. Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti S, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot C, Sood AK, Mukerjee S, Gray JW, Mills GB, Ram PT (2016). Functional proteomics identifies miRNA to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. *Oncogene* 35:691-701.

446. Bayer JL, Spitz DR, Christensen D, McCormick ML, Farley D, DeGeest K, Damoush L, Perkins S, Lubaroff D, Sood AK, Lutgendorf SK (2015). Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma. *Brain, Behavior, and Immunity* 50:58 – 62.
447. Bhalwal AB, Nick AM, dos Reis R, Chen CL, Munsell MF, Ramalingam P, Salcedo MP, Ramirez PT, Sood AK, Schmeler KM (2016). Carcinoma of the Bartholin's gland: A review of 33 cases. *International Journal of Gynecological Cancer* 26(4):785-789.
448. Cho MS, Rupaimoole R, Choi HJ, Noh K, Chen J, Hu Q, Sood AK, Afshar-Kharghan V (2016). Complement component 3 (C3) is regulated by TWIST1 and mediates epithelial-mesenchymal transition. *Journal of Immunology* 196(3):1412-1418.
449. Srivastava A, Filant J, Moxley KM, Sood AK, McMeekin S, Ramesh R (2015). Exosomes: A role for naturally occurring nanovesicles in cancer growth, diagnosis and treatment. *Current Gene Therapy* 15(2):182-192.
450. Zand B, Previs RA, Zacharias NM, Rupaimoole R, Nagaraja AS, Guindani M, Dalton HJ, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala, LS, Rodriguez-Aguayo C, Taylor M, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Bar Eli M, Lopez-Berestein G, Bhattacharya PK, Sood AK (2016). Role of increased n-acetylaspartate levels in ovarian carcinoma. *Journal of the National Cancer Institute* 108(6):djv426; doi:10.1093/jnci/djv426
451. Hansen JM, Coleman RL, Sood AK (2016). Targeting the tumor microenvironment in ovarian cancer. *European Journal of Cancer* 56:131-143.
452. Mitamura T, Gourley C, Sood AK (2016). Prediction and failure of anti-angiogenesis escape. *Gynecologic Oncology* 141:80 – 85.
453. Zhang M, Liu G, Xue F, Edwards R, Sood AK, Zhang W, Yang D (2016). Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. *Gynecologic Oncology* 141(1):57-64.
454. Dwivedi SKD, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya R (2016). Therapeutic evaluation of microRNA-15a and microRNA-16 in Ovarian Cancer. *Oncotarget* 7(12):15093-15104.
455. Han HD, Cho YJ, Cho CK, Byeon Y, Jeon HN, Lopez-Berestein G, Sood AK, Shin BC, Park YM, Lee JW (2016). Therapeutic efficacy of linalool nanoparticles as a novel anticancer agent for epithelial ovarian carcinoma. *Molecular Cancer Therapeutics* 15(4):618-627.
456. Nagaraja AS, Sadaoui NC, Dorniak PL, Lutgendorf SK, Sood AK (2016). SnapShot: Stress and disease. *Cell Metabolism* 23(2):388-388.e1.
457. Rytelewski M, Vareki SM, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick J (2016). Reciprocal positive selection for weakness – preventing olaparib resistance by inhibiting BRCA2. *Oncotarget* 7(15):20825-20839.

458. Huang T, Poole EM, Eliassen AH, Okereke OI, Kubzansky LD, Sood AK, Forman JP, Tworoger SS (2016). Hypertension, use of antihypertensive medications and risk of epithelial ovarian cancer. *International Journal of Cancer* 139:291-299.
459. Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Yang D, Zhang M, Cooper LNJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK (2016). MiR-192/HOXB9 regulatory network controls the angiogenic switch in cancer. *Nature Communications* 7:11169; doi: 10.1038/ncomms11169.
460. Huang J, Hu W, Hu L, Dalton HJ, Yang XY, Sun Y, Bottsford-Miller J, Rupaimoole R, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK (2016). DII4 inhibition plus aflibercept markedly reduces ovarian tumor growth. *Molecular Cancer Therapeutics* 15(6):1344 – 1352.
461. Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK (2016). Platelet FAK is a critical regulator of tumor growth after withdrawal of anti-angiogenic therapy. *Journal of Clinical Investigation* 126(5):1885-1896. (Covered in: *Nature Reviews Clinical Oncology*)
462. Dao F, Schlappe BA, Tseng J, Lester J, Lutgendorf SK, McMeekin S, Coleman RL, Nick AM, Moore KN, Karlan BY, Sood AK, Levine DA (2016). Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. *Gynecologic Oncology* 141:260-263.
463. Chung JF, Lee CS, Sood AK (2016). Immunological and pleiotropic effects of individual β -blockers and their relevance in cancer therapies. *Expert Opinion on Investigational Drugs* 25(5):501-505.
464. Feng S, Kroll M, Nick AM, Sood AK, Afshar-Kharghan V (2016). Platelets are not hyperreactive in patients with ovarian cancer. *Platelets* 27(7): DOI:10.3109/09537104.2016.1174204
465. Zhou M, Melancon M, Stafford J, Nick AM, Tian M, Sood AK, Li C (2016). Precision nanomedicine using dual positron emission tomography and magnetic resonance temperature imaging-guided photothermal therapy. *Journal of Nuclear Medicine* 57(11):1778-1783.
466. Zhang S, Mercado-Uribe I, Sood AK, Bast RC, Liu J (2016). Coevolution of neoplastic epithelial cells and multilineage stroma *via* polyploidy giant cells during immortalization and transformation of mullerian epithelial cells. *Genes & Cancer* 7(3-4):60 – 72; doi: 10.18632/genesandcancer.102
467. Robertson GA, Pan Y, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Chan C, Chu A, Wen Y, Zhang X, Patil SL, Basu-Roy U, Mansukhani A, Sipahimalani P, Bowlby R, Brooks D, Thiessen N, Ma Y, Moore RA, Schein JE, Mungall AJ, Pecot CV, Sood AK, Jones SJM, Marra MA, Gunaratne P (2016). MicroRNA 509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. *Oncotarget* 7(18):25930 – 25948.
468. Poole EM, Kubzansky L, Sood AK, Okereke O, Tworoger SS (2016). A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients. *Cancer Causes and Control* 27(5):661-668.

469. Hou MH, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Coleman RL, Sood AK, Tsimberidou A, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S (2016). Continuous anti-angiogenesis beyond tumor progression in patients with recurrent high-grade epithelial ovarian cancer: Phase I trial experience. *Oncotarget* 7(23):35132 – 35143.
470. Christensen D, Armaiz-Pena G, Ramirez E, Matsuo K, Zimmerman B, Zand B, Shinn E, DeGeest K, Bender D, Goodheart MJ, Penedo F, Mendez L, Thaker PH, Domann F, Sood AK, Lutgendorf SK (2016). SSRI use and clinical outcomes in epithelial ovarian cancer. *Oncotarget* 7(22): 33179 – 33191.
471. Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, Coarfa C, Gunaratne PH, Tsai KY, Flores ER (2016). Δ Np63/DGCR8-dependent microRNAs mediate therapeutic efficacy of HDAC inhibitors in cancer. *Cancer Cell* 29:874-888.
472. Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Moss T, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Lopez-Berestein, Ram P, Liu J, Lu Y, Calin G, Sood AK, Mills GB (2016). Direct upregulation of STAT3 by microRNA-551b deregulates growth and metastasis of ovarian cancer. *Cell Reports* 15:1493-1504.
473. Jenner Z, Sood AK, Coleman RL (2016). Rucaparib and next-generation sequencing-based companion diagnostic evaluation in the current PARP inhibitor landscape for recurrent ovarian cancer treatment. *Future Oncology* 12(12):1439-1456.
474. Matsuo K, Cahoon SS, Shida M, Kakuda M, Adachi S, Yoshihara K, Moeini A, Machida H, Garcia-Sayre J, Ueda Y, Enomoto T, Mikami M, Roman LD, Sood AK (2016). Association of low-dose aspirin and survival of women with endometrial cancer. *Obstetrics and Gynecology* 128(1):127 – 137.
475. Key NS, Khorana A, Mackman N, McCarty O, White GC, Francis CF, McCrae K, Palumbo J, Raskob G, Sood AK (2016). Thrombosis in cancer: Research priorities of the National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. *Cancer Research* 76(13):3671-3675.
476. Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Fotso DC, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Salah E, Abdul Azeez K, Elkins JM, Campo L, Myers KA, Klotz D, Bivona S, Dhar S, Bast RC, Saya H, Choi HG, Gray NS, Fischer R, Kessler BM, Sood AK, Motohara T, Knapp S, Ahmed AA (2016). The salt-inducible kinase 2 (SIK2) couples ovarian cancer cell metabolism with survival at the adipocyte-rich metastatic niche. *Cancer Cell* 30:273-289.
477. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan B (2016). Ovarian cancer. *Nature Reviews Disease Primers* 2: 16061. doi: 10.1038/nrdp.2016.61
478. Chung JF, Yoon CJ, Cheon SA, Seo ES, Park SH, Yang JS, Kim B, Joo MY, Park TJ, Kim KH, Sood AK, Lee SJ (2016). NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil. *Oncotarget* 7(30): 47576-47585.
479. Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y, Cogdell D, Liu J, Sood AK, Broaddus R, Xue F, Zhang W (2016). MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. *Journal of Hematology & Oncology* 9:112. DOI 10.1186/s13045-016-0342-6

480. Harjes U, Bridges E, Gharpure K, Roxannis I, Sheldon H, Miranda F, Mangala LS, Pradeep S, Lopez-Berestein, Ahmed A, Fielding B, Sood AK, Harris A (2017). FABP4 in endothelial cells is a key link between metabolism and angiogenesis and regulates tumour growth. *Oncogene* 36:912-921.
481. Hu Q, Wang M, Cho MS, Wang C, Nick AM, Thiagarajan P, Aung FM, Han X, Sood AK, Afshar-Kharghan V (2017). Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. *Platelets* 28(1):99-102.
482. Seviour EG, Sehgal V, Mishra D, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Lee JS, Sood AK, Kim MP, Mills GB, Ram PT (2017). Targeting KRas-dependent tumor growth, circulating tumor cells and metastasis in vivo by clinically significant miR-193a-3p. *Oncogene* 36(10):1339 – 1350.
483. Yasukawa M, Liu Y, Hu L, Cogdell D, Gharpure KM, Pradeep S, Nagaraja A, Sood AK, Zhang W (2017). ADAMTS16 mutations sensitize ovarian cancer cells to platinum therapy. *Oncotarget* 8(51):88410-88420.
484. Whiting N, Hu J, Millward NZ, Bankson J, Volk D, Previs R, Sood AK, Bhattacharya P (2016). Developing hyperpolarized silicon particles for *in vivo* MRI targeting of ovarian cancer. *Journal of Medical Imaging* 3(3):036001; doi.org/10.1117/1.JMI.3.3.036001.
485. Abeydeera ND, Egli M, Cox N, Mercier K, Conde JN, Pallan PS, Mizurini DM, Sierant M, Hibti FE, Hassell T, Want T, Liu F, Liu H, Martinez C, Sood AK, Frydman C, Monteiro RQ, Gomer R, Nawrot B, Yang X (2016). Evoking picomolar binding in RNA by a single phosphorodithioate linkage. *Nucleic Acids Research* 44(17):8052 – 8064.
486. Barata P, Sood AK, Hong DS (2016). RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. *Cancer Treatment Reviews* 50:35-47.
487. Yokoyama Y, Zhu H, Lee JH, Kossenkov A, Wu SY, Wickramasinghe JM, Yin X, Palozola K, Gardini A, Showe L, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, Zhang Z, Sood AK, Ordog T, Bitler BG, Zhang R (2016). BET inhibitors suppress ALDH activity by targeting ALDH super-enhancer in ovarian cancer. *Cancer Research* 76(21):6320 – 6330.
488. Huang Y, Lichtenberger LM, Taylor M, Bottsford-Miller JN, Lyons Y, Hu W, Previs RA, Hansen JM, Fang D, Dorniak PL, Filant J, Dial EJ, Shen F, Hatakeyama H, Sood AK (2016). Anti-tumor and anti-angiogenic effects of aspirin-PC in ovarian cancer. *Molecular Cancer Therapeutics* 15(12):2894-904.
489. Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar R, Li L, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Maiti SN, Cooper LJN, Bulayeva N, Choi HJ, Dorniak PL, Rosenblatt KP, Tanaka T, Lopez-Berestein G, Gorenstein D*, Sood AK* (2016). Improving tumor vascular maturation using non-coding RNAs increases anti-tumor effect of chemotherapy. *Journal of Clinical Investigation Insight* 1(17):e87754. doi:10.1172/jci.insight.87754 *Joint senior authors
490. Sun Y, Ji P, Chen T, Zhou X, Yang D, Liu Y, Hu L, Xia D, Multani AS, Shmulevich I, Kucherlapati R, Sood A, Hamilton SR, Sun B, Zhang W (2017). MIIP haploinsufficiency induces chromosomal instability and promotes tumor progression in colorectal cancer. *The Journal of Pathology* 241:67 – 79.

491. Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Jennings N, Shim J, Dorniak PL, Mangala LS, Petrillo M, Petyuk VA, Schepmoes AA, Shukla AK, Torres-Lugo M, Lee JS, Rodland KD, Fagotti A, Lopez-Berestein, Li C, Sood AK (2016). Role of CTGF in sensitivity to hyperthermia in ovarian and uterine cancers. *Cell Reports* 17:1621 – 1631.
492. Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA (2016). MicroRNA therapeutics in cancer – an emerging concept. *eBioMedicine* 12:34-42.
493. Han HD, Byeon Y, Jeon HN, Kang TH, Jung ID, Shin BC, Lopez-Berestein G, Sood AK, Park YM (2016). TLR-3-induced immune response by PLGA nanoparticles for dendritic cell-based cancer immunotherapy. *International Journal of Nanomedicine* 11:5729-5742.
494. Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini J, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, Nagaraja AS, Derichsweiler M, Plackemeier T, Mercado-Uribe I, Lopez-Berestein G, Moss T, Ram PT, Liu J, Lu X, Mok S, Sood AK*, Nagrath D* (2016). Targeting glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth. *Cell Metabolism* 24:685-700. *Co-corresponding authors (*Commentary by Drs. Mylene Tajan and Karen H. Vousden)
495. Trudel-Fitzgerald C, Poole EM, Idahl A, Lundin E, Sood AK, Kawachi I, Kubzansky LD, Tworoger SS (2017). The association of work characteristics with ovarian cancer risk and mortality. *Psychosomatic Medicine* 79(9):1059 – 1067.
496. Yatsenko SA, Mittal P, Wood-Trageser MA, McGuire MM, Cercone SC, Jones M, Hoffner L, Surti U, Lev D, Edwards RP, Sood AK, Jiang H, Rajkovic A (2017). Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays. *Fertility and Sterility* 107(2):457 – 466.
497. Arun B, Austin B, Babiera GV, Basen-Engquist K, Carmack CL, Chaoul A, Cohen L*, Connelly L, Haddad R, Harrison C, Li Y, Mallaiah S, Nagarathna R, Parker PA, Perkins GH, Reuben JM, Shih Y-CT, Spelman A, Sood A, Yang P, Yeung S-CJ (2017). A comprehensive lifestyle randomized clinical trial: Design and initial patient experience. *Integrative Cancer Therapies* 16(1):3-20.
498. Kanlikilicer P, Rashed MH, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Rodriguez-Aguayo C, Filant J, Bayraktar E, Picher M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G (2016). Ubiquitous release of exosomal miR-6126 from ovarian cancer cells. *Cancer Research* 76(24):7194 – 7207.
499. Niu N, Zhang J, Zhang N, Mercado-Uribe I, Tao F, Han Z, Pathak S, Multani AS, Kuang J, Bast RC, Sood AK, Hung MC, Liu J (2016). Linking genomic reorganization to tumor initiation *via* the giant cell cycle. *Oncogenesis* 5(12): e281; doi: 10.1038/oncsis.2016.75
500. Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Huang J, Hansen JM, Haemmerle M, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, Dorniak PL, Linesch SL, Mangala LS, Pradeep S, Wu SY, Coleman RL, Sood AK (2017). YAP1 expression predicts sensitivity to dual AKT and P70S6K inhibition in ovarian and uterine malignancies. *Journal of the National Cancer Institute* 109 (7): djw296 (doi: 10.1093/jnci/djw296).
501. Han HD, Byeon Y, Jang J-H, Jeon HN, Kim GH, Kim MG, Pack CG, Kang TH, Jung ID, Lim YT, Lee

- YJ, Lee JW, Shin BC, Ahn HJ, Sood AK, Park YM (2016). *In vivo* stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. *Scientific Reports* 6:38348; DOI: 10.1038/srep38348
502. Ravoori M, Singh S, Bhavane R, Sood AK, Anvari B, Bankson J, Annapragada A, Kundra V (2016). Multimodal magnetic resonance and near infrared-fluorescent imaging of intraperitoneal ovarian cancer using a dual-mode dual-gadolinium liposomal contrast agent. *Scientific Reports* 6, 38991; doi: 10.1038/srep38991
503. Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA (2016). Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. *Clinical Cancer Research* 23(11):2891 – 2904.
504. Manchon JFM, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS (2016). TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. *Aging* 8(12):3507 – 3519.
505. Pi F, Zhang H, Li H, Thiviyanathan V, Gorenstein D, Volk D, Sood AK, Guo P (2017). RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor specific doxorubicin delivery. *Nanomedicine: Nanotechnology, Biology, and Medicine* 13(3):1183 – 1193.
506. Rashed MH, Kanlikilicer P, Aguayo CR, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Filant J, Calin GA, Sood AK, Abd-Allah MF, Helal GK, Lopez-Berestein G (2017). Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. *Oncotarget* 8(12):20145 – 20164.
507. Gangwar R, Meena AS, Shukla PK, Nagaraja AS, Dorniak PL, Pallikkuth S, Kalyanaraman B, Waters C, Sood AK, Rao RK (2017). Intracellular calcium-mediated mitochondrial oxidative stress plays a crucial role in stress-induced disruption of intestinal epithelial tight junctions. *Biochemical Journal* 474:731 – 749. (*Cover illustration)
508. Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Iurascu MG, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, Wei D, Sood AK, Hung MC, Shureiqi I (2017). Metastasis regulation by PPAR δ expression in cancer cells. *Journal of Clinical Investigation Insight* 2(1):e91419 (doi:10.1172/jci.insight.91419)
509. Matsuo K, Machida H, Takiuchi T, Grubbs BH, Roman LD, Sood AK, Gershenson DM (2017). Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. *Gynecologic Oncology* 144:496 – 502.
510. Wang H, Li X, Riojas E, Angel M, Nick AM, Sood AK, Rosenblatt KP, Gorenstein DG (2016). Morph-X-Select, a morphologically-based aptamer tissue selection for personalized ovarian cancer biomarker discovery. *Biotechniques* 61(5):249-259.
511. Previs RA, Sood AK, Mills GB, Westin SN (2016). The rise of genomic profiling in ovarian cancer. *Expert Review of Molecular Diagnostics* 16(12):1337-1351.

512. Hu Q, Cho MS, Thiagarajan P, Aung FM, Sood AK, Afshar-Kharghan (2017). A small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets. *Platelets* 28(1):99-102.
513. Wagner MJ, Ravi V, Menter D, Sood AK (2017). Molecular pathways in endothelial cell neoplasms. *NPG Precision Oncology* 1:11 ; doi:10.1038/s41698-017-0013-2
514. Wagner MJ, Mitra R, Baze W, Barnhart K, Wu S, Rodriguez-Aguayo C, Coleman RL, Lopez-Berestein G, Sood AK (2017). Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA). *Molecular Cancer Therapeutics* 16(6); 1114–23.
515. Rabinowicz N, Mangala LS, Brown KR, Checa-Rodriguez C, Castiel A, Moskovich O, Levy-Barda A, Trakhenbrot L, Rodriguez-Aguayo C, Pradeep S, Zarfati F, Praag YV, Jiang D, Lopez-Berestein G, David A, Harel M, Geiger T, Huertas P, Rottapel R, Sood AK, Izraeli S (2017). Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. *Oncotarget* 8:27380-27392.
516. Sans M, Gharpure K, Liang L, Liu J, Tibshirani R, Sood AK, * Eberlin L* (2017). Molecular markers of serous ovarian cancer aggressiveness and surgical outcome by ambient ionization mass spectrometry imaging. *Cancer Research* 77(11):2903 – 2913. *Co-corresponding authors
517. Wang Y, Xu X, Yu S, Jeong KJ, Zhou Z, Han L, Tsang YH, Li J, Chen H, Mangala LS, Yuan Y, Eterovic AK, Lu Y, Sood AK, Scott KL, Mills GB, Liang H (2017). Systematic characterization of A-to-I editing hotspots in microRNAs across human cancers. *Genome Research* 27:1112 – 1125.
518. Court KA, Hatakeyama H, Wu S, Mangala LS, Rodriguez-Aguayo C, Lopez- Berestein G, Lee JS, Rinaldi C, Juan EJ, Sood AK, Torres-Lugo M (2017). HSP70 inhibition synergistically enhances the effects of magnetic fluid hyperthermia in ovarian cancer. *Molecular Cancer Therapeutics* 16(5):966 – 976.
519. Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M, Fellman B, Matzo M, Slavich GM, Goodman MT, Tew WP, Lester J, Moore KM, Karlan BY, Levine DA, Sood AK (2017). Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. *Gynecologic Oncology* 146:101 – 108.
520. Tseng JH, Bisogna M, Hoang LN, Olvera N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Levine DA, Jelinic P (2017). miR-200c-driven mesenchymal-to-epithelial transition is a therapeutic target in uterine carcinosarcomas. *Scientific Reports* 7:3614; DOI:10.1038/s41598-017-03972-7
521. Hu Q, Hisamatsu T, Hammerle M, Cho MS, Pradeep S, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Wong STC, Sood AK,* Afshar-Kharghan V* (2017). Role of platelet-derived Tgfβ1 in progression of ovarian cancer. *Clinical Cancer Research* 23(18):5611 – 5621. *Co-corresponding authors
522. Mitamura T, Pradeep S, McGuire M, Wu S, Ma S, Hataheyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Chen X, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, Coleman RL, Sood AK (2018). Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). *Oncogene* 37:722-731.
523. Cho MS, Noh K, Haemmerle M, Li D, Park H, Hu Q, Hisamatsu T, Mitamura T, Mak SL, Kunapuli S,

- Ma Q, Sood AK,* Afshar-Kharghan V* (2017). Role of ADP receptors on platelets in the growth of ovarian cancer. *Blood* 130(10):1235 – 1242. *Co-corresponding authors
524. Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V*, Sood AK* (2017). Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. *Nature Communications* 8:310. DOI: 10.1038/s41467-017-00411-z
525. Menter DG, Kopetz S, Hawk E, Sood AK, Gresele P, Honn KV (2017). Platelet “first responders” in wound response, cancer, and metastasis. *Cancer and Metastasis Reviews* 36:199 – 213.
526. Cueno MG, Schrepf A, Slavich GM, Thaker PH, Goodheart M, Bender D, Cole SW, Sood AK, Lutgendorf SK (2017). Diurnal cortisol rhythms, fatigue and psychosocial factors in five year survivors of ovarian cancer. *Psychoneuroendocrinology* 84:139 – 142.
527. Rodriguez-Aguayo C, Monroig P, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Sood AK, Calin GA, Lopez-Berestein G (2017). Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-Ras axis in chemotherapy-resistant ovarian cancer. *Cell Discovery* 3:17029; doi:10.1038/celldisc.2017.29
528. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Pena G, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK (2017). Adrenergic mediated increases in INHBA drive CAF phenotype and collagens. *Journal of Clinical Investigation Insight* 2(16): e93076; doi.org/10.1172/jci.insight.93076
529. Sarkar S, Bristow CA, Dey P, Rai K, Perets R, Ramirez-Cardenas A, Malasi S, Haemmerle M, Wu SY, McGuire M, Protopopov A, Garvey J, Liu JF, Hirsch MS, Chang Q, Lazar AJ, Sood AK, Drapkin R, DePinho R, Chin L (2017). PRKCI promotes immune suppression in ovarian tumors through YAP1. *Genes and Development* 31(11):1109 – 1121. doi: 10.1101/gad.296640.117
530. Li L, Zheng H, Huang Y, Huang C, Zhang S, Tian J, Li P, Sood AK, Zhang W, Chen K. DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer (2017). *Carcinogenesis* 38(8):797-805.
531. Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond A, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi r, Gabra H, Roman LD, Sood AK, Gershenson DM (2018). Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. *Journal of Surgical Oncology* 117:236 – 244.
532. Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Urive I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK (2017). Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. *Oncotarget* 8(57):96496 – 96505.
533. Lyons YA, Wu SY, Overwijk WW, Baggerly KA, Sood AK (2017). Immune cell profiling: Molecular approaches to cell-specific identification. *NPJ Precision Oncology* 1:26; doi:10.1038/s41698-017-

0031-0

534. Fleming N, Coleman RL, Tung C, Westin SN, Hu W, Sun Y, Bhosale P, Munsell M, Sood AK (2017). Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. *Gynecologic Oncology* 147:41 – 46.
535. Dalton HJ*, Pradeep S*, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu S, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK (2017). Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression. *Clinical Cancer Research* 23(22):7034-7046 *Equal authors
536. Lutgendorf SK, Thaker PH, Arevalo JM, Goodheart MJ, Slavich GM, Sood AK, Cole SW (2018). Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma. *Cancer* 124:580-586.
537. Richardson DL, Sill MW, Carney M, Pearl ML, Kehoe SM, Hanjani P, Zhou XC, Van Le L, Landrum LM, Gray HJ, Hu W, Sood AK, Coleman RL (2017). A randomized placebo controlled phase IIb trial of weekly paclitaxel plus/minus pazopanib in persistent or recurrent ovarian cancer: an NRG Oncology/Gynecologic Oncology Group study. *Journal of the American Medical Association Oncology* 4(2):196 – 202. doi:10.1001/jamaoncol.2017.4218
538. Takiuchi T, Blake EA, Matsuo K, Sood AK, Brasky TM (2018). Aspirin use associated with endometrial cancer risk and survival. *Gynecologic Oncology* 148:222-232. *Cover illustration
539. Matsuo K, Machida H, Roman LD, Sood AK, Gershenson (2018). Trends of low-grade serous ovarian carcinoma between 1973 and 2013 in the United States. *Journal of Gynecologic Oncology* 29(1):e15. DOI.org/10.3802/jgo.2018.29.e15
540. Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, De Marzo AM, Sood AK*, Zhang L*, Dang CV* (2017). MYC targeted long non-coding RNA DANCR promotes cancer in part by reducing p21 levels. *Cancer Research* 78(1):64-74. *Co-corresponding authors
541. Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, Hung MC, Marks JR, Gallick GE, Lopez-Berestein G, Flores E, Sood AK, Huang S, Yu D, Yang L, Lin C (2017). JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. *Journal of Clinical Investigation* 127(12):4498 – 4515.
542. Nilsson M, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Webster A, Rowe P, Howells K, Haddad V, Gomez D, Tran H, Armaiz-Pena G, Wang J, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach J (2017). Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β -blockers. *Science Translational Medicine* 9, eaao4307; DOI: 10.1126/scitranslmed.aao4307
543. McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin EL, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Manrique SZ, Liu C, Huang L, Chen Y, Forget M-A, Haymaker C, Bernatchez C, Satani N, Muller FL, Roszik J, Kalra AV, Heffernan TP, Sood AK, Hu J, Amaria R, Davis RE, Hwu P (2018). The effect of topoisomerase I inhibitors on the efficacy of T-cell-based cancer immunotherapy. *Journal of the National Cancer Institute* 110(7):777 – 786; doi.org/10.1093/jnci/djx257

544. Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, Lopez-Berestein G, Landis MD, Rosato RR, Dave B, Wong S, Marchetti D, Sood AK, Chang JC (2018). HN1L promotes triple-negative breast cancer stem cells through LEPR-STAT3 pathway. *Stem Cell Reports* 10:212 – 227. DOI.org/10.1016/j.stemcr.2017.11.010
545. Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS (2018). Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. *Molecular and Cellular Neuroscience* 86:65-71.
546. Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, Mitra R, Gorenstein DG, Volk DE, de Franciscis V, Sood AK, Lopez-Berestein G (2017). Therapeutic targeting of AXL tyrosine Kinase inhibits tumor growth and intraperitoneal metastasis in ovarian cancer models. *Molecular Therapy Nucleic Acids* 15(9):251-262.
547. Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA (2018). Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. *Nature Communications* 9:476. DOI: 10.1038/s41467-017-02811-7
548. Velazquez-Torres G, Shoshan E, Ivan C, Huang, Fuentes-Mattei E, Parret H, Kim SJ, Rodriguez-Aguayo C, Brooks D, Jones SJM, Robertson AG, Calin G, Lopez-Berestein G, Sood AK, Bar-Eli B (2018). A-to-I miR-378a-3p editing can prevent melanoma progression *via* regulation of PARVA expression. *Nature Communications* 9(1):[461]. DOI: 10.1038/s41467-018-02851-7
549. Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK (2018). RNA interference-based therapy and its delivery systems. *Cancer and Metastasis Reviews* 37(1):107-124.
550. Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho MS, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer M, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AK (2017). Differential effects of EGFL6 on tumor *versus* wound angiogenesis. *Cell Reports* 21:2785-2795.
551. Huang Y, Hu W, Huang J, Shen F, Ivan C, Pradeep S, Sun Y, Jiang D, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Ali R, Vishakha P, Woodlyne R, Jennings NB, Nick AM, Coleman RL, Sood AK (2017). Inhibiting nuclear translocation of phospho-progesterone receptor enhances antitumor activity of onapristone in uterine cancer. *Molecular Cancer Therapeutics* 17(2):464-473. * Selected for Highlights
552. Liu Q, Lu C, Dai W, Li K, Xu J, Huang Y, Li G, Kang Y, Sood AK, Xu C (2018). Association of biobehavioral factors with non-coding RNAs in cervical cancer. *BioScience Trends* 12(1):24-31.
553. Vu HT, Kotla S, Ko KA, Fujii Y, Tao Y, Medina J, Thomas T, Hada M, Sood AK, Singh PK, Milgrom S, Krishnan S, Fujiwara K, Le NT, Abe JI (2018). Ionizing radiation induces endothelial inflammation and apoptosis via p90RSK-mediated ERK5 S496 phosphorylation. *Frontiers in Cardiovascular Medicine* 5:23. doi: 10.3389/fcvm.2018.00023

554. Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong STC, Birrer MJ, Mok SC (2018). Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. *The Journal of Clinical Investigation* 128(2):589-606.
555. Ma S, Pradeep S, Hu W, Coleman RL, Sood AK (2018). The role of tumor microenvironment in resistance to anti-angiogenic therapy. *F1000 Research* 7 (F1000 Faculty Rev):326 (<https://doi.org/10.12688/f1000research.11771.1>)
556. Gharpure KM*, Lara OD*, Wen Y, Pradeep S, LaFargue C, Ivan C, Rupaimoole R, Hu W, Mangala LS, Wu SY, Nagaraja AS, Baggerly K, Sood AK (2018). ADH1B promotes mesothelial clearance and ovarian cancer infiltration. *Oncotarget* 9(38):25115 – 25126. *Joint first-authors
557. Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q, Kim J, Fan Y, Rodriguez-Aguayo C, Ton BN, Lee M, Wang Y, Zhou Z, Zheng L, Hu X, Lawhon SE, Siverly AN, Su X, Li J, Xie X, Cheng X, Liu LC, Chang HW, Chiang SF, Lopez-Berestein G, Sood AK, Chen J, You MJ, Sun SC, Liang H, Huang Y, Yang X, Sun D, Sun Y, Hung MC, Ma L (2018). ZRANB1 is an EZH2 deubiquitylase and a potential therapeutic target in breast cancer. *Cell Reports* 23:823 – 837.
558. Bergmeier W, Antoniak S, Conway EM, Denis CV, George LA, Isermann B, Key NS, Krishnaswamy S, Lam WA, Lillicrap D, Liu J, Looney MR, Lopez JA, Maas C, Peyvandi F, Ruf W, Sood AK, Versteeg HH, Wolberg AS, Wong PC, Wood J, Weiler H (2018). Advances in clinical and basic science of coagulation: Illustrated abstracts of the 9th Chapel Hill symposium on hemostasis. *Research and Practice in Thrombosis and Haemostasis* 2:407-428. DOI: 10.1002/rth2.12095
559. Haemmerle M*, Stone RL*, Menter DG, Afshar-Kharghan V**, Sood AK** (2018). The platelet lifeline to cancer: Challenges and opportunities. *Cancer Cell* 33:965 – 983. *Co-first authors; **Co-corresponding authors
560. Dal Molin GZ, Omatsu K, Sood AK, Coleman RL (2018). Rucaparib in ovarian cancer: An update on safety, efficacy and place in therapy. *Therapeutic Advances in Medical Oncology* 10:1758835918778483. doi: 10.1177/1758835918778483
561. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna R, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N, The Cancer Genome Atlas Research Network, Weinstein JN, Mills GB, Levine DA, Akbani R (2018). A comprehensive pan-cancer molecular study of gynecologic and breast cancers. *Cancer Cell* 33:690 – 705.
562. Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AK (2018). Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction. *Cancer Research* 78(12):3233-3242.

563. Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Sood AK, Gunaratne PH, Sumazin P, The Cancer Genome Atlas Network (2018). LncRNA dysregulation alters the activity of cancer genes. *Cell Reports* 23:297 – 312.
564. Armer JS, Clevenger L, Davis LZ, Cuneo M, Thaker PH, Goodheart MJ, Bender DP, Dahmouh L, Sood AK, Cole SW, Slavich GM, Lutgendorf SK (2018). Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. *Cancer* 124:3401-3418.
565. Zhang L, Peng D, Sood AK, Dang CV, Zhong X (2018). Shedding light on the dark cancer genomes: Long noncoding RNAs as novel biomarkers and potential therapeutic targets for cancer. *Molecular Cancer Therapeutics* 17(9):1816 – 1823.
566. Dood R, Yang Z, Armbruster SD, Coleman RL, Tworoger S, Sood AK*, Baggerly KA* (2018). Defining survivorship across patients with solid tumors: An evidence-based approach. *Journal of the American Medical Association – Oncology* 4(11):1519 – 1526. *Co-corresponding authors
567. Haldar R, Shaashua L, Lavon H, Lyons YA, Zmora O, Sharon E, Birnbaum Y, Allweis T, Sood AK, Barshack I, Cole SW, Ben-Ellyahu S (2018). Perioperative inhibition of b-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. *Brain, Behavior and Immunity* 73:294-309.
568. Kim GH, Byeon Y, Kim MG, Won JE, Park YY, Lee JW, Kang TH, Jung ID, Shin BC, Ahn HJ, Lee YJ, Sood AK, Han HD, Park YM (2018). Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. *Drug Delivery* 25(1):1394-1402.
569. Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Armaiz Pena G, Kondetimmermanhalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, Eberlin L, Sood AK (2018). FABP4 as a key determinant of metastatic potential of ovarian cancer. *Nature Communications* 9:2923. DOI: 10.1038/s41467-018-04987-y
570. Gonzalez-Gonzalez A, Munoz-Muela E, Marchal JA, Cara FE, Molina M, Jimenez G, Verma A, Ramirez A, Qian W, Chen W, Kozielski A, Elemento O, Martin MD, Luque R, Rosa-Garrido C, Landeira D, Quintana-Romero M, Rosato R, Garcia MA, Ramirez-Tortosa C, Kim H, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Lorente J, Sanchez-Rovira P, Chang JC, Granados-Principal S (2018). Activating transcription factor-4 modulates TGF β -induced aggressiveness in triple negative breast cancer via SMAD2/3/4 and mTORC2 signaling. *Clinical Cancer Research* 24(22):5697 – 5709.
571. Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK (2018). When ovarian cancer is not: Characterizing nonovarian cancer pathology in a laparoscopy-based triage system. *International Journal of Gynecological Cancer* 28:1485-1490.
572. Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC (2018). Paclitaxel sensitivity of ovarian cancer can be enhanced by knocking down pairs of kinases that regulate MAP4 phosphorylation and microtubule stability. *Clinical Cancer Research* 24(20):5072-5084.
573. Umamaheswaran S, Dasari SK, Yang P, Lutgendorf SK, Sood AK (2018). Stress, inflammation and

- eicosanoids: An emerging perspective. *Cancer and Metastasis Reviews* 37:203 – 211.
574. Ha JH, Radhakrishnan R, Jayaraman M, Yan M, Ward JD, Fung KM, Moxley K, Sood AK, Isidoro C, Mukherjee P, Song YS, Dhanasekaran DN (2018). LPA induces metabolic reprogramming in ovarian cancer via pseudohypoxic response. *Cancer Research* 78(8):1923-1934.
575. Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK (2018). Laparoscopic surgical algorithm to triage the timing of tumor reductive surgery in advanced ovarian cancer. *Obstetrics and Gynecology* 132(3):545 – 554.
576. Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz GA, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK (2018). PRKRA/PACT expression promotes chemoresistance in mucinous ovarian cancer. *Molecular Cancer Therapeutics* 18(1):162 – 172.
577. Byeon Y, Lee JW, Kim GH, Kim MG, Won JE, Kang TH, Jung ID, Cho YJ, Ahn HJ, Shin BC, Lee YJ, Sood AK, Han HD, Park YM (2018). Overcoming chemoresistance in epithelial ovarian cancer using CD44-targeted PLGA nanoparticles encapsulating paclitaxel and FAK siRNA as two-in-one delivery carrier. *Cancer Research* 78(21):6247 – 6256.
578. Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND (2018). Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. *Gynecologic Oncology* 151:428 – 432.
579. Yuan J, Hu Z, Mahal B, Pi J, Wei X, Jiang J, Wang Y, Zhang Y, Hu X, Li C, Zhong X, Huang Q, Guan G, Fan Y, Tanyi JL, Zhang Y, Sood AK, Rebbeck TR, Dang CV, Zhang L (2018). Integrated analysis of genetic ancestry and genomic alterations across human cancers. *Cancer Cell* 34:549 – 560.
580. Inoue K, Deng Z, Chen Y, Giannopoulou E, Xu R, Gong S, Greenblatt M, Mangala LS, Lopez-Berestein G, Kirsch D, Sood AK, Zhao L, Zhao B (2018). Bone protection by inhibiting microRNA-182. *Nature Communications* 9(1):4108, DOI: 10.1038/s41467-018-06446-0. PMID:30291236
581. Salcedo MP, Sood AK, dos Reis R, Ramalingam P, Chen C, Frumovitz M, Jhingran A, Pitcher B, Urbauer D, Ramirez PT, Schmeler KM (2019). Clinical implications of perineural invasion (PNI) in vulvar carcinoma. *Gynecologic Oncology* 152(1):101 – 105.
582. LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL (2019). Exploring and comparing adverse events between PARP inhibitors. *Lancet Oncology* 20: e15–28
583. Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly KA, Rodriguez-Aguayo C, Lopez-Berestein G, Yang SM, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK (2019). Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein Brd4. *Molecular Cancer Therapeutics* 18(2):421 – 436.
584. An J, Du Y, Fan X, Wang Y, Ivan C, Zhang XG, Sood AK, An Z, Zhang N (2019). EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. *Oncogene* 38:2123 – 2134.
585. Kanlikilicer P, Bayraktar, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Bayraktar E, Zhang X,

- Rodriguez-Aguayo C, Ozkayar O, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G (2018). Exosomal miRNA regulates drug resistance via the Cav1/p-gp axis in ovarian cancer. *EBioMedicine* 38:100 – 112.
586. Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik AH, Shen H, Yang X, Sood AK, Lopez-Berestein G (2019). PTGER3 induces ovarian tumorigenesis and confers resistance to cisplatin therapy through constitutive Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis hyperactivation. *EBioMedicine* 40:290-304.
587. Radhakrishnan R, Ha JH, Jayaraman M, Liu J, Isidoro C, Sood AK, Moxley K, Song YS, Dhanasekaran DN (2019). Lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. *Cancer Letters* 442:464 – 474.
588. Gunaratne PH, Rao AK, Lin C, Hernandez-Herrera A, Pan Y, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Sood AK, Rowat AC, Coarfa C, Pirolo KF, Flores ER, Chang EH (2019). Activating p53-family member Tap63: A novel therapeutic strategy for targeting p53-altered tumors. *Cancer* 125(14):2409 – 2422.
589. Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greeberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L (2019). Critical questions in ovarian cancer research and treatment: Report of an AACR special conference. *Cancer* 125:1963-1972.
590. Matsuo K, Machida H, Mandelbaum RS, Grubbs BH, Roman LD, Sood AK, Gershenson DM (2019). Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. *Gynecologic Oncology* 153:230 – 237.
591. Murillo OD, Thistlethwaite W, Rozowsky J, Subramanian SL, Lucero R, Shah N, Jackson AR, Srinivasan S, Chung A, Laurent CD, Kitchen RR, Galeev T, Warrell J, Diao JA, Welsh JA, Hanspers K, Riutta A, Burgstaller-Muehlbacher S, Shah R, Yeri A, Jenkins LM, Ahsen ME, Cordon-Cardo C, Dogra N, Gifford SM, Smith JT, Stolovitzky G, Tewari AK, Wunsch BH, Yadav KK, Danielson KM, Filant J, Moeller C, Nejad P, Paul A, Simonson B, Wong DK, Zhang X, Balaj L, Gandhi R, Sood AK, Alexander RP, Wang L, Wu C, Wong D, Galas DJ, Van Keuren-Jensen K, Patel T, Jones JC, Das S, Cheung K-H, Pico A, Su AI, Raffai RL, Laurent LC, Roth ME, Gerstein MB, Milosavljevic A (2019). ExRNA atlas analysis reveals distinct extracellular RNA cargo types present across human biofluids. *Cell* 177:463-477.
592. Duc-Hiep B, Lee SK, Sood AK (2019). Circular RNAs in cancer. *Molecular Therapy – Nucleic Acids* 16:118 – 129.
593. Shi S, Li T, Wen X, Wu SY, Xiong C, Zhao J, Lincha VR, Chow DS, Liu Y, Sood AK, Li C (2019). Copper-64 labeled PEGylated exosomes for in vivo positron emission tomography and enhanced tumor retention. *Bioconjugate Chemistry* 30:2675-2683.
594. Sans M, Zhang J, Lin JQ, Feider CL, Giese N, Breen MT, Sebastian K, Liu J, Sood AK, Eberlin LS (2019). Performance of the MasSpec Pen for rapid diagnosis of ovarian cancer. *Clinical Chemistry* 65:

DOI: 10.1373/clinchem.2018.299289

595. Ma S, Pradeep S, Villar-Prados A, Wen Y, Mangala LS, Kim MS, Wu S, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram P, Schlacher K, Coleman RL, Sood AK (2019). GnRH-R targeted lytic peptide sensitizes BRCA wild-type ovarian cancer to PARP inhibition. *Molecular Cancer Therapeutics* 18(5):969 – 979. DOI:10.1158/1535-7163.MCT-18-0770
596. Jazaeri A, Coleman R, Sood AK, Frumovitz M, Soliman P, Shafer A, Cutrera J, Klinger M, Sharafi S, Johnson C, Villanueva V, Dickens A, Cain KE, Anderson JE, Lu K, Westin S (2019). A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. *Gynecologic Oncology* 151:374 – 380.
597. Azam SH, Porrello A, Harrison EB, Leslie PL, Liu X, Waugh TA, Belanger A, Mangala LS, Lopez-Berestein G, Wilson HL, McCann JV, Kim WY, Sood AK, Liu J, Dudley AC, Pecot CV (2019). Quaking Orchestrates a Post-Transcriptional Regulatory Network of Endothelial Cell Cycle Progression Critical to Angiogenesis and Metastasis. *Oncogene* 38:5191 – 5210.
598. Srinivasan S, Yeri AS, Cheah PS, Chung A, Danielson K, DeHoff P, Filant J, Laurent CD, Laurent LD, Magee R, Moeller C, Nejad P, Paul A, Rigoutsos I, Rodosthenous R, Shah R, Simonson B, To C, Wong D, Yan IK, Zhang X, Balaj L, Breakefield XO, Gandhi R, Lapidus J, Londin E, Murthy V, Patel T, Raffai R, Sood AK, Das S, Laurent LC (2019). Deconvolution analysis of small RNAseq data from exRNAs isolated using different methods reveals multiple carrier subclasses and identifies optimal methods for isolation of total and EV-specific exRNA. *Cell* 177:446-462.
599. Cueno MG, Szeto A, Schrepf A, Kinner E, Schachner BI, Ahmed R, Thaker PH, Goodheart M, Bender D, Sood AK, Cole SW, McCabe PM, Lutgendorf SK, Mendez AJ (2019). Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. *Psychoneuroendocrinology* 106:244 – 251.
600. Zhaorigetu S, Prathipati P, Rodriguez-Aguayo C, Walton BL, Sood AK, Lopez-Berestein G (2019). Fatty acid binding protein-4 silencing attenuates atherosclerosis progression by affecting macrophage apoptosis and autophagy. *Journal of Biosciences and Medicines* 7:99 – 109.
601. Das S, The Extracellular RNA Communication Consortium; Sood AK – co-author) (2019). The extracellular RNA communication consortium: Establishing foundational knowledge and technologies for extracellular RNA research. *Cell* 177:231-242.
602. McGuire MH*, Herbrich SM*, Dasari SK, Wu SY, Wang Y, Rupaimoole R, Lopez-Berestein G, Baggerly KA**, Sood AK** (2019). Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells. *EBioMedicine* 43:127-137. *Equal first-authors; **Joint senior authors
603. Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, Lacko AG, Sood AK (2019). Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. *Oncogene* 38:6095 – 6108.
604. Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN (2019). PARP inhibitor window of opportunity trial highlights adaptive response as a predictive tool for PARP-based combination therapy. *Oncotarget* 10(37):3533 – 3546.

605. Yang H, Zhang S, Jiang Y, Mao W, Pang L, Redwood A, Jennings N, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, Lopez-Berestein G, Le Xiao-Feng, Jones P, Ahmed AA, Piwnica-Worms H, Sood AK, Bast RC, Lu Z (2019). A glycolytic enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFKFB2), regulates paclitaxel sensitivity in ovarian and breast cancer cells and xenografts with WT p53. *Clinical Cancer Research* 25(18):5702 – 5716.
606. Bach DH, Zhang W, Sood AK (2019). Chromosomal instability in tumor initiation and development. *Cancer Research* 79:3995 – 4002.
607. Arend RC, Armstrong DK, Bala S, Coleman RL, Mills GB, Sood AK, Herzog T, Beaver JA (2019). Advancing drug development in gynecologic malignancies. *Clinical Cancer Research* 25(16):4874 – 4880.
608. Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JM, Dizon T, Coleman RL, Cole SW, Sood AK (2019). Prospective combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation of its impact on circulating immune cell gene expression. *Gynecologic Oncology* 154:524-530.
609. Shuford S, Rayner M, Millard M, Mattingly C, Lotstein A, Smith A, Guo Q, O'Donnell L, Elder J, Puls L, Weroha J, Nick A, Barnett J, Maxwell L, Conrads T, Corless C, Sood AK, Orr D, Holmes L, Gevaert M, Crosswell HE, DesRochers TM (2019). *Ex vivo* 3D culture assay provides early, accurate prospective prediction of clinical response to first-line chemotherapy in newly diagnosed ovarian cancer patients. *Scientific Reports* 9:11153; doi.org/10.1038/s41598-019-47578-7.
610. Trudel-Fitzgerald C, Poole EM, Sood AK, Okerke OI, Kawachi I, Kubzansky LD, Tworoger SS. Social integration, marital status, and ovarian cancer risk: A 20-year prospective cohort study (2019). *Psychosomatic Medicine* 81:833-840.
611. Roh JW, Choi JE, Han HD, Hu W, Matsuo K, Nishimura M, Lee JS, Kwon SY, Cho CH, Kim J, Coleman RL, Lopez-Berestein G, Sood AK (2019). Clinical and biological significance of EZH2 expression in endometrial cancer. *Cancer Biology and Therapy* 21(2):147-156.
612. Yokoi A, Villar-Prados A, Oliphint PA, Zhang J, Song X, De Hoff P, Money R, Liu J, Roszik J, Clise-Dwyer K, Burks JK, O'Halloran TJ, Laurent LC, Sood AK (2019). Mechanisms of nuclear content loading to exosomes. *Science Advances* 5 (11), eaax8849; DOI: 10.1126/sciadv.aax8849
613. Kurnit KC, Sinno A, Fellman BM, Varghese A, Stone RL, Sood AK, Gershenson DM, Schmeler KM, Fader AN, Frumovitz M (2019). The impact of gastrointestinal adjuvant chemotherapy regimens in women with mucinous ovarian cancer. *Obstetrics and Gynecology* 134(6):1253 – 1259.
614. Oncul S, Amero P, Rodriguez-Aguayo C, Calin GA, Sood AK, Lopez-Berestein G (2020). Long non-coding RNAs in ovarian cancer: Expression profile and functional spectrum. *RNA Biology: Noncoding RNAs in Cancer* 17:11, 1523 – 1534. DOI: 10.1080/15476286.2019.1702283.
615. Xu X, Wang Y, Mojumdar K, Zhou Z, Jeong KJ, Mangala LS, Yu S, Tsang Y-H, Rodriguez-Aguayo C, Lu Y, Lopez-Berestein G, Sood AK, Mills GB, Liang H (2019). A-to-I edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. *Journal of Clinical Investigation*

129(12):5343 - 5356.

616. Handley KF, Sood AK (2020). A solution to the dilution: The role for biomarkers in advanced ovarian cancer. *Clinical Cancer Research* 26:9 – 10.
617. Parashar D, Geethadevi A, Ragle-Aure M, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, Liang M, Rader JS, Ramchandran R, You M, Sood AK, Kristensen VN, Mills GB, Pradeep S, Chaluvally-Raghavan P (2019). MiRNA551b-3p activates an oncostatin signaling module for the progression of triple-negative breast cancer. *Cell Reports* 29:4389 – 4406. doi.org/10.1016/j.celrep.2019.11.085
618. Xiong C, Wen Y, Zhao J, Yin D, Xu L, Yao C, Liu J, Chaudhari RR, Zhang S, Sood AK, Li C (2020). Targeting forward and reverse EphB4/EFNB2 signaling by a peptide with dual functions. *Scientific Reports* 10:520; doi.org/10.1038/s41598-020-57477-x
619. Lara OD, Krishnan S, Wang Z, Corvigno S, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin S, Fleming N, Cristini V, Rao A, Burks J, Sood AK (2019). Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. *Scientific Reports* 9:17589; doi.org/10.1038/s41598-019-53872-1
620. Han C, Wang C, Chen Y, Wang J, Xu X, Hilton T, Cai W, Zhao Z, Wu Y, Li K, Houck K, Liu L, Sood AK, Wu X, Xue F, Li M, Dong J-F, Zhang J (2020). Placenta-derived microvesicles induce preeclampsia in mouse models. *Hematologica* 105(6):1686 – 1694.
621. Matsuo K, Machida H, Matsuzaki S, Grubbs BH, Klar M, Roman LD, Sood AK, Gershenson DM, Wright JD (2020). Evolving population-based statistics for rare epithelial ovarian cancers. *Gynecologic Oncology* 157:3 – 11.
622. Lara OD, Wang Y, Asare A, Xu T, Shiu H-S, Liu Y, Hu W, Sumazin P, Uppal S, Zhang L, Rauh-Hain JA, Sood AK (2020). Pan-cancer clinical and molecular analysis of racial disparities. *Cancer* 126(4):800 – 807. doi.org/10.1002/cncr.32598
623. Matsuo K, Machida H, Grubbs BH, Matsuzaki S, Klar M, Roman LD, Sood AK, Gershenson DM (2020). Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. *Gynecologic Oncology* 157:21-28.
624. Seiler A, Sood AK, Jenewein J, Fagundes C (2020). The impact of stress and the role of the tumor microenvironment in the formation of brain metastases. *Brain Behavior and Immunity* 87:860 – 880.
625. Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley D, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernandez ML, Gershenson DM (2020). Low-grade serous ovarian cancer: State of the science. *Gynecologic Oncology* 156:715 – 725.
626. El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Alama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G (2020). GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. *Cellular Signaling* 68:109539; doi.org/10.1016/j.cellsig.2020.109539.

627. Wi TI, Byeon Y, Won JE, Lee JM, Kang TH, Lee JW, Lee YJ, Sood AK, Han HD, Park YM (2020). Selective tumor-specific antigen delivery to dendritic cells using mannose-labeled PLGA nanoparticles for cancer immunotherapy. *Journal of Biomedical Nanotechnology* 16(2):201 – 211.
628. Salcedo MP, Sood AK, Jhingran A, Eifel PJ, Klopp AH, Iyer RB, Fellman BM, Jimenez C, Schmeler KM (2020). Pelvic fractures and changes in bone mineral density following radiotherapy for cervical, endometrial and vaginal cancer. *Cancer* 126:2607 – 2613.
629. Coleman RL, Handley K, Burger R, Dal Molin GZ, Stagg R, Sood AK, Moore KN (2020). Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. *Gynecologic Oncology* 157:386 – 391.
630. Cata JP, Gorur A, Yuan X, Berg NK, Sood AK, Eltzschig H (2020). Role of microRNA for pain after surgery – narrative review of animal and human studies. *Anesthesia & Analgesia* 130(6):1638 – 1652.
631. Cao Q, Wang W, Zhou M, Huang Q, Wen X, Zhao J, Shi S, Geng K, Li F, Hatakeyama H, Xu C, Piwnicka-Worms D, Peng W, Zhou D, Sood AK, Li C (2020). Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition. *Nanomedicine* doi: 10.1016/j.nano.2020.102169
632. Matsuo K, Chang EJ, Matsuzaki S, Mandelbaum RS, Matsushima K, Grubbs BH, Klar M, Roman LD, Sood AK, Wright JD (2020). Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes. *Gynecologic Oncology* 158:59-65.
633. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK (2020). Molecular analysis of clinical defined subsets of high-grade serous ovarian cancer. *Cell Reports* 31, 107502. Doi.org/10.1016/j.celrep.2020.03.066
634. Nusbaum DJ, Mandelbaum RS, Machida H, Roman LD, Sood AK, Gershenson DM, Matsuo K (2020). Significance of lymph node ratio on survival of women with borderline ovarian tumors. *Archives of Gynecology and Obstetrics* 301:1289 – 1298.
635. Matsuo K, Huang Y, Matsuzaki S, Klar M, Roman LD, Sood AK, Wright JD (2020). Minimally invasive surgery and increased risk of capsule rupture for early-stage ovarian cancer. *Journal of the American Medical Association Oncology* 6(7):1110 – 1113.
636. Maoz A, Matsuo K, Ciccone M, Matsuzaki S, Klar M, Roman LD, Sood AK, Gershenson DM (2020). Molecular pathways and targeted therapies for malignant ovarian germ cell tumors and sex cord-stromal tumors: a contemporary review. *Cancers* 12(6):1398; doi.org/10.3390/cancers12061398
637. Miyake TM, Pradeep S, Wu SY, Gharpure KM, Rodriguez-Aguayo C, Lee JS, Lopez-Berestein G, Coleman RL, Sood AK (2020). NRG1/ErbB3 pathway activation induces acquired resistance to XPO1 inhibitors. *Molecular Cancer Therapeutics* 19:1727 – 1735.
638. Lutgendorf SK, Thaker PH, Arevalo JMG, Goodheart MJ, Dahmouch L, Penedo F, Slavich GM, Sood

- AK, Cole SW (2020). Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation. *Cancer* 126:4407 – 4413.
639. Li Y, Yang S, Sadaoui NC, Hu W, Dasari SK, Mangala LS, Sun Y, Zhao S, Wang L, Liu Y, Ramondetta LM, Li K, Lu C, Kang Y, Cole SW, Lutgendorf SK, Sood AK (2020). Sustained adrenergic activation of YAP1 induces anoikis resistance in cervical cancer cells. *iScience* 23, 101289; doi.org/10.1016/j.isci.2020.101289
640. Cata JP, Sood AK, Eltzschig HK (2020). Anesthetic drugs and cancer progression: Fact or fiction. *Anesthesiology* 133:698-699.
641. Peres LC, Sinha S, Townsend MK, Fridley BL, Karlan BY, Lutgendorf SK, Shinn E, Sood AK, Tworoger SS (2020). Predictors of survival trajectories among women with epithelial ovarian cancer. *Gynecologic Oncology* 156:459-466.
642. Lara OD, Bayraktar E, Amero P, Ma S, Ivan C, Hu W, Wang Y, Mangala LS, Dutta P, Bhattacharya P, Ashizawa AT, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AK (2020). Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. *Oncotarget* 11(29):2819-2833. *Cover illustration
643. Kim MS*, Ma S, Chelariu-Raicu A, Leushner C, Alila HW, Lee S, Coleman RL, Sood AK* (2020). Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancer. *Molecular Cancer Therapeutics* 19:2396-2406. *Co-corresponding authors
644. Cobb LP, Sun CC, Iyer R, Nick AM, Fleming ND, Westin S, Sood AK, Wong KK, Silva EG, Gershenson DM (2020). The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative resistance. *Gynecologic Oncology* 158:653 – 658.
645. Prathipati P, Rodriguez-Aguayo C, Walton BL, Sood AK, Greaver J, Janssen CF, Lopez-Berestein G (2020). A retrospective analysis for different routes of administration in mice-percutaneous retro-orbital, jugular catheter, tail vein and femoral cut down injections. *Journal of Biosciences and Medicines* 8:131-141.
646. Saha B, Mathur T, Handley KF, Hu W, Afshar Kharghan V, Sood AK, Jain A (2020). OvCa-chip microsystem recreates vascular endothelium-mediated platelet extravasation in ovarian cancer. *Blood Advances* 4(14):3329 – 3342.
647. Wen Y*, Wang Y, Chelariu-Raicu A, Stur E, Liu Y, Corvigno S, Bartsch F, Redfern L, Zand B, Kang Y, Liu J, Baggerly KA, Sood AK* (2020). Blockade of the short form of prolactin receptor induces FOXO3a/EIF-4EBP1-mediated cell death in uterine cancer. *Molecular Cancer Therapeutics* 19:1943 – 1954. *Co-corresponding authors
648. Liu Y, Wu S, Koo Y, Yang A, Dai Y, Osman S, Chowdhury M, Kim M, Nguyen M, Wei H, Tang E, Ma S, Duc-Hiep B, Chehab EW, Braam J, Sood AK (2020). Characterization of and isolation methods for plant leaf nanovesicles and exosomes. *Nanomedicine: Nanotechnology, Biology, and Medicine* 29, 102271; doi.org/10.1016/j.nano.2020.102271
649. Hong B, Chapa V, Saini U, Modgil P, Cohn DE, He G, Siddik ZH, Sood AK, Yan Y, Karuppaiyah S, Pei G, Zhao Z, Yoo JY, Kaur B (2021). Oncolytic HSV therapy modulates vesicular trafficking inducing

- cisplatin sensitivity and anti-tumor immunity. *Clinical Cancer Research* 27(2), 542-553. <https://doi.org/10.1158/1078-0432.CCR-20-2210>
650. Kim O, Park EY, Kwon SY, Shin S, Emerson RE, Shin YH, DeMayo FJ, Lydon JP, Coffey DM, Hawkins SM, Quilliam LA, Cheon DJ, Fernandez FM, Nephew KP, Karpf AR, Widschwendter M, Sood AK, Bast RC, Godwin AK, Miller KD, Cho CH, Kim J (2020). Targeting progesterone signaling prevents metastatic ovarian cancer. *Proceedings of the National Academy of Sciences* 117(50):31993 – 32004.
651. Matsuo K, Matsuzaki S, Nusbaum DJ, Maoz A, Oda K, Klar M, Roman LD, Sood AK (2020). Neoadjuvant chemotherapy for advanced ovarian cancer: Recent trends and outcomes in the United States. *Gynecologic Oncology* 160:32 – 39.
652. Sasano T, Cho MS, Rodriguez-Aguayo C, Bayraktar E, Taki M, Afshar-Kharghan V, Sood AK (2021). Role of tissue-factor bearing extracellular vesicles released from ovarian cancer cells in platelet aggregation in vitro and venous thrombosis in mice. *Thrombosis Update* 2, 100020; doi.org/10.1016/j.tru.2020.100020
653. Noh K, Bach DH, Choi HJ, Kim MS, Wu SY, Pradeep S, Ivan C, Cho MS, Bayraktar E, Rodriguez-Aguayo C, Dasari SK, Stur E, Mangala LS, Lopez-Berestein G, Sood AK (2021). The hidden role of paxillin: Localization to nucleus promotes tumor angiogenesis. *Oncogene* 40:384 – 395.
654. Matsuzaki S, Klar M, Matsuzaki S, Sood AK, Roman LD, Matsuo K (2021). Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. *Gynecologic Oncology* 160:586 – 601. <https://doi.org/10.1016/j.ygyno.2020.10.043>
655. Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AK (2021). Clinical significance of homologous recombination deficiency score testing in endometrial cancer. *Gynecologic Oncology* 160:777 – 785.
656. Lee S, Zhao L, Little LD, Westin SN, Jazaeri AA, Fleming ND, Zhang J, Futreal PA, Sood AK (2021). Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups. *iScience* doi.org/10.1016/j.isci.2021.102053.
657. Joseph R, Soundararajan R, Vasaikar S, Yang F, Allton KL, Tian L, den Hollander P, Isgandarova S, Haemmerle M, Mino B, Zhou T, Shin C, Martinez-Paniagua M, Sahin AA, Rodriguez-Canales J, Gelovani J, Chang JT, Acharya G, Sood AK, Wistuba II, Gibbons DL, Solis LM, Barton MC, Varadarajan N, Rosen JM, Zhang XH, Mani SA (2021). CD8⁺ T cells inhibit metastasis and CXCL4 regulates its function. *British Journal of Cancer* 125:176-189. doi.org/10.1038/s41416-021-01338-5
658. Coleman RL, Hu W, Soliman P, Nick A, Ramirez P, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, Meyer L, Sood AK (2021). Dasatinib, paclitaxel and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. *Gynecologic Oncology* 161:104-112.
659. Elsayed AM, Bayraktar E, Amero P, Salama SA, Abdelaziz AH, Ismail RS, Ivan C, Zhang X, Sood AK, Lopez-Berestein G, Rodriguez-Aguayo C (2021). PRKAR1B-AS2 long noncoding RNA promotes tumorigenesis, survival, and chemoresistance via PI3K/AKT/mTOR pathway. *International Journal of Molecular Sciences* 22(4), 1-25. [1882]. <https://doi.org/10.3390/ijms22041882>

660. How J, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Naing A. Phase II study of the clinical efficacy and safety of single-agent pembrolizumab in patients with granulosa cell tumors of the ovary. *Investigational New Drugs* 39(3), 829-835. <https://doi.org/10.1007/s10637-020-01043-9>
661. Ma S, McGuire MH, Mangala LS, Lee S, Stur E, Hu W, Bayraktar E, Villar-Prados A, Ivan C, Wu SY, Yokoi A, Dasari SK, Jennings NB, Liu J, Lopez-Berestein G, Ram P, Sood AK (2021). Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. *Cell Reports* 34, 108726. [Doi.org/10.1016/j.celrep.2021.108726](https://doi.org/10.1016/j.celrep.2021.108726)
662. Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, Lu KH, Meyer LA (2021). Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. *Gynecologic Oncology* 161:56-62.
663. Patel AB, Iyer P, Matsuzaki S, Matsuo K, Sood AK, Fleming ND (2021). Emerging trends in neoadjuvant chemotherapy for ovarian cancer. *Cancers* 13, 626. [Doi.org/10.3390/cancers13040626](https://doi.org/10.3390/cancers13040626)
664. Zhong Y, Liu L*, Li X, Westin SN, Malpica A, Lawson BC, Lee S, Fellman BM, Coleman RL, Sood AK*, Fleming N* (2021). A modified 2-tier chemotherapy response score (CRS) and other histopathologic features for predicting outcomes of patients with advanced extrauterine high-grade serous carcinoma after neoadjuvant chemotherapy. *Cancers* 13,704. [Doi.org/10.3390/cancers13040704](https://doi.org/10.3390/cancers13040704). *Corresponding authors
665. Cho MS, Li J, Gonzalez-Delgado R, Lee H, Vasquez M, He T, He Y, Liu K, Sasano T, Nürnberg B, Sood AK, Wong STC, Afshar-Kharghan V (2021). The effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer. *Blood Advances*, 5(7), 1947-1951. <https://doi.org/10.1182/BLOODADVANCES.2020003410>
666. Garvin L, Slavich GM, Schrepf A, Davis LZ, Thaker PH, Goodheart MJ, Cole SW, Sood AK, Lutgendorf SK (2021). Chronic difficulties are associated with poorer psychosocial functioning in the first year post-diagnosis in epithelial ovarian cancer patients. *Psycho-Oncology* 30:954-961.
667. Cueno MG, Szeto A, Schrepf A, Thaker PH, Goodheart M, Cole SW, Sood AK, McCabe PM, Mendez AJ, Lutgendorf SK (2021). Positive psychosocial factors and oxytocin in the ovarian tumor microenvironment. *Psychosomatic Medicine* 83(5), 417-422. <https://doi.org/10.1097/PSY.0000000000000935>
668. Bailey CD, Previs RA, Fellman B, Zaid TM, Huang M, Brown A, Enbaya A, Balakrishnan N, Broaddus RR, Bodurka DC, Soliman PT, Fleming ND, Nick AM, Sood AK, Westin SN (2021). Pathologic distribution at the time of interval tumor reductive surgery informs personalized ovarian cancer surgery for high-grade ovarian cancer. *International Journal of Gynecologic Cancer* 31:232 – 237.
669. Lei G, Zhang Y, Hong T, Zhang X, Liu X, Mao C, Yan Y, Koppula P, Chen W, Sood AK, Liu J, Gan B (2021). Ferroptosis as a mechanism to mediate p53 function in tumor radioresistance. *Oncogene* 40:3533-3547.
670. Fleming ND, Westin SN, Meyer LA, Shafer A, Rauh-Hain JA, Onstad M, Cobb L, Bevers M, Fellman BM, Burzawa JK, Bhosale P, Zand B, Jazaeri A, Levenback C, Coleman RL, Soliman PT, Sood AK (2021). Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. *International Journal of Gynecologic Cancer* 31:92 – 97.

671. Nitecki R, Fleming ND, Fellman B, Meyer B, Meyer LA, Sood AK, Lu KH, Rauh-Hain A (2021). Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. *Gynecologic Oncology* 161(3), 660-667. <https://doi.org/10.1016/j.ygyno.2021.04.012>
672. Wagner MJ, Lyons YA, Siedel JH, Dood R, Nagaraja AS, Haemmerle M, Mangala LS, Chanana P, Lazar AJ, Wang W-L, Ravi V, Holland EC, Sood AK (2021). Combined VEGFR and MAPK pathway inhibition in angiosarcoma. *Scientific Reports* 11:9362. doi.org/10.1038/s41598-021-88703-9
673. Amero P, Lokesh GLR, Chaudhari RR, Cardenas-Zuniga R, Schubert T, Attia YM, Motanvo-Gonzalez E, Elsayed AM, Ivan C, Wang Z, Cristini V, de Franciscis V, Zhang S, Volk DE, Mitra R, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G (2021). Conversion of RNA aptamer into modified DNA aptamers provides for prolonged stability and enhanced antitumor activity. *Journal of the American Chemical Society* 143:7655-7670.
674. Niu N, Shen W, Zhong Y, Bast RC, Jazaeri A, Sood AK, Liu J (2021). Expression of B7-H4 and IDO1 is associated with drug resistance and prognosis in high-grade serous ovarian carcinomas. *Human Pathology* 113:20-27.
675. Bindra S, McGill MA, Triplett MK, Tyagi A, Thaker PH, Dahmouh L, Goodheart MJ, Ogden RT, Owusu-Ansah E, Karan K, Cole S, Sood AK, Lutgendorf SK, Picard M (2021). Mitochondria in epithelial ovarian carcinoma exhibit abnormal phenotypes and blunted associations with biobehavioral factors. *Scientific Reports* 11:11595; [doi.org/s41598-021-89934-6](https://doi.org/10.1038/s41598-021-89934-6)
676. Gao C, Jin G, Forbes ME, Mangala LS, Wang Y, Rodriguez-Aguayo C, Amero P, Bayraktar E, Yan Y, Gabriel Lopez-Berestein, Broaddus RR, Sood AK, Xue F, Zhang W (2021). Inactivating mutations of the IK gene weaken Ku80/Ku70-mediated DNA repair and sensitize endometrial cancer to chemotherapy. *Cancers* 13(10), [2487]. <https://doi.org/10.3390/cancers13102487>
677. Secord AA, O'Malley DM, Sood AK, Westin SN, Liu JF. Rationale for combination PARP inhibitor and anti-angiogenic treatment in advanced epithelial ovarian cancer: A review. *Gynecologic Oncology* 62(2), 482-495. <https://doi.org/10.1016/j.ygyno.2021.05.018>
678. Saha B, Tronolone JJ, Chokshi M, Oney S, Lokhande G, Gaharwar AK, Barondeau DP, Afshar-Kharghan V, Sood AK, Bao G, Jain A (2021). Human Tumor MicroEnvironment-Chip evaluates the consequences of platelet extravasation and antitumor-antiplatelet therapy in ovarian cancer. *Science Advances* 2020; 7(30), [eabg5283]. <https://doi.org/10.1126/sciadv.abg5283>
679. Virani S, Baiocchi G, Bowtell D, Cabasag C, Cho KR, Fortner RT, Fujiwara K, Kim JW, Kobel M, Kurtz JE, Levine DA, Menon U, Norquist BM, Pharoah PDP, Sood AK, Tworoger SS, Wentzensen N, Chanock SJ, Brennan P, Trabert B (2021). Joining IARC/NCI International Cancer Seminar Series Report: Expert consensus on future directions for ovarian carcinoma research. *Carcinogenesis* 42(6):785 – 793.
680. Hunt AL, Bateman NW, Barakat W, Makohorn-Moore S, Hood BL, Conrads KA, Zhou M, Calvert V, Pierobon M, Loffredo J, Litz J, Oliver J, Mitchell D, Gist G, Rojas C, Blanton B, Robinson EL, Odunsi K, Sood AK, Casablanca Y, Darcy KM, Shriver CD, Petricoin EF, Rao UNM, Maxwell GL, Conrads TP (2021). Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens. *iScience* 24, 102757.

Doi.org/10.1016/j.isci.2021.102757

681. Kanikarla-Marie P, Fowlkes NW, Afshar-Kharghan V, Sorokin A, Shen JP, Morris VK, Dasari A, You N, Sood AK, Overman MJ, Kopetz S, Menter DG (2021). The provocative roles of platelets in liver disease and cancer. *Frontiers in Oncology* 11, [643815]. <https://doi.org/10.3389/fonc.2021.643815>
682. McGuire MH, Dasari SK, Yao H, Wen Y, Mangala LS, Bayraktar E, Ma W, Ivan C, Shoshan E, Wu SY, Jonasch E, Bar-Eli M, Wang J, Baggerly KA, Sood AK. Gene body methylation of the lymphocyte-specific gene CARD11 results in its overexpression and regulates cancer mTOR signaling. *Molecular Cancer Research (In Press)*
683. Wood C, Han S, Kim CS, Wen Y, Sampaio DRT, Harris JT, Homan KA, Swain JL, Emelianov SY, Sood AK, Cook JR, Sokolov KV, Bouchard RR (2021). Clinically translatable quantitative molecular photoacoustic imaging with liposome-encapsulated ICG J-aggregates. *Nature Communications* 12:5410. doi.org/10.1038/s41467-021-25452-3
684. Lutgendorf SK, Ramirez E, Schrepf A, Valentine MC, Charlton M, Zimmerman MB, Goodheart MJ, Zia S, Sood AK, Thaker PH (2021). Rural residence is related to shorter survival in epithelial ovarian cancer patients. *Gynecologic Oncology* 163(1), 22-28. <https://doi.org/10.1016/j.ygyno.2021.07.035>. *Cover mention; accompanying editorial by Clair KH and Bristow RE; pages 3-4.
685. Wu Y, Huang J, Ivan C, Sun Y, Ma S, Mangala LS, Fellman BM, Urbauer DL, Jennings NB, Ram P, Coleman RL, Hu W*, Sood AK* (2021). MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. *Gynecologic Oncology* 163(1), 181-190. <https://doi.org/10.1016/j.ygyno.2021.08.003> *Corresponding authors
686. Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK (2021). Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. *Gynecologic Oncology* 162:65-71.
687. Ma S, Mangala LS, Hu W, Bayraktar E, Yokoi A, Hu W, Pradeep S, Lee S, Piehowski PD, Villar – Prados A, Wu SY, McGuire MH, Lara OD, Rodriguez-Aguayo C, LaFargue CJ, Jennings NB, Rodland KD, Liu T, Kundra V, Ram PT, Ramakrishnan S, Lopez-Berestein G, Coleman RL Sood AK (2021). CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. *Cell Reports* 36, 109549. Doi.org/10.1016/j.celrep.2021.109549
688. Westin SN, Labrie M, Litton J, Blucher A, Fang Y, Vellano C, Marszalek JR, Feng N, Ma XY, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase Ib dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer. *Clinical Cancer Research (In Press)*
689. Niu N, Yao J, Qi L, Bast RC, Sood AK, Liu J (2021). IL-6 promotes drug resistance through of polyploid giant cancer cells and stromal fibroblast reprogramming. *Oncogenesis* 10(9), [65]. <https://doi.org/10.1038/s41389-021-00349-4>
690. Corvigno S, Burks JK, Hu W, Zhong Y, Jennings NB, Fleming ND, Westin SN, Fellman B, Liu J, Sood AK (2021). Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. *Journal of Cancer Research and Clinical Oncology* 147(12), 3545-

3555. <https://doi.org/10.1007/s00432-021-03778-1>
691. Huang T, Townsend MK, Dood RL, Sood AK, Tworoger SS (2021). Antihypertensive medication use and ovarian cancer survival. *Gynecologic Oncology* 163: 342-347.
692. George J, Li Y, Kadembari IP, Parashar D, Tsaih SW, Gupta P, Geethadevi A, Chen CL, Ghosh C, Sun Y, Ramchandran R, Rader JS, Rui H, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AK, Dey M, Pradeep S, Chaluvally-Raghavan P (2021). RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to translation start site. *Cell Reports* 37(5), [109934]. <https://doi.org/10.1016/j.celrep.2021.109934>
693. Handley KF, Rodriguez-Aguayo C, Ma S, Stur E, Joseph R, Bayraktar E, Dasari SK, Nguyen N, Powell RT, Sobieski M, Ivan C, Kim M, Umamaheswaran S, Glassman D, Wen Y, Amero P, Stephan C, Coleman RL, Landesman Y, Westin SN, Ram PT, Sood AK. Rational combination of CRM1 inhibitor selinexor and olaparib shows synergy in ovarian cancer cell lines and mouse models. *Molecular Cancer Therapeutics (In Press)*
694. Ketcher D, Lutgendorf SK, Leighton S, Matzo M, Carter J, Peddireddy A, Karlan B, Tew WP, Sood AK, Shinn EH (2021). Attributions of survival and methods of coping of long-term ovarian cancer survivors: A qualitative study. *BMC Women's Health* 21:376; doi.org/10.1186/s12905-021-01476-1
695. Liu J, Niu N, Li X, Zhang X, Sood AK (2021). The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions. *Seminars in cancer biology*. <https://doi.org/10.1016/j.semcan.2021.10.005>
696. Sasano T#, Gonzalez-Delgado R#, Munoz NM, Carlos-Alcade W, Cho MS, Sheth RA*, Sood AK*, Afshar-Kharghan V* (2021). Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer. *Journal of Thrombosis and Haemostasis* <https://doi.org/10.1111/jth.15544> #Contributed equally; *Co-corresponding authors
697. Wu Y, Jennings NB, Sun Y, Dasari SK, Bayraktar E, Corvigno S, Stur E, Glassman D, Mangala LS, Lankenau Ahumada A, Westin SN, Sood AK*, Hu W* (2022). Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. *Journal of Cancer Research and Clinical Oncology* <https://doi.org/10.1007/s00432-021-03885-z> *Co-corresponding authors
698. Gershenson DM, Sun CC, Westin SN, Eyada M, Cobb LP, Nathan LC, Sood AK, Malpica A, Hillman RT, Wong KK. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. *Gynecologic Oncology (In Press)*
699. Menter DG, Afshar-Kharghan V, Shen JP, Martch SL, Maitra A, Kopetz S, Honn KV, Sood AK. Of vascular defense, hemostasis, cancer and platelet biology: an evolutionary perspective. *Cancer and Metastasis Reviews (In Press)*
700. Wen Y*, Chelariu-Raicu A, Umamaheswaran S, Nick AM, Stur E, Hanjra P, Jiang D, Jennings NB, Chen X, Corvigno S, Glassman D, Lopez-Berestein G, Liu J, Hung MC, Sood AK* (2022). Endothelial p130Cas confers resistance to anti-angiogenesis therapy. *Cell Reports* 38(4): <https://doi.org/10.1016/j.celrep.2022.110301> *Corresponding authors
701. Stur E*, Corvigno S*, Xu M, Chen K, Tan Y, Lee S, Liu J, Ricco E, Kraushaar D, Castro P, Zhang J,

- Sood AK (2022). Spatially resolved transcriptomics of high-grade serous ovarian carcinoma. *iScience* 25:103923; doi.org/10.1016/j.isci.2022.103923 *Equal authors
702. Asare A, Yao H, Lara O, Wang Y, Zhang L, Sood AK (2022). Race-associated molecular changes in gynecologic malignancies. *Cancer Research Communications (In Press)*
703. LaFargue C, Handley KF, Fleming ND, Nick AM, Chelariu-Raicu A, Fellman B, Castellano T, Ogasawara A, Hom-Tedla M, Blake EA, da Costa A, Crim AK, Rauh-Hain A, Westin SN, Coleman RL, Matsuo K, Baiocchi G, Hasegawa K, Moore K, Sood AK. Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. *Gynecologic Oncology (In Press)*
704. Glassman D, Bateman NW, Lee S, Yao J, Tan Y, Ivan C, Rangel KM, Zhang J, Conrads KA, Hood BL, Abulez T, Futreal PA, Fleming ND, Afshar-Kharghan V, Maxwell GL, Conrads TP, Chen K, Sood AK (2022). Molecular correlates of venous thromboembolism (VTE) in ovarian cancer. *Cancers* 14(6), 1496; <https://doi.org/10.3390/cancers14061496>
705. Wu J, Lakomy DS, Fellman BM, Salcedo MP, Sood AK, Jhingran A, Klopp AH, Iyer RB, Jimenez C, Colbert LE, Eifel PJ, Schmeler KM, Lin LL. Longitudinal changes in bone mineral measurements inside and outside radiation fields used for cervical cancer treatment. *Practical Radiation Oncology (In Press)*
706. Handley K, Sood AK, Dal Molin GZ, Westin SN, Meyer LA, Fellman B, Soliman PT, Coleman RL, Fleming ND. Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes. *Gynecologic Oncology (In Press)*
707. Corvigno S, Johnson AM, Wong KK, Cho MS, Afshar-Kharghan V, Menter DG, Sood AK (2022). Novel markers for liquid biopsies in cancer management: Circulating platelets and extracellular vesicles. *Molecular Cancer Therapeutics* 21:1067-1075.
708. Cho MS, Lee H, Gonzalez-Delgado R, Li D, Sasano T, Carlos-Alcalde W, Ma Q, Liu J, Sood AK, Afshar-Kharghan V. Platelets increase the expression of PD-L1 in ovarian cancer. *Cancers (In Press)*
709. Zhao L, Corvigno S, Ma S, Celestino J, Fleming ND, Hajek RA, Ahumada AL, Jennings NB, Thompson EJ, Tang H, Westin SN, Jazaeri AA, Zhang J, Futreal PA, Sood AK, Lee S. Molecular profiles of serum-derived extracellular vesicles in high-grade serous ovarian cancer. *Cancers (In Press)*
710. Jensen DM, Han P, Mangala LS, Lopez-Berestein G, Sood AK, Liu J, Kriegel AJ, Usa K, Widlansky ME, Liang M (2022). Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications. *Molecular Therapy* 30(11):3462-3476.
711. Stur E, Bayraktar E, Dal Molin GZ, Wu SY, Mangala LS, Yao H, Wang Y, Ram PT, Corvigno S, Tworoger SS, Levine DA, Lutgendorf SK, Liu J, Moore K, Baggerly KA, Karlan BY, Sood AK (2022). Molecular analysis of short- versus long-term survivors of high-grade serous ovarian carcinoma. *Cancers* 14, 4198; doi.org/10.3390/cancers14174198
712. Lutgendorf SK, Thaker PH, Arevalo JM, Goodheart MJ, Slavich GM, Sood AK, Cole SW. Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma. *Cancer (In Press)*
713. Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, Yam C, Hsu JL, Wang HL, Chang WC, Yamaguchi H, Jiang Z, Liu C, Li CF, Nie L, Chan LC, Gao Y, Wang SC, Liu J, Westin SN, Lee S, Sood AK, Yang L, Hortobagyi GN, Yu D, Hung MC. Targeting the ALK/CDK9-Y19 kinase cascade sensitizes

- ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. *Nature Cancer* (In Press)
714. Mateescu B, Jones JC, Sood AK (co-author)....Laurent LC (corresponding) (2022). Phase 2 of extracellular RNA communication consortium charts next-generation approaches for extracellular RNA research. *iScience* 25, 104653, doi.org/10.1016/j.isci.2022.104653
715. Zhang X, Yao J, Niu N, Li X, Liu Y, Huo L, Euscher E, Wang H, Bell D, Sood AK, Wang G, Lawson BC, Malpica A, Ramalingam P, Sahin A, Ding Q, Liu J. SOX17: A highly sensitive and specific marker for ovarian and endometrial carcinomas. *Modern Pathology* (In Press)
716. Westin SN, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin H, Hong DS, Pant S, Carter B, Jazaeri A, Gershenson D, Sood AK, Coleman RL, Shah J, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. *Gynecologic Oncology* (In Press)
717. Handley KF, Sims TT, Bateman NW, Glassman D, Foster KI, Lee S, Yao J, Yao H, Fellman BM, Liu J, Lu Z, Conrads KA, Hood BL, Barakat W, Zhao L, Zhang J, Westin SN, Celestino J, Rangel KM, Badal S, Pereira I, Ram PT, Maxwell GL, Eberlin LS, Futreal PA, Bast RC, Fleming ND, Conrads TP, Sood AK. Classification of high-grade serous ovarian cancer using tumor morphology. *Journal of the American Medical Association Network Open* (In Press)
718. Wong KK, Bateman NW, Ng CW, Tsang YTM, Sun CS, Celestino J, Nguyen TV, Malpica A, Hillman RT, Zhang J, Futreal PA, Rojas C, Conrads KA, Hood BL, Dalgard CL, Wilkerson MD, Phippen NT, Conrads TP, Maxwell GL, Sood AK, Gershenson DM. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. *Journal of Translational Medicine* (In Press)
719. Li X, Zhong Y, Zhang X, Sood AK, Liu J. Spatiotemporal view of malignant histogenesis and macroevolution via formation of polyploid giant cancer cells. *Oncogene* (In Press)
720. Glassman D, Kim MS, Spradlin M, Badal S, Taki M, Bhattacharya P, Dutta P, Kingsley CV, Foster KI, Animasahun O, Jeon JH, Achreja A, Jayaraman A, Kumar P, Nenwani M, Wuchu F, Bayraktar E, Wu Y, Stur E, Mangala L, Lee S, Yap TA, Westin SN, Eberlin LS, Nagrath D, Sood AK (2023). Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. *iScience* 26, 106020; <https://doi.org/10.1016/j.isci.2023.106020>
721. Dasari SK, Joseph R, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell TR, Sobieski M, Liu Y, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AK (2023). Combination of EphA2- and Wee1-targeted therapies in endometrial cancer. *International Journal of Molecular Science* 24, 3915; <https://doi.org/10.3390/ijms24043915>
722. Gajjela CC, Brun M, Mankar R, Corvigno S, Kennedy N, Zhong Y, Liu J, Sood AK, Mayerich D, Berisha S, Reddy R. Leveraging mid-infrared spectroscopic imaging and deep learning for tissue subtype classification in ovarian cancer. *Analyst* (In Press)
723. Foster KI, Handley KF, Glassman DM, Sims TT, Javadi S, Palmquist SM, Saleh M, Fellman BM, Fleming ND, Bhosale PR, Sood AK. Characterizing morphologic subtypes of high-grade serous ovarian cancer by CT: A retrospective cohort study. *International Journal of Gynecologic Cancer* (In Press)

Press)

724. LaFargue CJ*, Amero P*, Noh K*, Mangala LS, Wen Y, Bayraktar E, Umamaheswaran S, Stur E, Dasari SK, Ivan C, Pradeep S, Yoo W, Lu C, Jennings NB, Vathipadiekal V, Hu W, Chelariu-Raicu A, Ku Z, Hui D, Xiong W, Choi HJ, Hu M, Kiyama T, Mao CA, Ali-Fehmi R, Birrer MJ, Liu J, Zhang N, Lopez-Berestein G, de Franciscis V, An Z, Sood AK (2023). Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. *Nature Communications* 14, 2407; <https://doi.org/10.1038/s41467-023-36910-5>. *Contributed equally
725. Foster KI, Legarreta AF, Kamat R, Handley KF, Glassman D, How JA, Lawson BC, Westin SN, Ramondetta LM, Frumovitz M, Gershenson DM, Sood AK, Hillman RT. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors. *The American Journal of Obstetrics & Gynecology* (In Press)
726. Liu Y, Ahumada AL, Bayraktar E, Schwartz P, Chowdhury M, Shi S, Sebastian MM, Khant H, de Val N, Bayram NN, Zhang G, Vu TC, Jie Z, Jennings NB, Rodriguez-Aguayo C, Swain J, Stur E, Mangala LS, Wu Y, Nagaraju S, Ermias B, Li C, Lopez-Berestein G, Braam J, Sood AK (2023). Enhancing oral delivery of plant-derived vesicles. *Journal of Controlled Release* 357:472-483.
727. Nelson BE, Fu X, Tsimberidou A, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SA. A phase I trial of bevacizumab and temsirolimus in combination with valproic acid in advanced solid tumors. *The Oncologist* (In Press)
728. Matsuo K, Matsuzaki S, Maeda M, Rau AR, Yoshihara K, Tamura R, Shimada M, Machida H, Mikami M, Klar M, Roman LD, Wright JD, Sood AK, Gershenson DM. Uptake and outcomes of neoadjuvant chemotherapy among US patients with less common epithelial ovarian tumors, 2006 – 2019. *Journal of the American Medical Association Network Open* (In Press)
729. Zhang X, Yao J, Li X, Niu N, Hajek RA, Peng G, Westin S, Sood AK*, Liu J*. Targeting polyploid giant cancer cells potentiates therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer. *Science Advances* (In Press) *Joint senior authors
730. Bateman NW, Abulez T, Soltis AR, McPherson A, Choi S, Garsed DW, Pandey A, Tian C, Hood BL, Conrads KA, Teng P-N, Oliver J, Gist G, Mitchell D, Litzi T, Tarney DM, Crothers BA, Mhawech-Fauceglia P, Dalgard CL, Wilkerson MD, Pierobon M, Petricoin EF, Yan C, Meerzaman D, Bodelon C, Wentzensen N, Lee JSH, The APOLLO Research Network (Sood AK), Huntsman DG, Shah S, Shriver CD, Phippen NT, Darcy KM, Bowtell D, Conrads TP, Maxwell GL. Proteogenomic alterations associated with immune infiltration and homologous recombination deficiency in high grade serous ovarian cancer identified in enriched tumor epithelium. *NPJ Precision Oncology* (In Press)
731. Grisham RN, Slomovitz BM, Andrews N, Banerjee S, Brown J, Carey MS, Chui H, Coleman RL, Fader AN, Gaillard S, Gourley C, Sood AK, Monk BJ, Moore KN, Ray-Coquard I, Shih I-M, Westin SN, Wong KK, Gershenson. Low-grade serous ovarian cancer: Expert consensus report on the state of the science. *International Journal of Gynecological Cancer* (In Press)
732. Corvigno S, Badal S, Spradlin ML, Keating M, Pereira I, Stur E, Bayraktar E, Foster KI, Bateman NW, Barakat W, Darcy KM, Conrads TP, Maxwell GL, Lorenzi PL, Lutgendorf SK, Wen Y, Zhao L, Thaker PH, Goodheart MJ, Liu J, Fleming N, Lee S, Eberlin LS, Sood AK. *In situ* profiling reveals metabolic alterations in the tumor microenvironment of high-grade serous ovarian tumors after neoadjuvant chemotherapy. *NPJ Precision Oncology* (In Press)

733. Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming N, Gershenson D, Vikram R, Bathala T, Vining D, Ganeshan D, Lu K, Sun CC, Meyer LA, Jazaeri A. Randomized Phase II Trial of Tremelimumab and Durvalumab in Combination versus Sequentially in Recurrent Platinum-Resistant Ovarian Cancer. *Cancer* (In Press)

Manuscripts submitted or in revision:

734. Barnard ME, Poole EM, Huang T, Sood AK, Kubzansky LD, Tworoger SS. Caregiver burden and risk of epithelial ovarian cancer in the Nurses' Health Studies. (Submitted)
735. Zeleznik OA, Huang T, Patel C, Poole EM, Clish CB, Armaiz-Pena GN, Nagaraja AS, Eliassen AH, Balasubramanian R, Kubzansky LD, Hankinson SE, Sood AK, Tworoger SS. Plasma and ovarian metabolomic responses to chronic stress in female mice. (Submitted)
736. Nelson BE, Fu X, Tsimberidou A, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SA. A phase I trial of bevacizumab and temsirolimus in combination with valproic acid in advanced solid tumors. (Submitted)

Abstracts:

- Over 450 abstracts accepted and presented at meetings (as poster or oral presentations; full details available upon request)

OTHER PRESENTATIONS:

1. Lecturer, University of Florida College of Medicine, Physician's Assistant program. "Management of the menopause". 1993.
2. Grand Rounds, University of Florida College of Medicine, Department of Obstetrics and Gynecology. "Vaginal Adenocarcinoma". September, 1994.
3. Lecturer, University of Florida College of Medicine, Physician's Assistant program. "Evaluation of a pelvic mass". 1994.
4. Grand Rounds, University of Iowa Hospitals and Clinics, Department of Obstetrics and Gynecology. "Molecular Prognostic Factors for Breast Cancer". March, 1996.
5. Invited Speaker for Scofield Advanced Oncology Nursing conference, Williamsburg, Iowa. "Menopausal Concerns in the Oncology Patient". April, 1996.
6. Grand Rounds, University of Iowa Hospitals and Clinics, Department of Obstetrics and Gynecology. "Ovarian Cancer: Can We Alter Survival of The Fittest". February, 1997.
7. Health Beat Radio Show, University of Iowa Hospitals and Clinics. "Management of menopause". June, 1997.
8. Grand Rounds, University of Iowa Hospitals and Clinics, Department of Obstetrics and Gynecology. "Ovarian Cancer: The role for primary surgical cytoreduction". January, 1998.

9. Resident Lecture Series, University of Iowa Hospitals and Clinics. "Repair of Surgical Injuries to Bowel and Urinary Tract". April, 1998.
10. Eleventh Annual Cancer Symposium, Covenant Medical Center, Waterloo, Iowa. "Menopause in the Cancer Patient". May, 1998.
11. Invited speaker, The Genetics Institute, Chicago, IL. "Ovarian cancer: An update". October, 1998.
12. Invited speaker, Gynecologic Oncology Support Group, University of Iowa Hospitals and Clinics. "Clinical Trials". November, 1998.
13. Grand Rounds, Broadlawns Medical Center, Des Moines, IA. "Vulvar neoplasms: Premalignant and malignant". June, 1999.
14. Grand Rounds, Mercy Hospital Medical Center, Des Moines, IA. "Ovarian cancer: An update". June, 1999.
15. Invited speaker, family Practice Program, Mercy Hospital, Iowa City, IA. "Issues in gynecologic cancer". September, 1999.
16. Invited speaker, Grand Rounds, Mercy Hospital Medical Center, Mason City, IA. "Indications for prophylactic oophorectomy". September, 1999.
17. "Person to person" live call-in radio show, WMT, University of Iowa Hospitals and Clinics. "Gynecologic Cancers". September, 1999.
18. Invited speaker, Postgraduate Conference, University of Iowa, Iowa City, IA. "Prophylactic oophorectomy: for whom?" October, 1999.
19. Resident Lecture Series, University of Iowa Hospitals and Clinics. "Evaluation of the bowel function in the postoperative patient. May, 2000.
20. Invited speaker, Oncology Nursing Society conference, Des Moines, IA. "Clinical trials in ovarian cancer". May, 2000.
21. Invited speaker, Human Anatomy and Physiology Society, Charlotte, NC. "Ovarian cancer vasculogenesis: Clinical and research perspectives". June, 2000.
22. Invited speaker, Gilda's Club, Davenport, Iowa. "Clinical trials for gynecological malignancies". August, 2000.
23. Grand Rounds, Broadlawns Medical Center, Des Moines, IA. "Issues in gynecologic cancer: Work-up and treatment of a patient with a pelvic mass". September, 2000.
24. Invited speaker, American Cancer Society, Iowa Council Volunteer Board of Directors Meeting, Amana, Iowa. "Vasculogenic mimicry in ovarian carcinoma". September, 2000.
25. Invited speaker, Northeastern Ohio Universities College of Medicine 7th Annual Current Topics in Ob/Gyn, Women's Malignancies – Year 2000 Update, Rootstown, Ohio. "Genetic screening for

women's malignancies". November, 2000.

26. Invited speaker, Northeastern Ohio Universities College of Medicine 7th Annual Current Topics in Ob/Gyn, Women's Malignancies – Year 2000 Update, Rootstown, Ohio. "Cancer of the ovary: Surgical prevention". November, 2000.
27. Resident Lecture Series, University of Iowa Hospitals and Clinics. "Methods to Repair Obstetric Lacerations". January, 2001.
28. Invited speaker, Postgraduate Course, The 49th Annual College Meeting of the American College of Obstetricians and Gynecologists, Chicago, IL. "Genetic Insights into Gynecologic Disorders: Genetic screening for gynecologic malignancies". April, 2001.
29. Invited speaker, Postgraduate Course, The 49th Annual College Meeting of the American College of Obstetricians and Gynecologists, Chicago, IL. "Genetic Insights into Gynecologic Disorders: Prophylactic options for gynecologic malignancies". April, 2001.
30. Invited speaker, Postgraduate Course, The 49th Annual College Meeting of the American College of Obstetricians and Gynecologists, Chicago, IL. "Genetic Insights into Gynecologic Disorders: Future prospects for molecular treatments". April, 2001.
31. Invited speaker, joint gynecologic oncology conference of Washington University and Saint Louis University, St. Louis, MO. "Genetic screening and medicolegal ramifications". August, 2001.
32. Invited speaker, Grand Rounds, Saint Louis University, St. Louis, MO. "Prophylactic approaches for ovarian cancer". August, 2001.
33. Invited speaker, "On the Horizon of Oncology Nursing" conference, Des Moines, IA. "Ovarian Cancer: Genetic Insights and Management". October, 2001.
34. Invited speaker, Mercy Medical Center, Sioux City, IA. "Benign and malignant vulvar neoplasms". October, 2001.
35. Grand Rounds, University of Iowa Hospitals and Clinics, Department of Obstetrics and Gynecology. "Genetic screening for ovarian cancer: Medicolegal implications". October, 2001.
36. Grand Rounds, The University of Texas M. D. Anderson Cancer Center, Department of Gynecologic Oncology. "Molecular determinants of ovarian cancer plasticity." February, 2002.
37. Invited speaker, Postgraduate Course, The 50th Annual College Meeting of the American College of Obstetricians and Gynecologists, Los Angeles, CA. "Genetic Screening for Gynecologic Malignancies". May, 2002.
38. Resident Lecture Series, University of Iowa Hospitals and Clinics. "Operative notes and dictations". June, 2002.
39. Invited discussant for Dr. Johnathan Lancaster's presentation, "High expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is associated with favorable survival in ovarian cancer. The 33rd Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2002.

40. Grand Rounds, University of Florida, Department of Obstetrics and Gynecology. "Molecular determinants of ovarian cancer plasticity". December, 2002.
41. Grand Rounds, The University of Texas M. D. Anderson Cancer Center, Department of Gynecologic Oncology. "The complexity of tumor vascularity." April, 2003.
42. Grand Rounds, Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, TX. "The complexity of tumor vascularity: Role of tumor cell plasticity". April, 2003
43. Invited speaker, Fourth Annual International Conference on Ovarian Cancer, Memorial Sloan-Kettering Cancer Center, New York, NY. "Angiogenesis and beyond in ovarian carcinoma". September, 2003.
44. Charles A. Hunter, Jr. Prize Thesis Award Presentation, The American Gynecological and Obstetrical Society, Napa, CA. "Functional role of matrix metalloproteinases in ovarian tumor cell plasticity". September, 2003.
45. Invited discussant for Dr. Rouba Ali-Fehmi's presentation, "Cox-2 in ovarian carcinoma". The 35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2004.
46. Invited speaker for the "Exploring the Integration of Psychoneuroimmunology and Tumor Immunology in Cancer Control Research" conference sponsored by the Basic Biobehavioral Research Branch (BBRB) of the National Cancer Institute, Bethesda, Maryland. "The seed and soil of cancer metastasis". April, 2004.
47. Invited speaker, Academy of Behavioral Medicine Research, Teton Village, WY. "Neuroendocrine modulation of tumor metastasis". June, 2004.
48. Invited speaker, University of California, Davis, CA. "Anti-vascular therapy for ovarian carcinoma". February, 2005
49. Invited speaker, University of California, Davis, CA. "Molecular biology of ovarian carcinoma". February, 2005.
50. Invited speaker, 2005 Winter Meeting of the Society of Gynecologic Oncologists: Controversies in Gynecologic Oncology. "Modified vertical rectus abdominis myocutaneous (VRAM) flap for pelvic reconstruction". February, 2005.
51. Invited discussant for Dr. Angeles Alvarez-Secord's presentation, "Co-expression and prognostic relevance of angiogenic markers in advanced epithelial ovarian cancer: A Gynecologic Oncology Group (GOG) study". The 36th Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2005.
52. Invited speaker, The 7th International Symposium on Anti-Angiogenic Agents: Recent Advances and Future Directions in Cell Biology and Clinical Research, San Diego, CA. "Anti-angiogenic therapy for treatment of ovarian cancer". February, 2005.
53. Invited speaker, The 12th Annual Meeting of the Psychoneuroimmunology Research Society, Denver, CO. Symposia on "Multidisciplinary models of neuroendocrine modulation of tumor progression: Integrative views and historical perspectives on immunological and non-immunological

mechanisms". June 2005.

54. Invited speaker, Fox Chase Cancer Center, Philadelphia, PA. "Therapeutic silencing of EphA2 in ovarian cancer". July, 2005.
55. Invited speaker, Ovarian Cancer State of the Science Meeting, National Cancer Institute, Rockville, MD. "Antiangiogenic approaches in ovarian carcinoma: Opportunities and challenges". September, 2005.
56. Invited speaker, University of California, San Diego. "Therapeutic targeting of EphA2 in ovarian cancer". October, 2005.
57. Invited speaker, Sixth Annual International Conference on Ovarian Cancer, Memorial Sloan-Kettering Cancer Center, New York, NY. "Effects of behavioral factors and stress on tumor microenvironment". November, 2005.
58. Invited speaker, Grand Rounds, The Ohio State University Comprehensive Cancer Center, Columbus, OH. "Therapeutic silencing of EphA2 in ovarian cancer". December, 2005.
59. Invited speaker, The Ohio State University Institute for Behavioral Medicine Research, Columbus, OH. "Effects of chronic stress on cancer metastasis". December, 2005.
60. Invited speaker, 5th Annual Clinical Cancer Update (sponsored by the University of California, San Francisco). "Targeted therapy in ovarian cancer". North Lake Tahoe, CA. January, 2006.
61. Invited speaker, 2006 Ovarian Survivors Course (sponsored by the Gynecologic Cancer Foundation). "Stress and its effect on the treatment of ovarian cancer". University of California, San Diego Medical Center Moores Cancer Center, San Diego, CA. January, 2006.
62. Invited speaker, Gynecologic Oncology Group Semi-Annual Meeting, San Diego, CA. "Angiogenesis: Emerging therapeutic targets". January, 2006.
63. "Therapeutic gene silencing with siRNA". Plastic Surgery Seminar Series, M. D. Anderson Cancer Center, Houston, TX. February, 2006.
64. Invited speaker, The 37th Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA. "Principles of Targeted Therapy". March, 2006.
65. Invited speaker, 97th Annual Meeting of the American Association for Cancer Research, Washington, DC. "Therapeutic gene silencing *in vivo* using RNA interference" in the session entitled "Dissecting the Genomic Architecture of Cancer". April, 2006.
66. Invited speaker, Grand Rounds, Cedars-Sinai Medical Center, Department of Obstetrics and Gynecology, Los Angeles, CA. "Anti-vascular therapy for ovarian cancer". May, 2006.
67. Invited speaker, Grand Rounds, Cousins Center for Psychoneuroimmunology, University of California, Los Angeles, CA. "Effects of chronic stress on cancer metastasis". May, 2006.
68. Lutgendorf SK, Sood AK. Neuroendocrine influences on tumor growth processes. Short Course, PNI and Disease Processes: Fundamentals and clinical perspectives. The 13th Annual Meeting of

the Psychoneuroimmunology Research Society, Miami, FL. June, 2006.

69. Invited speaker, 1st International Conference on Ovarian Cancer: State of the Art and Future Directions, Crete, Greece. "Angiogenesis mechanisms in ovarian cancer." June, 2006.
70. Invited speaker, "Neuroendocrine influences on cancer metastasis". University of California at San Francisco, CA. August, 2006.
71. Invited speaker, 2006 Ovarian Survivors Course (sponsored by the Gynecologic Cancer Foundation). "Stress and its effect on the treatment of ovarian cancer". Washington University School of Medicine, St. Louis, MO. September, 2006.
72. Invited Speaker, 11th Biennial Meeting of the International Gynecologic Cancer Society, Santa Monica, CA. "VEGF, angiogenesis and its implications in gynecological cancer." October, 2006.
73. Invited Speaker, The 6th Samsung Medical Center - M. D. Anderson Cancer Center International Symposium, Seoul, South Korea. "Controversies in management of endometrial cancer." November, 2006.
74. Invited Speaker, The 6th Samsung Medical Center - M. D. Anderson Cancer Center International Symposium, Seoul, South Korea. "Angiogenesis and tumor environment in gynecologic cancer." November, 2006.
75. Invited Speaker, The Fifth Annual AACR International Conference. Frontiers in Cancer Prevention Research. Neuroendocrine regulation of cancer progression: Biological mechanisms and clinical relevance." November, 2006.
76. Advances in Oncology Institutional Grand Rounds, Chair, New Developments in Ovarian Cancer, M. D. Anderson Cancer Center, Houston, TX. "Therapeutic gene silencing *in vivo* using RNA interference." December, 2006.
77. Invited speaker, Grand Rounds, Department of Obstetrics and Gynecology, Emory University, Atlanta, GA. "Role of VEGF and angiogenesis in gynecologic cancer". February, 2007.
78. Invited speaker, Keystone Symposia: Mechanisms linking inflammation and cancer. "Influence of biobehavioral factors on tumor biology: pathways and mechanisms". February, 2007.
79. Division of Surgery Grand Rounds. "New Developments in Ovarian Cancer". M. D. Anderson Cancer Center, Houston, TX. March, 2007.
80. Invited speaker, The 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA. "Anti-Angiogenesis Approaches in Ovarian Carcinoma". Postgraduate Course 6: Translational Research: Developments from the Ovarian Cancer SPOREs. March, 2006.
81. Invited speaker, 36th Meeting of the Board of Scientific Advisors, National Cancer Institute. Biobehavioral Influences on Cancer Biology: An Emerging Opportunity. "Effects of Chronic Stress on Cancer Growth and Progression". March, 2007.
82. Invited speaker and Director, Mini-symposium: Vascular Targeting for Gynecologic Malignancies and other Gynecologic Disorders. "Therapeutic Gene Silencing *In Vivo* using RNA Interference". 54th

Annual Meeting of the Society for Gynecologic Investigation, Reno, NV, March, 2007.

83. Invited speaker, The Annual Dinner Symposium, Reproductive Scientist Development Program, Senior RSDP Scholar Presentation. "Therapeutic Targeting of Focal Adhesion Kinase (FAK) using *In Vivo* RNA Interference". Reno, NV, March, 2007.
84. Invited speaker, 11th International Forum on Ovarian Cancer, Helene Harris Memorial Trust. "Therapeutic gene silencing *in vivo* using RNA interference." Lake Como, Italy, March, 2007.
85. Invited speaker, Integrative Medicine Program Lecture. "Influence of Biobehavioral Factors on Tumor Biology: Pathway and Mechanisms. M. D. Anderson Cancer Center, April, 2007.
86. Invited speaker, Hematology and Medical Oncology Grand Rounds, Memorial Sloan-Kettering Cancer Center, New York, NY. "Therapeutic Gene Silencing *In Vivo* using RNA Interference". April, 2007.
87. Invited speaker, Obstetrics and Gynecology Grand Rounds, Wayne State University School of Medicine/Detroit Medical Center. "Anti-Vascular Therapy for Ovarian Cancer". May, 2007.
88. Invited speaker, "Neuroendocrine modulation of the tumor microenvironment". Symposium on New Perspectives on Stress Regulation and Tumor Cell Biology. 14th Annual Meeting of the Psychoneuroimmunology Research Society, Arcachon, France. May, 2007.
89. Invited speaker, "Emerging anti-angiogenesis strategies for gynecologic malignancies". The 37th Annual Meeting of the Felix Rutledge Society, Houston, TX; June, 2007.
90. Invited speaker, "Neuroendocrine Influences on Cancer Metastasis". National Cancer Institute, Center for Cancer Research. Bethesda, MD; June, 2007.
91. Invited speaker, Grand Rounds, Department of Obstetrics and Gynecology, Vanderbilt University, Nashville, TN. "Antivascular therapy for ovarian cancer". July, 2007.
92. Invited speaker, Grand Rounds, Department of Obstetrics and Gynecology, Carolinas Medical Center, Charlotte, NC. "Antivascular therapy for ovarian cancer". October, 2007.
93. Invited speaker, Grand Rounds, Department of Biology, University of North Carolina, Charlotte, NC. "Angiogenesis and tumor microenvironment in gynecologic malignancies". October, 2007.
94. Invited speaker, National Ovarian Cancer Coalition, Houston, TX. "Translational Research in Ovarian Carcinoma". November, 2007.
95. Invited speaker, State of the Art Conference: Novel therapies and supportive care in the treatment of patients with ovarian cancer, Society of Gynecologic Oncologists, Chicago, IL. "Therapeutic gene silencing *in vivo* using RNA interference." December, 2007.
96. Invited speaker, University of California, San Francisco, Breast Oncology Program Retreat. "Therapeutic gene silencing *in vivo* using RNA interference". January, 2008.
97. Invited speaker, The 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL. "The coming revolution of therapies". Postgraduate Course 2: New Discoveries from the

Gynecologic Cancer SPOREs. March, 2008.

98. Invited speaker, The 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL. "Translating Discovery to the patient". Postgraduate Course 4: Novel Agents in the Treatment of Gynecologic Malignancies. March, 2008.
99. Invited speaker, The 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL. "Selectivity Filters for Molecular Therapy". Sunrise Session 7: State of the Science – Ovarian Cancer. March, 2008.
100. Invited speaker, "Neuroendocrine Influences on Cancer Metastasis". Lineberger Cancer Center, University of North Carolina, Chapel Hill. April, 2008.
101. Invited speaker, The 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA. "Interfering with cancer: An update on siRNA therapeutics. April, 2008.
102. Invited speaker, Grand Rounds, Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX. "Therapeutic gene silencing *in vivo* using RNA interference". April, 2008.
103. Invited speaker, Consensus Conference, Department of Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN. "Angiogenesis and tumor microenvironment in gynecologic malignancies". May, 2008.
104. Invited speaker, "Impact of microenvironment on tumor growth: Mechanisms and targets". Educational Short Course. The 15th Annual Meeting of the Psychoneuroimmunology Research Society, Madison, WI. May, 2008.
105. Invited speaker, "Effects of neuroendocrine pathways on ovarian cancer growth and progression". Biobehavioral Influences on Tumor Biology: Preclinical Models of Neuroendocrine Regulation, National Cancer Institute, Bethesda, MD. June, 2008.
106. Invited speaker, "Neuroendocrine influences on cancer metastasis." From Molecules to Societies: The Psychobiological Determinants of Health and Well-Being, University of British Columbia Workshop, Vancouver, BC, Canada. July, 2008.
107. Invited speaker, "Therapeutic Targeting of Angiogenesis *in vivo* using RNA interference". Experimental Therapeutics Lecture Series, M. D. Anderson Cancer Center, Houston, TX, 2008.
108. Keynote speaker, "On the Horizon: Developing Therapeutics". 7th Biennial Ovarian Cancer Research Symposium, Marsha Rivkin Center, Seattle, WA, 2008.
109. Probstin Lecturer. "Neuroendocrine influences on cancer metastasis." Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO, 2008.
110. Probstin Lecturer. "Therapeutic targeting of angiogenesis." Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO, 2008.
111. Invited speaker. Research forecast 2009: Novel therapeutics and developing therapies. Oncology Nursing Society (ONS) 9th Annual Institutes of Learning Program; Recurrent Ovarian Cancer: Challenges and Management Strategies. Seattle, WA, 2008.

112. Invited speaker, "Angiogenesis and tumor microenvironment in gynecologic malignancies." Grand Rounds, Department of Obstetrics and Gynecology, University of Florida, Gainesville, FL, 2008.
113. Invited Plenary Speaker, "Angiogenesis as a therapeutic target in gynecologic malignancies." Fertility 2009 (6th biannual conference of the UK Fertility Societies), Edinburgh, Scotland, 2009.
114. Invited speaker, "Therapeutic gene silencing *in vivo* using RNA interference." Sheba Medical Center, Tel Aviv, Israel, 2009.
115. Invited speaker, "Biological approaches to ovarian cancer therapy." SGO Special Symposia: Ovarian Cancer Translational Research. Prospects for Advances in Genetic Risk Assessment, Screening, and Biological Therapy. Society of Gynecologic Oncologists 40th Annual Meeting on Women's Cancer, San Antonio, TX, 2009.
116. Invited speaker, "SiRNA targeting of the tumor vasculature." The 11th International Symposium on Anti-Angiogenic Agents, San Diego, CA, 2009.
117. Invited speaker, "Interfering with tumor vasculature." The University of Puerto Rico, Mayaguez, 2009.
118. Invited speaker, "Therapeutic gene silencing *in vivo* using RNA interference." Center for Research on Reproduction and Women's Health, University of Pennsylvania, 2009.
119. Invited speaker, "Therapeutic gene silencing *in vivo* using RNA interference." Dongguk University, Gyeongju City, South Korea, 2009.
120. Invited speaker, "Toxicities of targeted therapy." The 8th Korean Gynecologic Oncology Group Meeting, Daegu, South Korea, 2009.
121. Invited speaker, "Effects of neuroendocrine pathways on ovarian cancer growth and progression." The 8th Korean Gynecologic Oncology Group Meeting, Daegu, South Korea, 2009.
122. Invited speaker, "Anti-angiogenesis agents." The 24th Annual Meeting of the Korean Society of Gynecologic Oncology and Colposcopy, Daegu, South Korea, 2009.
123. Invited speaker, "Emerging therapeutic approaches." The 24th Annual Meeting of the Korean Society of Gynecologic Oncology and Colposcopy, Daegu, South Korea, 2009.
124. Invited speaker, "Therapeutic targeting of angiogenesis *in vivo* using RNA interference." Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, 2009.
125. Invited speaker, "Therapeutic targeting of angiogenesis." Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC, 2009.
126. Invited speaker, "Therapeutic gene silencing *in vivo* using RNA interference." The Screening Technologies Branch of the Developmental Therapeutics Program, National Cancer Institute, Frederick, MD, 2009.
127. Invited speaker, "Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor- κ B pathway". Symposium: Complementary and alternative medicine approaches

- to health and wellness. The 16th Annual Meeting of the Psychoneuroimmunology Research Society, Breckenridge, CO. June, 2009.
128. Invited speaker, "Targeting angiogenesis in ovarian carcinoma." Department of Obstetrics and Gynecology, Mount Sinai School of Medicine, New York, NY, 2009.
 129. Invited speaker, "Therapeutic gene silencing *in vivo* using RNA interference." Department of Obstetrics and Gynecology, Mount Sinai School of Medicine, New York, NY, 2009.
 130. Invited speaker, "New directions in anti-angiogenesis therapy." Eighth Annual International Conference on Ovarian Cancer, Memorial Sloan-Kettering Cancer Center, New York, NY, 2009.
 131. Invited speaker, "Interfering with tumor vasculature." Grand Rounds, Department of Biochemistry and the Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, 2009.
 132. Invited speaker, "Angiogenesis and tumor microenvironment in gynecologic malignancies." Grand Rounds, Department of Obstetrics and Gynecology, University of Wisconsin, Madison, WI, 2009.
 133. Invited speaker, "Effects of chronic stress on cancer metastasis". In Educational Session "Biological consequences of stress". Eighth Annual International Conference of Frontiers in Cancer Prevention Research, Houston, TX, 2009.
 134. Invited speaker, "Therapeutic gene silencing *in vivo* using RNA interference". 4th International Liposome Society Conference: Liposome Advances: Progress in Drug and Vaccine Discovery, University of London, London, UK, 2009.
 135. Invited speaker, "Targeted gene silencing *in vivo* using rHDL nanoparticles". 4th International Liposome Society Conference: Liposome Advances: Progress in Drug and Vaccine Discovery, University of London, London, UK, 2009.
 136. Invited speaker, "Neuroendocrine Influences on Cancer Metastasis". Department of Cancer Biology, Wake Forest University, Winston Salem, NC. January, 2010.
 137. Invited speaker, "Interfering with Tumor Vasculature". First Global Congress on NanoEngineering for Medicine and Biology (NEMB), American Society of Mechanical Engineers (ASME). Session on Challenges in Biomedicine for Engineers, Houston, TX. February, 2010.
 138. Invited speaker, "Novel Therapies in Ovarian Cancer". II M. D. Anderson International Conference in Gynecologic Oncology, Madrid, Spain. February, 2010.
 139. Invited speaker, "Angiogenesis, Invasion, and Metastasis". A Primer on Cancer Biology and Plausible Mechanisms and Pathways for Stress-Mediated Effects on Cancer Biology". 68th Annual Meeting of the American Psychosomatic Society, Portland, OR. March, 2010.
 140. Invited speaker, "Systemic Regulation of Tumor Progression II: Sympathetic Nervous System". A Primer on Cancer Biology and Plausible Mechanisms and Pathways for Stress-Mediated Effects on Cancer Biology". 68th Annual Meeting of the American Psychosomatic Society, Portland, OR. March, 2010.
 141. Invited speaker, "Effects of Chronic Stress on Cancer Metastasis". First Annual University of Florida

Department of Obstetrics and Gynecology Meeting, Orlando, FL. March, 2010.

142. Invited speaker, "Ovarian Cancer: Clinical Aspects". Ultrasound in the New Millennium: The Cancer Patient, Houston, TX. April 2010.
143. Invited speaker, "Neuroendocrine Influences on Cancer Metastasis". Department of Cancer and Cell Biology, University of Cincinnati, Cincinnati, OH. May 2010.
144. Invited speaker, "Molecular and Biological Effects of Stress on Cancer Metastasis". NCI Symposium: The role of host factors in the development and progression of neoplastic disease. The 17th Annual Meeting of the Psychoneuroimmunology Research Society, Dublin, Ireland. June, 2010.
145. Invited speaker, "Microenvironment and pathogenesis of epithelial ovarian cancer". The Sixth International Symposium on Hormonal Oncogenesis, Tokyo, Japan. September, 2010.
146. Invited speaker, "Neuroendocrine influences on cancer metastasis". Epidemiology of Psychological and Social Influences on Cancer Outcome, A Think Tank meeting sponsored by the NCI, Los Angeles, CA. September, 2010.
147. Invited speaker, "Neuroendocrine Influences on Cancer Metastasis". Program in Hormone Related Malignancies, University of Colorado, Denver, CO. October 2010.
148. Invited speaker, "Neuroendocrine Influences on Cancer Metastasis". Huntsman Cancer Institute Seminar Series, University of Utah, Salt Lake City, UT. November 2010.
149. Invited speaker, SGO's 2010 State of the Art Conference, Society of Gynecologic Oncologists, Chicago, IL. "New concepts in therapeutic targets and platforms." December, 2010.
150. Invited speaker, 12th International Forum on Ovarian Cancer, Helene Harris Memorial Trust. "Bad blood: The role of platelets in ovarian carcinoma." Hallandale, Florida, January, 2011.
151. Invited speaker, "Translational Progress Towards Personalized Medicine in Gynecologic Cancers". New Trends in Managing Gynecologic Cancers: The Need for Personalized Medicine, San Diego, CA. January, 2011.
152. Invited speaker, "Regulation of tumor angiogenesis by EZH2." The 13th International Symposium on Anti-Angiogenic Agents, San Diego, CA, 2011.
153. Invited speaker, "Molecular targeting of metastatic cancer." Symposium on Mechanisms and Management of Tumor Metastasis. 58th Annual Meeting of the Society for Gynecologic Investigation, Miami, FL, 2011.
154. Invited speaker, "Neuroendocrine influences on cancer metastasis." First Annual Kidney Cancer Collaborative Symposium. M. D. Anderson Cancer Center, Houston, TX, 2011.
155. Invited speaker, "Adrenergic regulation of tumor microenvironment." In Major Symposium, "Neuroendocrine influences on cancer progression", the 102nd Annual Meeting of the American Society for Cancer Research, Orlando, FL, 2011.
156. Invited speaker, "Translational research: Training and beyond." In Professional Advancement Series

- Session, "Translational Research: Where do you fit in and what you need to succeed", the 102nd Annual Meeting of the American Society for Cancer Research, Orlando, FL, 2011.
157. Invited speaker, "Neuroendocrine influences on cancer metastasis." Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA. May, 2011.
 158. Keynote speaker, "Neuroendocrine influences on cancer metastasis." In Stress and Disease: Lessons for Research on Cancer. Dana-Farber Cancer Institute, Yawkey Center for Cancer Care, Boston, MA. May, 2011.
 159. Invited speaker, "Interfering with tumor vasculature." Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA. May, 2011.
 160. Invited speaker, "Targeting the EphA2 axis in uterine carcinoma." 7th Annual Uterine Cancer Biology Symposium, Houston, TX. May, 2011.
 161. Invited speaker, "RNAi therapeutics: Translation from bench to bedside." In: Next-Generation Therapeutic Targets and Drugs; 47th Annual Meeting, American Society of Clinical Oncology, Chicago, IL. June, 2011.
 162. Invited speaker, "Stromal influences of stress in cancer: The role of macrophages." In: NCI Symposium: PNI and Cancer: Role of the Tumor Macro(phage)-Environment. 18th Annual Meeting of the PsychoNeuroImmunology Research Society, Chicago, IL. June, 2011.
 163. Invited speaker, "Stress effects on tumor microenvironment." In: NCI Symposium: Cancer Mechanisms. Annual Meeting of the Academy of Behavioral Medicine Research, Deer Valley, UT. June, 2011.
 164. Invited speaker, "RNAi therapeutics: Challenges and future directions". The Leukemia Research Meeting, M.D. Anderson Cancer Center, Houston, TX, August, 2011.
 165. Invited speaker, "Interfering with tumor vasculature". Nuffield Department of Obstetrics and Gynaecology, Oxford University, Oxford, United Kingdom, September, 2011.
 166. Invited speaker, "Neuroendocrine influences on cancer metastasis". Hematology/Oncology Cancer Epidemiology, Prevention & Control Grand Rounds, Henry Ford Health System, Detroit, MI, September, 2011.
 167. Invited speaker, "Interfering with tumor vasculature". Roswell Park Cancer Institute Faculty Forum, Buffalo, NY, October, 2011.
 168. Papamarkou Lecturer, "Neuroendocrine influences on cancer metastasis." Department of Surgery Grand Rounds, Memorial Sloan-Kettering Cancer Center, New York, NY. November, 2011.
 169. Invited speaker, "Interfering with tumor vasculature". Department of Surgery Research Group, Memorial Sloan-Kettering Cancer Center, New York, NY. November, 2011.
 170. Invited speaker, "Therapeutic gene silencing using RNA interference". 67th Southwest Regional Meeting of the American Chemical Society. Austin, TX, November 2011.

171. Invited speaker, "New directions in anti-angiogenesis therapy." The 9th International Conference on Ovarian Cancer, M.D. Anderson Cancer Center, Houston, TX, December 2011.
172. Invited speaker, "Neuroendocrine influences on tumor microenvironment." The Department of Biochemistry and Molecular Biology Seminar Series, The University of Texas-Houston Medical School, Houston, TX, December 2011.
173. Keynote speaker, "Interfering with tumor vasculature". The Mary Jane & George Clymer Ovarian Cancer Research Retreat, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, December, 2011.
174. Invited speaker, "Exploiting ovarian cancer microenvironment and metabolic circuits for therapeutic purposes." Capitalizing on Biology to Develop Novel Prevention and Treatment Approaches to Gynecologic Cancer, Gynecologic Oncology Group 84th Semi-Annual Meeting, San Diego, CA, January, 2012.
175. Invited speaker, "Targeted therapy for ovarian cancer." Molecular Approaches to Managing Women's Cancers, Baylor College of Medicine/M.D. Anderson Cancer Center Joint Symposium, February, 2012.
176. Invited speaker, "Small interfering RNA: Promises for treatment and problems in delivery." Delivering on the Promise of the Human Genome Project. 178th Meeting of the American Association for the Advancement of Science, Vancouver, Canada, 2012.
177. Invited speaker, "Interfering with tumor vasculature". Grand rounds, Massachusetts General Hospital Cancer Center, Harvard University. Boston, MA, 2012.
178. Invited speaker, "Integrated genomic analysis in ovarian cancer: The Cancer Genome Atlas". Molecular Biology of Gynecologic Cancers: The Basic Principles of Translational Research. III M. D. Anderson International Conference in Gynecologic Oncology, Madrid, Spain. March 2012.
179. Invited speaker, "Novel agents for targeted therapy in gynecologic oncology". Molecular Biology of Gynecologic Cancers: The Basic Principles of Translational Research. III M. D. Anderson International Conference in Gynecologic Oncology, Madrid, Spain. March 2012.
180. Invited speaker, "Integrated translational research in gynecologic cancers". Education Forum III: Critical pathways in gynecologic cancers. The 2012 Annual Meeting on Women's Cancer, Austin, TX. March 2012.
181. Invited keynote speaker, "Promises and challenges with use of RNA interference for therapy". 28th Southern Biomedical Engineering Conference, Houston, TX. May 2012.
182. Invited speaker, "Interfering with tumor vasculature". Grand rounds, Tulane Cancer Center, New Orleans, LA, 2012.
183. Invited speaker, "Mechanisms of stress effects on cancer". Cancer Survivorship Research: Translating Science to Care (6th Biennial Cancer Survivorship Research Conference. Alexandria, VA, 2012.
184. Invited speaker, "Therapeutic gene silencing *in vivo* using RNA interference". Cancer Nanotech

(TechConnect Summit & Expo), Santa Clara, CA, 2012.

185. Invited Keynote speaker, "Promises and challenges of RNAi Therapeutics". 2nd Annual Trainees' Research Retreat, University of Texas-Houston, TX, 2012.
186. Invited speaker, "Promises and challenges with use of RNA interference for therapy". 9th Biennial Ovarian Cancer Research Symposium, The Marsha Rivkin Center for Ovarian Cancer Research, Seattle, WA, 2012.
187. Invited Keynote speaker, "Neuroendocrine influences on cancer metastasis." 18th Annual Cancer Research Symposium, UC Davis Comprehensive Cancer Center, Sacramento, CA, September, 2012.
188. Invited speaker, "Targeting tumor angiogenesis using RNA interference." Oligonucleotide Delivery: Biology, Engineering and Development, Schloss Hernstein, Hernstein, Austria, October, 2012.
189. Invited speaker, "Targeting the tumor microenvironment in gynecologic cancers." In Educational Symposium: What is individualized medicine? The 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), Vancouver, Canada, October, 2012.
190. Invited speaker, "Translational research in gynecological oncology." The 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), Vancouver, Canada, October, 2012.
191. Invited speaker, "Neuroendocrine influences on cancer metastasis." University of Virginia Cancer Center, Charlottesville, VA, October, 2012.
192. Invited speaker, "Targeting tumor angiogenesis using RNA interference." Department of Pharmacology Seminar Series, University of Texas Medical Branch, Galveston, TX. November, 2012.
193. Keynote speaker, "Promises and challenges of RNAi therapeutics". Tumor Microenvironment and Drug Discovery, Peggy and Charles Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK. December, 2012.
194. Invited speaker, "Targeting tumor angiogenesis using RNA interference." Pathobiology Seminar Series, University of Chicago, Chicago, IL. December, 2012.
195. Invited speaker, "Interfering with tumor vasculature." Moores Cancer Center Director's Seminar Series, University of California San Diego, CA. February, 2013.
196. Patricia Cronin Memorial Lecture, "Bad blood: The role of platelets in ovarian carcinoma." Dana-Farber/Harvard Cancer Center Spring Symposium "Breast and Gynecologic Cancer Research at Harvard", Boston, MA. March 2013.
197. Invited speaker, "Therapeutic gene silencing *in vivo* using biocompatible nanoparticles". Symposium: New Tools for Cancer Using Nanomaterials, nanostructures, and Nanodevices. Materials Research Society, San Francisco, CA. April, 2013.
198. Keynote speaker, "Promises and challenges of RNAi therapeutics". Harper Cancer Research Institute, University of Notre Dame, South Bend, IN. December, 2012.

199. Invited speaker, "New directions in targeting the tumor microenvironment". C.M. Easley Symposium and Resident Research Day, Greenville, SC. May, 2013.
200. Invited speaker, "Mechanisms of paraneoplastic thrombocytosis". C.M. Easley Symposium and Resident Research Day, Greenville, SC. May, 2013.
201. Invited speaker, "Targeting tumor angiogenesis using RNA interference. Director's Lectureship Series, University of New Mexico Cancer Center, Albuquerque, NM. May, 2013.
202. Keynote speaker, The Stephen Williams Lectureship. "Targeting tumor angiogenesis using RNA interference. 2013 Indiana University Simon Cancer Center's Cancer Research Day, Indianapolis, IN. May, 2013.
203. Invited speaker, "Two new directions: Metformin and stress signaling". Education Session: Pathways in Gynecologic Malignancies, 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL. June, 2013.
204. Keynote speaker, "Neuroendocrine influences on cancer metastasis". 2nd Red House International Obstetrics and Gynecology Peak Forum, Ob & Gyn Hospital of Fudan University, Shanghai, China. June, 2013.
205. Smith-Errington Lecture, "Promises and challenges of RNAi therapeutics". 10th Annual Oncology Research & Education Day, The Canadian Institutes of Health Research – Strategic Training Program in Cancer Research & Technology Transfer and The Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, Ontario. June, 2013.
206. Invited speaker, "Promises and challenges of RNAi therapeutics". 2nd International Michelangelo Conference: Promises and Challenges of Developing New Drugs in Oncology, Milan, Italy. July, 2013.
207. Invited speaker, "About Trousseau, platelets and ovarian cancer". The Wistar Institute, Philadelphia, PA. August, 2013.
208. Invited speaker, "Collection and analysis of "omic" data to provide accurate diagnosis and treatment". Annual Principal Investigators Meeting, NCI Alliance for Nanotechnology in Cancer, Bethesda, MD. September, 2013.
209. Invited speaker, "About George Engel and Mechanisms of Stress Effects on Cancer Metastasis". Annual meeting of the American Gynecological and Obstetrical Society, Chicago, IL. September, 2013.
210. Invited speaker, "Causes and consequences of paraneoplastic thrombocytosis". Advances in Ovarian Cancer Research: From Concept to Clinic, American Association for Cancer Research, Miami, FL. September, 2013.
211. Invited speaker, "Personalized therapy in gynecologic oncology: Biology, strategy, and assessment". In Session on Personalized Medicine. 18th International Meeting of the European Society of Gynaecological Oncology (ESGO), Liverpool, UK. October, 2013.

212. Ethel N. Ruvelson Memorial Lecture, "Causes and consequences of cancer-associated thrombocytosis." Fall Research Symposium, Masonic Cancer Center, University of Minnesota, Minneapolis, MN. November, 2013.
213. Invited speaker, "About Trousseau, platelets, microenvironment and cancer patients." New York Obstetrical Society, New York, NY. November, 2013.
214. Invited speaker, "New directions in targeting the tumor microenvironment." NYU, New York, NY. November, 2013.
215. Invited speaker, "Master microRNA regulatory networks in ovarian cancer." The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston. December, 2013.
216. Invited speaker, "Causes and consequences of cancer-associated thrombocytosis." In session on: Platelets and Cancer, 55th Annual Meeting of the American Society of Hematology, New Orleans, LA. December, 2013.
217. Invited speaker, "New directions in targeting the tumor microenvironment." Department of Obstetrics and Gynecology, Niigata University, Niigata, Japan. December, 2013.
218. Invited speaker, "What have we learned from the cancer genome atlas?" The 3rd Biennial Meeting of the Asian Society of Gynecologic Oncology, Kyoto, Japan. December, 2013.
219. Invited speaker, "Anti-angiogenesis therapy for ovarian cancer: Moving beyond VEGF." The 3rd Biennial Meeting of the Asian Society of Gynecologic Oncology, Kyoto, Japan. December, 2013.
220. Invited speaker, "Promises and challenges of RNAi therapeutics." Cincinnati Children's Hospital Medical Center, Cincinnati, OH. January, 2014.
221. Invited speaker, "The cancer genome atlas (TCGA): Innovations in ovarian and uterine cancer." IV MD Anderson International Meeting in Gynecologic Oncology: Emerging Therapies in Gynecological Cancer, Madrid, Spain. February, 2014.
222. Invited speaker, "RNAi strategies in future therapeutics of ovarian cancer." IV MD Anderson International Meeting in Gynecologic Oncology: Emerging Therapies in Gynecological Cancer, Madrid, Spain. February, 2014.
223. Invited speaker, "New directions in targeting the tumor microenvironment". European Institute of Oncology, Milan, Italy. March, 2014.
224. President's Achievement Award presentation: Targeting the undruggable: New directions in RNA interference and tumor microenvironment. 61st Annual Meeting of the Society for Gynecologic Investigation, Florence, Italy. March, 2014.
225. Invited speaker, "Nanotechnology from a clinician's point of view". Application of nanotechnology to the treatment of cancer patients. The 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA. April, 2014.
226. Invited speaker, "Neuroendocrine influences on cancer metastasis". The Second Hunan Provincial

Forum on Gynecology Oncology, Changsha, China. April, 2014.

227. Invited speaker, "Master microRNA regulatory networks in ovarian cancer". American Association of Pharmaceutical Scientists (AAPS): Emerging Trends in Gene/Cell-Based Therapeutics and Nanocarriers for Drug Discovery, Shanghai, China. April, 2014.
228. Invited speaker, "Promises and challenges of RNAi therapeutics." Reproductive Biology Seminar Series, UT Southwestern. April, 2014.
229. Invited speaker, "Biological validation of lethality targets using nanotechnology." 2nd Annual NCI Center for Strategic Scientific Initiatives (CSSI) Science Day, NCI, Bethesda, MD. June, 2014.
230. Invited speaker, "Master microRNA regulatory networks in ovarian cancer." Systems Medicine and Bioengineering Seminar Series, Houston Methodist Research Institute. July, 2014.
231. Keynote speaker, "From science to practice: Bridging the gap with translational research." 4th Annual Postdoctoral Science Symposium, M.D. Anderson Cancer Center, Houston, TX. August, 2014.
232. Keynote speaker, "Drugging the undruggable: New directions in RNAi therapeutics." Fourth Annual Women's Cancer Research Center Retreat, Magee-Womens Research Institute & Foundation, University of Pittsburgh. September, 2014.
233. Invited speaker, "Clinical perspectives of metabolism research." Symposium on Metabolism in Cancer, MD Anderson Cancer Center, Houston, TX. September, 2014.
234. Invited speaker, "Novel developments in targeted therapy in advanced epithelial ovarian cancer." Ovarian Cancer: A Comprehensive Symposium on Medical and Surgical Management. Medellin, Colombia. September, 2014.
235. Invited speaker, "Targeting stress signaling in ovarian cancer." Ovarian Cancer: A Comprehensive Symposium on Medical and Surgical Management. Medellin, Colombia. September, 2014.
236. Invited speaker, "Unmet Needs for Imaging in Cancer Patients and Cancer Biology." Workshop on Current Topics in Cancer Systems Biology: Multi-Scale Imaging for Cancer Biology (Sponsors: NCI and Methodist Hospital), Houston, TX. September, 2014.
237. Invited speaker, "Promises and challenges of RNAi therapeutics." Duke Cancer Institute Seminar Series, Duke University, Durham, NC. October, 2014.
238. Fred Benjamin, MD Memorial Lectureship, "About Trousseau, platelets, and ovarian cancer." Long Island Jewish Medical Center, New Hyde Park, NY. November, 2014.
239. Invited speaker: 1) "Crucial conversations: You get what you negotiate"; 2) "Grantsmanship and Career Development Proposals". SGO Early Career Educational Summit, Chicago, IL, 2014.
240. Invited speaker, "Hematogenous metastasis of ovarian cancer". Helene Harris Memorial Trust, 13th International Forum on Ovarian Cancer, Toledo, Spain. January, 2015.
241. Invited speaker, "New approaches for targeted and sustained delivery of ncRNAs". Gordon Research Conference: RNA Nanotechnology, Ventura, CA. February, 2015.

242. Invited speaker, "Molecular predictors of residual disease after cytoreduction." Symposium on Neoadjuvant chemotherapy for ovarian cancer – Clinical considerations and research opportunities. Gynecologic Oncology Group Winter 2015 Meeting, San Diego, CA. February, 2015.
243. Keynote speaker. "Promises and challenges of RNAi therapeutics." Molecular Pathways to Therapeutics: Paradigms and Challenges in Oncology; jointly organized by the Carcinogenesis Foundation (USA) and the Advanced Center for Treatment, Research and Education in Cancer (ACTREC), Mumbai, India. February, 2015.
244. Invited speaker. "Small RNAs: From biomarkers to cancer therapy." Advances in Molecular Diagnostics, Houston, TX. March, 2015.
245. Invited speaker. "Targeting lncRNA in ovarian cancer." Cambridge Healthtech Institute's Extracellular Biomarkers Summit, Boston, MA. March, 2015.
246. Invited speaker, "About stress, nerves, and cancer metastasis." Workshop on the Role of Nerves in Cancer Progression, NCI, Rockville, MD. March, 2015.
247. Invited speaker, "Ovarian cancer metastasis: Re-thinking mode of spread". Department of Pathology Grand Rounds, Wayne State University, Detroit, MI. April, 2015.
248. Invited keynote speaker, "A framework for personalized approaches to ovarian cancer". 3rd Lowy Symposium – Drug Discovery to Personalized Medicine, Sydney, Australia. May, 2015.
249. Invited speaker, "Drugging the undruggable: New directions in RNAi therapeutics." Grand rounds, University of Connecticut Comprehensive Cancer Center. May, 2015.
250. Invited speaker, "About stress, nerves, and cancer metastasis". Fred Hutchinson Cancer Research Center, Seattle, WA. June, 2015.
251. Invited speaker, "A framework for personalized approaches to ovarian cancer." The 3rd International Red House Forum, Shanghai, China. June, 2015.
252. Invited speaker, "What have we learned from the Cancer Genome Atlas." The 3rd International Red House Forum, Shanghai, China. June, 2015.
253. Invited speaker, "Drugging the undruggable: New directions in RNAi therapeutics." Annual University Retreat for Research, University of Cincinnati Cancer Institute. July, 2015.
254. Invited speaker, "Adaptation to anti-angiogenesis therapy." Symposia on Cancer Research: Emerging Concepts in Host Response to Cancer, MD Anderson Cancer Center, Houston, TX. September, 2015.
255. Invited speaker, "A framework for personalized approaches to ovarian cancer." 4th Oncosalud International Symposium, Lima, Peru. September, 2015.
256. Invited speaker, "Novel agents for targeted therapy in gynecologic oncology." 4th Oncosalud International Symposium, Lima, Peru. September, 2015.

257. Invited speaker. "Promises and challenges of RNAi therapeutics." Joint Biologic Therapeutics Center (Washington University) and Chemistry Series (Monsanto) seminar, St. Louis, MO. September, 2015.
258. Invited speaker. "A framework for personalized approaches to ovarian cancer." Biologic Therapeutics Center's Translational Research Seminar Series, Washington University, St. Louis, MO. October, 2015.
259. Invited speaker. "Adaptation to anti-angiogenesis therapy." An AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities, Orlando, FL. October, 2015.
260. Invited speaker. "A framework for personalized approaches to ovarian cancer." iBRIGHT 2015 (Integrative Biostatistics Research for Imaging Genomics, & High-throughput Technologies in Precision Medicine), Houston, TX. November, 2015.
261. Invited speaker. "Promises and challenges of RNAi therapeutics." Institute for Cancer Research, University of North Texas Health Science Center, Fort Worth, TX. November, 2015.
262. Invited speaker. "Promises and challenges of RNAi therapeutics." Symposium on Drug Discovery & Development, College of Pharmacy, University of Kentucky, Lexington, KY. November, 2015.
263. Invited speaker. "Hematogenous metastasis of ovarian cancer: Rethinking mode of spread." An AACR Special Conference on Tumor Metastasis, Austin, TX. December, 2015.
264. Invited speaker. "About Trousseau, platelets, angiogenesis, and cancer patients." Molecular Pathology Seminar Series, Johns Hopkins University, Baltimore, MD. January, 2016.
265. Invited speaker. "Framework for overcoming resistance." Cancer Translational Research Initiative Planning Workshop, Ontario Institute for Cancer Research, Toronto, Canada. February, 2016.
266. Invited speaker. "About Trousseau, platelets, angiogenesis, and cancer patients." Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL. February, 2016.
267. Invited speaker, "Targeting angiogenesis in ovarian cancer: Overcoming adaptive responses." 5th MD Anderson International Meeting in Gynecologic Oncology: Tailoring Cancer-Therapy in the Era of Personalized Medicine, Madrid, Spain. February, 2016.
268. Invited speaker, "Predictors of residual disease in patients with ovarian cancer." 5th MD Anderson International Meeting in Gynecologic Oncology: Tailoring Cancer-Therapy in the Era of Personalized Medicine, Madrid, Spain. February, 2016.
269. Invited speaker, "Targeting stress neuroendocrine pathways in cancer." 5th MD Anderson International Meeting in Gynecologic Oncology: Tailoring Cancer-Therapy in the Era of Personalized Medicine, Madrid, Spain. February, 2016.
270. Invited speaker, "Emerging approaches for targeted and sustained delivery of ncRNAs." Workshop on RNA Nanobiology. Center for Cancer Research, National Cancer Institute, Rockville, MD. March, 2016.
271. Invited speaker, "Clinical and Translational Pathways". Nordic Society of Gynaecological Oncology,

Bergen, Norway. April, 2016.

272. Invited speaker, "Stress, nerves and cancer". Panel on Opportunities for Cancer Prevention during Early Adulthood: Putting Scientific Evidence into Public Health Practice. Centers for Disease Control (CDC) and the National Association of Chronic Disease Directors (NACDD), Atlanta, GA. April, 2016.
273. Invited speaker, "Promises and challenges of RNAi therapeutics". Center for Targeted Therapies Seminar Series, Vanderbilt University, Nashville, TN. April, 2016.
274. Invited speaker, "State of anti-angiogenic therapies and adaptive changes." SPORE Workshop on Translational Research in Ovarian/GYN Cancers, NCI Shady Grove, Rockville, MD. May, 2016.
275. Invited keynote speaker, "Drugging the undruggable: New directions in RNAi therapeutics." 8th Canadian Conference of Ovarian Cancer Research, Niagra, Ontario, Canada. May, 2016.
276. Invited speaker, "A framework for personalized approaches to ovarian cancer." 4th Annual Scientific Symposium, Basser Center for BRCA. University of Pennsylvania, Philadelphia, PA. May, 2016.
277. Invited speaker, "Drugging the undruggable: New directions in RNAi therapeutics." Sheba Medical Center, Tel Aviv, Israel. June, 2016.
278. Invited speaker, "Lessons learned from the Moonshot program." OvaCure Collaboration Lab, Copenhagen, Denmark. June, 2016.
279. Invited speaker, "Pathologist-surgeon communications on frozen section diagnosis." The 6th MD Anderson Cancer Center – China Sister Institute Pathology Conference, Shanghai, China. July, 2016.
280. Invited speaker, "Lessons learned from the Moonshot Program: A team approach to advance patient care." The 6th MD Anderson Cancer Center – China Sister Institute Pathology Conference, Shanghai, China. July, 2016.
281. Invited speaker, "New approaches for targeting tumor angiogenesis". Gordon Research Conference: Drug Carriers in Medicine and Biology, Waterville Valley, NH. August, 2016.
282. Invited speaker, "Lessons learned from the Moonshot program." Josephine Ford Cancer Institute (JFCI), Detroit, MI. August, 2016.
283. Keynote speaker, "Overcoming adaptive changes in the tumor microenvironment". The Rivkin Center for Ovarian Cancer and the AACR – 11th Biennial Ovarian Cancer Research Symposium, Seattle, WA. September, 2016.
284. Invited speaker, "Metabolic fingerprint of stress influences in cancer". NCI Network on Biobehavioral Pathways in Cancer Capstone Meeting, NCI, Rockville, MD. September, 2016.
285. Invited speaker, "Of Zebras and Lions: How stress influences cancer metastasis." Center for Pediatric Research Symposium, Sanford Research Center, Sioux Falls, SD. September, 2016.
286. Invited speaker: 1) About Trousseau, platelets, angiogenesis and cancer patients; 2) Personalized surgical therapy in ovarian cancer; 3) New drugs for targeted therapy in gynecologic oncology; 4)

- Peritoneal Carcinomatosis – Role of Hyperthermic intraperitoneal chemotherapy (HIPEC). 1st South Southeast Congress of Brazilian Society of Surgical Oncology, Florianópolis, Brazil. November, 2016.
287. Invited speaker, “Ovarian cancer metastasis: Mechanisms and therapy.” Metastatic Cancer Task Force Testimony and Operational Meeting, Department of Defense, Booz Allen Hamilton Conference Center, Tysons Corner, VA. December, 2016.
 288. Invited speaker, “A framework for personalized approaches to ovarian cancer.” Sidney Kimmel Cancer Center Grand Rounds, Thomas Jefferson University, Philadelphia, PA. December, 2016.
 289. Invited speaker, “Of Zebras and Lions: How stress influences cancer metastasis.” Center for Research on Reproduction and Women’s Health, University of Pennsylvania, Philadelphia, PA. January, 2017.
 290. Invited speaker, “Emerging role of platelets in adaptive changes to anti-angiogenesis therapy”. Gordon Research Conference: Cell Biology of Megakaryocytes & Platelets, Lucca (Barga), Italy. March, 2017.
 291. Invited speaker: 1) A framework for personalized approaches to ovarian cancer; 2) Targeting the undruggable: Advances and obstacles in RNAi therapy. ANZ-GOG Annual Scientific Meeting, Melbourne, Australia. March, 2017.
 292. Invited speaker, “Multi-level approaches to cancer.” Integrated Multi-Level Approaches to Psychosocial Processes & Health (sponsored by Cousins Center for Psychoneuroimmunology at the Society for Affective Science 4th Annual Conference), Boston, MA. April, 2017.
 293. Invited speaker: 1) New drugs for targeted therapy in gynecologic oncology; 2) New advances in chemotherapy for ovarian cancer.” The 4th Red House Forum, International Obstetrics & Gynecology Summit, Shanghai International Convention Center, Shanghai, China. June, 2017.
 294. Invited keynote speaker, “Emerging concepts in stress, inflammation, and tumor microenvironment.” 24th Annual Scientific Meeting of the PsychoNeuroImmunology Research Society, Galveston, TX. June, 2017.
 295. Invited speaker and Session Chair (RNA Delivery), “Systemic *in vivo* delivery using biocompatible nanoparticles.” 16th Annual World Preclinical Congress, Boston, MA. June, 2017.
 296. Invited speaker, “Prolactin and ovarian cancer.” Federation of American Societies for Experimental Biology (FASEB) meeting on “Growth hormone/prolactin family in biology and disease”, Steamboat Springs, CO. July, 2017.
 297. Invited speaker, “Therapeutic applications of non-coding RNAs.” First Conference on Biomotors, Virus Assembly, and Nanobiotechnology Applications, Ohio State University, Columbus, OH. August, 2017.
 298. Invited speaker: 1) “Crucial conversations: You get what you negotiate”; 2) “Successful grantsmanship”. SGO Early Career Educational Summit, Chicago, IL. September, 2017.
 299. Invited speaker. “Impact of stress on cancer biology.” XXIII Congreso Latinoamericano de

Bioquimica Clinica; XI Congreso Uruguayo de Bioquimica Clinica, Punta del Este, Uruguay. September 2017.

300. Invited speaker: "Selective targeting of tumor angiogenesis." 15th International Nanomedicine & Drug Delivery Symposium, University of Michigan, Ann Arbor, MI. September, 2017.
301. Invited speaker: 1) IOM recommendations, recent advances in ovarian cancer; 2) New directions in targeting angiogenesis. An AACR Special Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment, Pittsburgh, PA. October, 2017.
302. Invited speaker: "Leveraging the stress response in ovarian cancer management. State-of-the-Art Ovarian Cancer Conference. Memorial Sloan Kettering Cancer Center, New York, NY. October, 2017.
303. The 22nd Annual Robert C. Knapp, M.D. Lecture in Gynecology: "Dangerous liaisons between platelets and cancer." Brigham and Women's Hospital, Boston, MA. October, 2017.
304. Iowa Alumni Society Visiting Professor: 1) New drugs for targeted therapy in gynecologic oncology; 2) Crucial conversations: You get what you negotiate; 3) Lessons learned from the ovarian cancer Moon Shot program; 4) Dangerous liaisons between platelets and cancer. Ob/Gyn postgraduate conference: Advances in gynecologic cancers. University of Iowa, Iowa City, IA. November, 2017.
305. Invited speaker: 1) Updates from the ovarian cancer moon shot program; 2) Dangerous liaisons between platelets and cancer. 8th Trope – Kolstad meeting: Updates and Controversies in Gynecologic Oncology. The Norwegian Radium Hospital, Oslo, Norway. December, 2017.
306. Invited speaker, "Role of platelets in adaptive changes to anti-angiogenesis therapy." In session on: New Innovations in Platelet Regulation of Tumor Growth and Metastasis. 59th Annual Meeting of the American Society of Hematology, Atlanta, GA. December, 2017.
307. Invited speaker: 1) "Dangerous liaisons between platelets and cancer"; 2) "Lessons learned from the ovarian cancer Moon Shot program". Cancer Research UK Cambridge Institute, University of Cambridge, UK. December, 2017.
308. Invited speaker: "Overcoming adaptive changes in the tumor microenvironment". 20th annual MITO meeting, Naples, Italy. January, 2018.
309. Invited speaker: 1) "Therapeutic applications of non-coding RNAs" (Reproductive Sciences Seminar); 2) "Dangerous liaisons between platelets and cancer" (Ob-Gyn Clinical Grand Rounds). University of Colorado Anschutz Medical Campus, Denver, CO. February, 2018.
310. Invited speaker: "Dangerous liaisons between platelets and cancer". Grand rounds, Clinical Science and Translational Research Institute, College of Medicine, Texas A&M University, Bryan, TX. March, 2018.
311. Invited speaker: "Personalized surgical algorithm for advanced ovarian cancer". Plenary V: The Farr Nezhat Surgical Innovation Session on Surgical Decision Making in Advanced Ovarian Cancer. 49th Annual Meeting of Society of Gynecologic Oncology, New Orleans, LA. March, 2018.
312. Invited speaker: "The platelet lifeline to cancer." 9th Symposium on Hemostasis: Advances in the

clinical and basic sciences of coagulation, Chapel Hill, NC. April, 2018.

313. Invited speaker: "Targeting the tumor microenvironment in ovarian cancer metastasis." In the Session RAOS09 – Ovarian cancer metastasis. Annual Meeting of the American Association for Cancer Research, Chicago, IL. April, 2018.
314. Invited speaker: "Personalized surgical algorithm for advanced ovarian cancer." The 2018 Regional Meeting of the AAGL, Chongqing, China. April, 2018.
315. Invited speaker: "Dangerous liaisons between platelets and cancer." Oncology grand rounds, the Houston Methodist Hospital, Houston, TX. 2018.
316. Invited speaker, "Ovarian cancer moon shot program." 6th MD Anderson International Meeting in Gynecologic Oncology: Embracing New Standards of Care in Gynecologic Cancers, Madrid, Spain. May, 2018.
317. Invited keynote speaker, "Overcoming adaptive changes in the tumor microenvironment". Global Academic Programs Conference 2018, Karolinska Institute, Stockholm, Sweden. May, 2018.
318. Invited speaker, "Emerging opportunities in rare gynecologic cancers." FDA-AACR-SGO Workshop on drug development in gynecologic malignancies. FDA White Oak Campus, Silver Spring, MD. June, 2018.
319. Invited keynote speaker, "Therapeutic applications of non-coding RNAs." 2nd China International Medical Technology Conference. Lianyungang, China. August, 2018.
320. Invited speaker, "Dangerous liaisons between platelets and cancer." The Moffitt Cancer Center and Research Institute Basic Science Grand Rounds, Tampa, FL. September, 2018.
321. Invited speaker, "Therapeutic applications of non-coding RNAs." Center for Drug Delivery and Nanomedicine (CDDN), University of Nebraska Medical Center, Omaha, NE. September, 2018.
322. Invited speaker, "Overcoming adaptive changes in the tumor microenvironment." The American Cancer Society Jiler Professors & Fellows Conference, Minneapolis, MN. September, 2018.
323. Invited speaker, "Metronomic therapy: Lessons from the lab and clinic." Sixth International Meeting of Metronomic Chemotherapy in Oncology, Michigan State University Grand Rapids Research Center, Grand Rapids, MI. October, 2018.
324. Invited speaker, "Updates from the Ovarian Cancer Moon Shot." Joint meeting between the European Society of Gynaecological Oncology (ESGO – SEGO) and the Felix Rutledge Society (FRS), Barcelona, Spain. October, 2018.
325. Invited speaker: 1) Keynote address – "Updates from the ovarian cancer Moon Shot program; 2) Grand rounds – "Dangerous liaisons between platelets and cancer". Gynecologic oncology research retreat, Department of Obstetrics and Gynecology, Women's Health Institute, Cleveland Clinic, Cleveland, OH. January, 2019.
326. Invited speaker, "Ovarian cancer metastasis: Mechanisms and therapy." Inaugural Symposium on Cancer Metastasis in Honor of Isaiah J. Fidler, Celebrating 50 years of cancer metastasis research.

MD Anderson Cancer Center, Houston, TX. March, 2019.

327. Invited speaker, "Lessons learned from the Ovarian Cancer Moon Shot Program". Grand rounds, Massachusetts General Hospital Cancer Center, Harvard University. Boston, MA. March, 2019.
328. Invited speaker, "Overcoming adaptive changes in the tumor microenvironment." 71st Annual Congress of the Japan Society of Obstetrics and Gynecology, Nagoya, Japan. April, 2019.
329. Invited speaker, "The platelet lifeline to cancer." NCI 7th Molecular and Cellular Characterization of Screen-Detected Lesions (MCL) Consortium. Nashville, TN. April, 2019.
330. Invited speaker, Next Frontiers to Cure Cancer Annual Meeting (A.C. Camargo Cancer Center): 1) The role and therapeutic implications of thrombocytosis in ovarian cancer; 2) MD Anderson Moon Shot effort in ovarian cancer: Rationale, surgical triage, and updates; 3) Adaptive changes from antiangiogenic drugs; 4) New therapeutic strategies: RNA inhibitors and combinations with PARP inhibitors. Sao Paulo, Brazil. May, 2019.
331. Invited speaker: "Overcoming adaptive changes in the tumor microenvironment." The 5th Red House Forum, International Obstetrics & Gynecology Summit, Shanghai, China. June, 2019.
332. Invited to give COBRE Distinguished Speaker Plenary Lecture, "Lessons learned from the Ovarian Cancer Moon Shot Program." International Ovarian Cancer Research Consortium and International Symposium on Tumor Microenvironment, Oklahoma City, OK. June, 2019.
333. Invited speaker: 1) About Trousseau, platelets, angiogenesis, and cancer patients; 2) Updates from the ovarian cancer Moon Shot program. 61st Annual Meeting of the Japan Society of Gynecologic Oncology (JSGO), Niigata, Japan. July, 2019.
334. Invited keynote speaker: "Advances and obstacles in RNAi therapy." 2nd Conference on Biomotors, Virus Assembly, and Nanobiotechnology Applications (in conjunction with Bi-annual Meeting of the International Society of RNA Nanotechnology and Nanomedicine), Ohio State University, Columbus, OH. July, 2019.
335. Invited speaker for Distinguished Speakers Seminar Series: "Stress, nerves, and RNAi therapy." Roswell Park Comprehensive Cancer Center, Buffalo, NY. October, 2019.
336. Invited speaker, "Therapeutic considerations for ovarian carcinomas and adaptive changes." Tumour seminar on Difficult Questions in Ovarian Cancer Research", Joint meeting of the International Agency for Research on Cancer (IARC) and the NCI, Lyon, France. October, 2019.
337. Invited keynote speaker, "Overcoming adaptive changes in the tumor microenvironment." The UT MD Anderson Cancer Center Global Academic Programs and Israel Joint Symposium on Collaborative Cancer Research in the Era of Precision Medicine, Sheba Medical Center, Tel Aviv, Israel. December, 2019.
338. Invited Keynote Speaker: "Bench-to-bedside (and back): Adaptive changes in the tumor microenvironment". The Stephenson Cancer Center 2020 Cancer Research Symposium, University of Oklahoma, Oklahoma City, OK. February 2020.
339. Invited seminar: "Dangerous liaisons between platelets and cancer." Department of Obstetrics and

Gynecology, Yale University, New Haven, CT. February 2020.

340. Invited speaker: 1) Lessons learned from the Ovarian Cancer Moon Shot program; 2) The platelet lifeline to cancer. 2020 Ob/Gyn Residents' and Fellows' Research Day, Mayo Clinic, Rochester, MN. March 2020.
341. Invited speaker: "Overcoming adaptive changes in the tumor microenvironment." Distinguished Lecture Series in Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX. March 2021.
342. Invited speaker: "Understanding the mechanisms of adaptive resistance to anti-angiogenesis drugs." 9th CCBIO Annual Symposium 2021, Bergen, Norway (Virtual). May 2021.
343. Invited speaker: "Bench-to-bedside (and back): Collaboration between physicians and scientists." Faculty Development Session, Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI. June, 2021.
344. Invited speaker: "Understanding the mechanisms of adaptive resistance to anti-angiogenesis drugs." Division of Pathology and Laboratory Medicine Grand Rounds, MD Anderson Cancer Center, Houston, TX. October 2021.
345. Invited speaker: "Overcoming adaptive changes in the tumor microenvironment." Grand rounds, Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, TX. October 2021.
346. Invited speaker (Zoom): "Therapeutic applications of non-coding RNAs". Seminar, Center for Cancer Research; Cell Identity and Signaling (CIS). Purdue University, West Lafayette, IN. April, 2022.
347. Invited speaker: "Updates from the Ovarian Cancer Moon Shot Program". Kelly Society Lecture, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, Baltimore, MD. June, 2022.
348. Invited speaker: "Sharpening the scalpel with molecular biology." International Gynecologic Cancer Society (IGCS) Annual Global Meeting, New York, NY. September, 2022.
349. Keynote speaker. "Emerging opportunities for enhancing immune therapy." Ovarian Cancer Research Group Think Tank Meeting, University of Colorado, Denver, CO. October, 2022.
350. Invited speaker: 1) Can we detect and overcome PARPi resistance? 2) Capitalizing on vulnerabilities from adaptive changes to anti-angiogenesis drugs. 23rd European Congress on Gynecological Oncology, European Society of Gynaecological Oncology (ESGO), Berlin, Germany. October, 2022.
351. Invited speaker. "Capitalizing on adaptive changes in the tumor microenvironment." International Conference on Advanced Biomedical Sciences, Taichung, Taiwan. November, 2022.
352. Invited speaker. "Effects of neuroendocrine stress hormones on ovarian cancer growth and progression." Global Gynecological Oncology Summit, China (virtual meeting). November, 2022.
353. Invited speaker. "Extracellular vesicles as biomarkers and drivers of biology in ovarian cancer." Cancer Biomarkers in Vesicles & Beyond, MD Anderson cAncer Center. December, 2022.

354. Invited speaker. "Effects of neuroendocrine stress hormones on ovarian cancer growth and progression." Cardiology Grand Rounds, MD Anderson Cancer Center. December, 2022.
355. Invited speaker. "Opportunities across kingdoms for RNAi delivery." Gordon Research Conference RNA Nanotechnology: RNA self-assembly, packaging, imaging and therapeutics. Ventura, CA. January, 2023.
356. Invited keynote speaker. "Capitalizing on adaptive changes in the tumor microenvironment." TRANSCEND Cancer Initiative Symposium, MD Anderson Cancer Center. April, 2023.
357. Invited speaker for Leaders in the Field Seminar. "Catalyzing change: Ovarian cancer Moon Shot Journey." UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA. June, 2023.
358. Invited speaker for the Translational and Basic Science Research Program in Early Lesions (TBEL) meeting. "Extracellular vesicles as biomarkers and drivers of biology in ovarian cancer", Houston, TX. October 2023.